JPS61243099A - Triterpene alcohol organic acid ester and production thereof - Google Patents
Triterpene alcohol organic acid ester and production thereofInfo
- Publication number
- JPS61243099A JPS61243099A JP60085254A JP8525485A JPS61243099A JP S61243099 A JPS61243099 A JP S61243099A JP 60085254 A JP60085254 A JP 60085254A JP 8525485 A JP8525485 A JP 8525485A JP S61243099 A JPS61243099 A JP S61243099A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- group
- carbon atoms
- methoxy
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Triterpene alcohol organic acid ester Chemical class 0.000 title claims abstract description 145
- 238000004519 manufacturing process Methods 0.000 title claims description 39
- 239000002253 acid Substances 0.000 claims abstract description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 43
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 28
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims abstract description 22
- 150000001555 benzenes Chemical class 0.000 claims abstract description 22
- 235000013985 cinnamic acid Nutrition 0.000 claims abstract description 21
- 229930016911 cinnamic acid Natural products 0.000 claims abstract description 21
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 21
- 125000003277 amino group Chemical group 0.000 claims abstract description 18
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 17
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 17
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 15
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 15
- 125000001424 substituent group Chemical group 0.000 claims abstract description 15
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims abstract description 14
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 claims description 89
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 claims description 89
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 claims description 81
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 claims description 81
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 claims description 81
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 claims description 81
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 claims description 81
- 125000004432 carbon atom Chemical group C* 0.000 claims description 74
- CIBNJPPYSPYHDB-UHFFFAOYSA-N Cyclobranol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCC(C)=C(C)C)C)CCC3(C)C1CC2 CIBNJPPYSPYHDB-UHFFFAOYSA-N 0.000 claims description 66
- CIBNJPPYSPYHDB-UEBIAWITSA-N cyclobranol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC(C)=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 CIBNJPPYSPYHDB-UEBIAWITSA-N 0.000 claims description 65
- 150000002148 esters Chemical class 0.000 claims description 61
- KKSCKZFKHNHGEO-UHFFFAOYSA-N 24-methylenecycloartanol Natural products CC(CCC(=C)C(C)(C)O)C1CCC2C3CCC4C(C)(C)C(O)CCC45CC35CCC12C KKSCKZFKHNHGEO-UHFFFAOYSA-N 0.000 claims description 36
- BJZVHTWNCLKZGN-SPQNPFHSSA-N 24-methylidenecycloartanol Natural products CC(C)C(=C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C BJZVHTWNCLKZGN-SPQNPFHSSA-N 0.000 claims description 35
- BDHQMRXFDYJGII-UEBIAWITSA-N 24-methylenecycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@@]3(C)[C@@H]1CC2 BDHQMRXFDYJGII-UEBIAWITSA-N 0.000 claims description 33
- 150000007524 organic acids Chemical class 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 11
- 150000004820 halides Chemical class 0.000 claims description 11
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 10
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 9
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 9
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 9
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 9
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 9
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 9
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 9
- 229940058690 lanosterol Drugs 0.000 claims description 9
- YABASAWVVRQMEU-YBXTVTTCSA-N cycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 YABASAWVVRQMEU-YBXTVTTCSA-N 0.000 claims description 8
- IXHACUTUTOCSJE-UHFFFAOYSA-N Cyclolaudenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCC(C)C(C)=C)C)CCC3(C)C1CC2 IXHACUTUTOCSJE-UHFFFAOYSA-N 0.000 claims description 6
- IXHACUTUTOCSJE-HWTFXIFRSA-N cyclolaudenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CC[C@H](C)C(C)=C)C)CC[C@@]3(C)[C@@H]1CC2 IXHACUTUTOCSJE-HWTFXIFRSA-N 0.000 claims description 6
- BTLJUKNIXFTSMI-DFWJFPTDSA-N (23e) cyclosadol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)C/C=C(\C)C(C)C)CC[C@@]3(C)[C@@H]1CC2 BTLJUKNIXFTSMI-DFWJFPTDSA-N 0.000 claims description 5
- ZBFPGLKEWSMWSG-BQNIITSRSA-N (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]4(C)C3=CC[C@H]21 ZBFPGLKEWSMWSG-BQNIITSRSA-N 0.000 claims description 5
- DICCPNLDOZNSML-XGKJEQFASA-N (3S,5R,9R,10R,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound C[C@H](CCC=C(C)C)[C@@H]1CC[C@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]12C DICCPNLDOZNSML-XGKJEQFASA-N 0.000 claims description 5
- CIUWDTKQGZYEEE-UHFFFAOYSA-N Butyrospermol Natural products C12CCC3(C)C(C(CCC=C(C)C)C)CCC3(C)C2=CCC2C1CCC(O)C2(C)C CIUWDTKQGZYEEE-UHFFFAOYSA-N 0.000 claims description 5
- BTLJUKNIXFTSMI-IHLDJTSYSA-N Cyclosadol Natural products CC(C)C(=CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@]35CC[C@]12C)C BTLJUKNIXFTSMI-IHLDJTSYSA-N 0.000 claims description 5
- DICCPNLDOZNSML-UHFFFAOYSA-N Delta7-tirucallol Natural products CC1(C)C(O)CCC2(C)C(CCC3(C(C(CCC=C(C)C)C)CCC33C)C)C3=CCC21 DICCPNLDOZNSML-UHFFFAOYSA-N 0.000 claims description 5
- ZBFPGLKEWSMWSG-UHFFFAOYSA-N agnosterone Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C)C)CCC4(C)C3=CCC21 ZBFPGLKEWSMWSG-UHFFFAOYSA-N 0.000 claims description 5
- ZCBDFGFNCFLBOL-BQNIITSRSA-N (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]4(C)C3=CC[C@H]21 ZCBDFGFNCFLBOL-BQNIITSRSA-N 0.000 claims description 4
- CBFHVQNQZFSQRM-UHFFFAOYSA-N 2-[(4-butanoyloxy-3-methoxyphenyl)methylidene]butanoic acid Chemical compound CCCC(=O)OC1=CC=C(C=C(CC)C(O)=O)C=C1OC CBFHVQNQZFSQRM-UHFFFAOYSA-N 0.000 claims description 4
- JPOSRBNQHFELCB-UHFFFAOYSA-N 2-methyl-3-(4-propanoyloxyphenyl)prop-2-enoic acid Chemical compound CCC(=O)OC1=CC=C(C=C(C)C(O)=O)C=C1 JPOSRBNQHFELCB-UHFFFAOYSA-N 0.000 claims description 4
- INMUZOBPSGXABB-OJIQHVHUSA-N Cycloeucalenol Natural products CC(C)C(=C)CC[C@@H](C)[C@H]1CCC[C@@]2(C)[C@@H]3CC[C@H]4[C@H](C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C INMUZOBPSGXABB-OJIQHVHUSA-N 0.000 claims description 4
- HUNLTIZKNQDZEI-PGFZVWMDSA-N cycloeucalenol Chemical compound C[C@@H]([C@@H]1CC[C@H]2[C@]3(C)CC[C@@H]([C@]3(CC3)C)[C@H](C)CCC(=C)C(C)C)[C@@H](O)CC[C@]11[C@@]23C1 HUNLTIZKNQDZEI-PGFZVWMDSA-N 0.000 claims description 4
- ZCBDFGFNCFLBOL-UHFFFAOYSA-N gamma-Lanostadienol Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(C)CCCC(C)C)CCC4(C)C3=CCC21 ZCBDFGFNCFLBOL-UHFFFAOYSA-N 0.000 claims description 4
- XJLZCPIILZRCPS-CKCUNPICSA-N (3s,5r,10s,13s,14s,17s)-4,4,10,13,14-pentamethyl-17-[(2s)-6-methyl-5-methylideneheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@@]2(C)[C@H]([C@@H](C)CCC(=C)C(C)C)CC[C@@]21C XJLZCPIILZRCPS-CKCUNPICSA-N 0.000 claims description 3
- REJOBCUTAMAPIS-HWKANZROSA-N (e)-3-(3-methoxy-4-nitrophenyl)prop-2-enoic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1[N+]([O-])=O REJOBCUTAMAPIS-HWKANZROSA-N 0.000 claims description 3
- OHJGKUKNHMWTCP-UHFFFAOYSA-N 2-[(4-butanoyloxyphenyl)methylidene]butanoic acid Chemical compound CCCC(=O)OC1=CC=C(C=C(CC)C(O)=O)C=C1 OHJGKUKNHMWTCP-UHFFFAOYSA-N 0.000 claims description 3
- AWWVCUPVXCDDHS-UHFFFAOYSA-N 2-methyl-3-(4-nitrophenyl)prop-2-enoic acid Chemical compound OC(=O)C(C)=CC1=CC=C([N+]([O-])=O)C=C1 AWWVCUPVXCDDHS-UHFFFAOYSA-N 0.000 claims description 3
- AHHAVYVFUHKHHQ-UHFFFAOYSA-N 2-methyl-3-(5-nitro-2-propoxyphenyl)prop-2-enoic acid Chemical compound CCCOC1=CC=C([N+]([O-])=O)C=C1C=C(C)C(O)=O AHHAVYVFUHKHHQ-UHFFFAOYSA-N 0.000 claims description 3
- IBXDEDGIXFRCCW-UHFFFAOYSA-N 3-(3-methoxy-4-nitrophenyl)-2-methylprop-2-enoic acid Chemical compound COC1=CC(C=C(C)C(O)=O)=CC=C1[N+]([O-])=O IBXDEDGIXFRCCW-UHFFFAOYSA-N 0.000 claims description 3
- LLQXKNWGEYFOIG-UHFFFAOYSA-N 3-(3-methoxy-4-propanoyloxyphenyl)-2-methylprop-2-enoic acid Chemical compound CCC(=O)OC1=CC=C(C=C(C)C(O)=O)C=C1OC LLQXKNWGEYFOIG-UHFFFAOYSA-N 0.000 claims description 3
- MUYUDVPKJZCBOA-UHFFFAOYSA-N 3-(4-aminophenyl)-2-methylprop-2-enoic acid Chemical compound OC(=O)C(C)=CC1=CC=C(N)C=C1 MUYUDVPKJZCBOA-UHFFFAOYSA-N 0.000 claims description 3
- YHOAZFMXZXWRHC-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)-2-methylprop-2-enoic acid Chemical compound COC1=CC(C=C(C)C(O)=O)=CC=C1O YHOAZFMXZXWRHC-UHFFFAOYSA-N 0.000 claims description 3
- PWURRRRGLCVBMX-UHFFFAOYSA-N 3-methoxy-4-nitrobenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1[N+]([O-])=O PWURRRRGLCVBMX-UHFFFAOYSA-N 0.000 claims description 3
- XNCRUNXWPDJHGV-UHFFFAOYSA-N alpha-Methyl-cinnamic acid Chemical compound OC(=O)C(C)=CC1=CC=CC=C1 XNCRUNXWPDJHGV-UHFFFAOYSA-N 0.000 claims description 3
- VOKLEOFNMAVWIU-UHFFFAOYSA-N euphorbol Natural products CC(C)C(=C)CCC(C)C1CCC2(C)C3=C(CCC12C)C4CCC(O)C(C)(C)C4CC3 VOKLEOFNMAVWIU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- WZAMDSBJONFHAO-UHFFFAOYSA-N quercetin 3-alpha-L-rhamnofuranoside Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(=C)CCC=C(C)C)C4CCC3C21C WZAMDSBJONFHAO-UHFFFAOYSA-N 0.000 claims description 3
- PPVBATUJIOGJMW-UHFFFAOYSA-N 2-[(3-butanoyloxyphenyl)methylidene]butanoic acid Chemical compound CCCC(=O)OC1=CC=CC(C=C(CC)C(O)=O)=C1 PPVBATUJIOGJMW-UHFFFAOYSA-N 0.000 claims description 2
- VKKJXDLVEHTPOQ-UHFFFAOYSA-N 2-[(3-methoxy-4-pentanoyloxyphenyl)methylidene]pentanoic acid Chemical compound CCCCC(=O)OC1=CC=C(C=C(CCC)C(O)=O)C=C1OC VKKJXDLVEHTPOQ-UHFFFAOYSA-N 0.000 claims description 2
- XIXMPQYDAHJQNN-UHFFFAOYSA-N 2-[(4-nitrophenyl)methylidene]butanoic acid Chemical compound CCC(C(O)=O)=CC1=CC=C([N+]([O-])=O)C=C1 XIXMPQYDAHJQNN-UHFFFAOYSA-N 0.000 claims description 2
- CVZUPRDSNNBZLH-UHFFFAOYSA-N 2-methoxy-5-nitrobenzoic acid Chemical compound COC1=CC=C([N+]([O-])=O)C=C1C(O)=O CVZUPRDSNNBZLH-UHFFFAOYSA-N 0.000 claims description 2
- NGZYZOOMYKRLPT-UHFFFAOYSA-N 3-(3-ethoxy-4-hydroxyphenyl)-2-methylprop-2-enoic acid Chemical compound CCOC1=CC(C=C(C)C(O)=O)=CC=C1O NGZYZOOMYKRLPT-UHFFFAOYSA-N 0.000 claims description 2
- LWWPSEIFAKNPKQ-UHFFFAOYSA-N 5-amino-2-methoxybenzoic acid Chemical compound COC1=CC=C(N)C=C1C(O)=O LWWPSEIFAKNPKQ-UHFFFAOYSA-N 0.000 claims description 2
- CZJBMPUIZBEHSZ-UHFFFAOYSA-N CCCCCCCC(=O)OC1=CC=C(C=C(CCCC)C(O)=O)C=C1OC Chemical compound CCCCCCCC(=O)OC1=CC=C(C=C(CCCC)C(O)=O)C=C1OC CZJBMPUIZBEHSZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005947 deacylation reaction Methods 0.000 claims description 2
- GQBVUGXINLMDTO-UHFFFAOYSA-N 2-[(4-hydroxy-3-methoxyphenyl)methylidene]butanoic acid Chemical compound CCC(C(O)=O)=CC1=CC=C(O)C(OC)=C1 GQBVUGXINLMDTO-UHFFFAOYSA-N 0.000 claims 2
- BJXDOISSZUSFMH-UHFFFAOYSA-N 2-[(4-hydroxy-3-methoxyphenyl)methylidene]hexanoic acid Chemical compound CCCCC(C(O)=O)=CC1=CC=C(O)C(OC)=C1 BJXDOISSZUSFMH-UHFFFAOYSA-N 0.000 claims 2
- VUGVHRGTLSPHJV-UHFFFAOYSA-N 3-(4-amino-3-methoxyphenyl)-2-methylprop-2-enoic acid Chemical compound COC1=CC(C=C(C)C(O)=O)=CC=C1N VUGVHRGTLSPHJV-UHFFFAOYSA-N 0.000 claims 2
- QGMNUFDKFDEQRV-UHFFFAOYSA-N 3-(4-amino-3-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1N QGMNUFDKFDEQRV-UHFFFAOYSA-N 0.000 claims 2
- YNMMLKQHOGURNL-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2-methylprop-2-enoic acid Chemical compound OC(=O)C(C)=CC1=CC=C(O)C=C1 YNMMLKQHOGURNL-UHFFFAOYSA-N 0.000 claims 2
- JZINNAKNHHQBOS-AATRIKPKSA-N 3-methylcinnamic acid Chemical compound CC1=CC=CC(\C=C\C(O)=O)=C1 JZINNAKNHHQBOS-AATRIKPKSA-N 0.000 claims 2
- JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 claims 2
- 241001077419 Damas Species 0.000 claims 2
- JGAIVVRVQFXLAJ-UHFFFAOYSA-N 2-[(3-ethoxy-4-hydroxyphenyl)methylidene]butanoic acid Chemical compound CCOC1=CC(C=C(CC)C(O)=O)=CC=C1O JGAIVVRVQFXLAJ-UHFFFAOYSA-N 0.000 claims 1
- FUAIROQXVIRYSC-UHFFFAOYSA-N 2-[(3-ethoxy-4-hydroxyphenyl)methylidene]hexanoic acid Chemical compound CCCCC(C(O)=O)=CC1=CC=C(O)C(OCC)=C1 FUAIROQXVIRYSC-UHFFFAOYSA-N 0.000 claims 1
- JGVQTQGCFDAAOM-UHFFFAOYSA-N 2-[(3-hydroxyphenyl)methylidene]butanoic acid Chemical compound CCC(C(O)=O)=CC1=CC=CC(O)=C1 JGVQTQGCFDAAOM-UHFFFAOYSA-N 0.000 claims 1
- DWFRFZJGLGZTQN-UHFFFAOYSA-N 2-[(3-methoxy-4-nitrophenyl)methylidene]-3-methylbutanoic acid Chemical compound COC1=CC(C=C(C(C)C)C(O)=O)=CC=C1[N+]([O-])=O DWFRFZJGLGZTQN-UHFFFAOYSA-N 0.000 claims 1
- FXLBGQSQIMUFTL-UHFFFAOYSA-N 2-[(4-amino-3-methoxyphenyl)methylidene]-3-methylbutanoic acid Chemical compound COC1=CC(C=C(C(C)C)C(O)=O)=CC=C1N FXLBGQSQIMUFTL-UHFFFAOYSA-N 0.000 claims 1
- YYQXUJDILPJIFL-UHFFFAOYSA-N 2-[(4-aminophenyl)methylidene]butanoic acid Chemical compound CCC(C(O)=O)=CC1=CC=C(N)C=C1 YYQXUJDILPJIFL-UHFFFAOYSA-N 0.000 claims 1
- IOQOCMBLROXVCU-UHFFFAOYSA-N 2-[(4-hydroxy-3-methoxyphenyl)methylidene]pentanoic acid Chemical compound CCCC(C(O)=O)=CC1=CC=C(O)C(OC)=C1 IOQOCMBLROXVCU-UHFFFAOYSA-N 0.000 claims 1
- BMSDHNLVGPSDPD-UHFFFAOYSA-N 2-[(4-hydroxy-3-propoxyphenyl)methylidene]pentanoic acid Chemical compound CCCOC1=CC(C=C(CCC)C(O)=O)=CC=C1O BMSDHNLVGPSDPD-UHFFFAOYSA-N 0.000 claims 1
- BHRNSCAHRYQXGR-UHFFFAOYSA-N 2-[(4-hydroxyphenyl)methylidene]butanoic acid Chemical compound CCC(C(O)=O)=CC1=CC=C(O)C=C1 BHRNSCAHRYQXGR-UHFFFAOYSA-N 0.000 claims 1
- RHZVHLWYRDLWCT-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-2-methylprop-2-enoic acid Chemical compound OC(=O)C(C)=CC1=CC=CC=C1O RHZVHLWYRDLWCT-UHFFFAOYSA-N 0.000 claims 1
- RBOMGDPEJGZFNE-UHFFFAOYSA-N 3-(3-methoxy-4-propanoyloxyphenyl)prop-2-enoic acid Chemical compound CCC(=O)OC1=CC=C(C=CC(O)=O)C=C1OC RBOMGDPEJGZFNE-UHFFFAOYSA-N 0.000 claims 1
- SVFVHQGHLASEHB-UHFFFAOYSA-N 3-(4-hydroxy-3-propoxyphenyl)-2-methylprop-2-enoic acid Chemical compound CCCOC1=CC(C=C(C)C(O)=O)=CC=C1O SVFVHQGHLASEHB-UHFFFAOYSA-N 0.000 claims 1
- VGDIOBPWRTVKCF-UHFFFAOYSA-N 3-(5-amino-2-propoxyphenyl)-2-methylprop-2-enoic acid Chemical compound CCCOC1=CC=C(N)C=C1C=C(C)C(O)=O VGDIOBPWRTVKCF-UHFFFAOYSA-N 0.000 claims 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 claims 1
- AADHNFACECSNSY-LYZQKKJGSA-N C1C2C[C@H]3[C@@]4(CC[C@H]([C@H](C)CCC1C(C)C)[C@]4(CC[C@]31C[C@]11[C@@H]2C([C@H](CC1)O)(C)C)C)C Chemical compound C1C2C[C@H]3[C@@]4(CC[C@H]([C@H](C)CCC1C(C)C)[C@]4(CC[C@]31C[C@]11[C@@H]2C([C@H](CC1)O)(C)C)C)C AADHNFACECSNSY-LYZQKKJGSA-N 0.000 claims 1
- 230000020176 deacylation Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 35
- 229940114081 cinnamate Drugs 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 193
- 150000001875 compounds Chemical class 0.000 description 101
- 238000002844 melting Methods 0.000 description 78
- 230000008018 melting Effects 0.000 description 78
- 238000000034 method Methods 0.000 description 75
- 239000000203 mixture Substances 0.000 description 53
- 238000000921 elemental analysis Methods 0.000 description 49
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 48
- 239000002904 solvent Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 230000003287 optical effect Effects 0.000 description 28
- 230000007423 decrease Effects 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 24
- 239000013078 crystal Substances 0.000 description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 108010023302 HDL Cholesterol Proteins 0.000 description 21
- 101150041968 CDC13 gene Proteins 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 19
- 239000002994 raw material Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 10
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 235000005985 organic acids Nutrition 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 235000002378 plant sterols Nutrition 0.000 description 9
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 239000003524 antilipemic agent Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 229950005143 sitosterol Drugs 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003518 caustics Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000001785 ferulic acid Nutrition 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical class COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- 229940114124 ferulic acid Drugs 0.000 description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 4
- HDJNEBJXWDVTNZ-UEBIAWITSA-N (1S,3R,6S,8R,11S,12S,15R,16R)-7,7,12,16-tetramethyl-15-[(3S)-7-methyloct-1-en-3-yl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-6-ol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C=C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 HDJNEBJXWDVTNZ-UEBIAWITSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- 108010089254 Cholesterol oxidase Proteins 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 108010055297 Sterol Esterase Proteins 0.000 description 3
- 102000000019 Sterol Esterase Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- 239000001405 butyl (E)-3-phenylprop-2-enoate Substances 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 3
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- YKPXUVTWLVHJBM-UHFFFAOYSA-N 1,1,1,3-tetraethoxypropane Chemical compound CCOCCC(OCC)(OCC)OCC YKPXUVTWLVHJBM-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000028373 Neck injury Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- ZKQRGSXITBHHPC-VVQHAZRASA-N ergosta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 ZKQRGSXITBHHPC-VVQHAZRASA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- SFUVLEGIZGPPNN-UHFFFAOYSA-N (2-pyridin-2-ylacetyl) 2-pyridin-2-ylacetate Chemical compound C=1C=CC=NC=1CC(=O)OC(=O)CC1=CC=CC=N1 SFUVLEGIZGPPNN-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-ANOYILKDSA-N (3s,8r,9s,10s,13r,14s,17r)-17-[(2r,5s)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 LGJMUZUPVCAVPU-ANOYILKDSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- XNCRUNXWPDJHGV-BQYQJAHWSA-N (e)-2-methyl-3-phenylprop-2-enoic acid Chemical class OC(=O)C(/C)=C/C1=CC=CC=C1 XNCRUNXWPDJHGV-BQYQJAHWSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- LTELVWFHNTXZEV-UHFFFAOYSA-N 2-methyl-3-(2-propanoyloxyphenyl)prop-2-enoic acid Chemical compound CCC(=O)OC1=CC=CC=C1C=C(C)C(O)=O LTELVWFHNTXZEV-UHFFFAOYSA-N 0.000 description 1
- DMXDUJPYGUWROU-UHFFFAOYSA-N 2-methyl-3-(3-nitrophenyl)prop-2-enoic acid Chemical compound OC(=O)C(C)=CC1=CC=CC([N+]([O-])=O)=C1 DMXDUJPYGUWROU-UHFFFAOYSA-N 0.000 description 1
- LQVKYASAQRCFLB-UHFFFAOYSA-N 2-methyl-3-(3-propanoyloxyphenyl)prop-2-enoic acid Chemical compound CCC(=O)OC1=CC=CC(C=C(C)C(O)=O)=C1 LQVKYASAQRCFLB-UHFFFAOYSA-N 0.000 description 1
- INDVLXYUCBVVKW-RNWIMVDMSA-N 24-Methylene cholesterol Natural products O[C@@H]1CC=2[C@@](C)([C@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCC(C(C)C)=C)C)CC4)CC3)CC=2)CC1 INDVLXYUCBVVKW-RNWIMVDMSA-N 0.000 description 1
- INDVLXYUCBVVKW-PXBBAZSNSA-N 24-methylenecholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=C)C(C)C)[C@@]1(C)CC2 INDVLXYUCBVVKW-PXBBAZSNSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- WCPNDHITXVUFFM-UHFFFAOYSA-N 3-(3-aminophenyl)-2-methylprop-2-enoic acid Chemical compound OC(=O)C(C)=CC1=CC=CC(N)=C1 WCPNDHITXVUFFM-UHFFFAOYSA-N 0.000 description 1
- QMEKCJZOVMTLFW-UHFFFAOYSA-N 3-(4-acetamido-3-methoxyphenyl)-2-methylprop-2-enoic acid Chemical compound COC1=CC(C=C(C)C(O)=O)=CC=C1NC(C)=O QMEKCJZOVMTLFW-UHFFFAOYSA-N 0.000 description 1
- HMQHIKNWTOXPQS-UHFFFAOYSA-N 3-amino-2-methyl-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(C)=C(N)C1=CC=CC=C1 HMQHIKNWTOXPQS-UHFFFAOYSA-N 0.000 description 1
- SXOPCLUOUFQBJV-UHFFFAOYSA-N 3-methoxyanthranilic acid Chemical compound COC1=CC=CC(C(O)=O)=C1N SXOPCLUOUFQBJV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- AQKDWYGXFNDNCB-UHFFFAOYSA-N 4-acetamido-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(C)=O AQKDWYGXFNDNCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- PYGLCYFOFXTHOC-UHFFFAOYSA-N C(CCCCCCCCCCCCC)OC=1C=C(C=CC(=O)O)C=CC=1 Chemical compound C(CCCCCCCCCCCCC)OC=1C=C(C=CC(=O)O)C=CC=1 PYGLCYFOFXTHOC-UHFFFAOYSA-N 0.000 description 1
- 101100511466 Caenorhabditis elegans lon-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108010000659 Choline oxidase Proteins 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-WZLOIPHISA-N Euphol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@@]2(C)[C@H]([C@@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-WZLOIPHISA-N 0.000 description 1
- QFPQAPVPUNXXDR-UHFFFAOYSA-N Euphol Natural products CC(=CCCCC1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3)C QFPQAPVPUNXXDR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- INDVLXYUCBVVKW-UHFFFAOYSA-N Methylencholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=C)C(C)C)C1(C)CC2 INDVLXYUCBVVKW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 241001653634 Russula vesca Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101150082269 TSHB gene Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- JYIGIJSHSKBQQT-UHFFFAOYSA-N acetyl acetate;chloroform Chemical compound ClC(Cl)Cl.CC(=O)OC(C)=O JYIGIJSHSKBQQT-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- RUETZBUVTWCCIZ-UHFFFAOYSA-N alpha-ethyl cinnamic acid Natural products CCC(C(O)=O)=CC1=CC=CC=C1 RUETZBUVTWCCIZ-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- FYXKZNLBZKRYSS-UHFFFAOYSA-N benzene-1,2-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=CC=C1C(Cl)=O FYXKZNLBZKRYSS-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- KZJWDPNRJALLNS-STIDJNKJSA-N gamma-sitosterol Natural products CC[C@@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C KZJWDPNRJALLNS-STIDJNKJSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000020975 high cholesterol intake Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000001572 propyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940033331 soy sterol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利用分野:
本発明は抗高脂血症活性を有する新規な化合物及び製造
法に関する。更に詳しくは、本発明は優れた抗高脂血症
活性と低い毒性即ち安全で新規なトリテルペンアルコー
ルの一置換基又は二置換基をベンゼン核に結有するα一
炭素数1〜4のアルキルケイヒ酸エステル、又は炭素数
1〜4のアルコキシ基とニトロ基、炭素数1〜4のアル
コキシ基とアミノ基又は炭素数1〜4のアルコキシ基と
炭素数2〜5のアシルアミノ基の二置換基をベンゼン核
に結有する安息香酸もしくはケイヒ酸エステル及びそれ
らの製造方法に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application: The present invention relates to novel compounds having antihyperlipidemic activity and methods for their preparation. More specifically, the present invention provides excellent antihyperlipidemic activity and low toxicity, i.e., safe and novel alkylcinnamic acids having 1 to 4 carbon atoms, which have triterpene alcohol mono- or di-substituents attached to the benzene nucleus. ester, or a disubstituted group of an alkoxy group having 1 to 4 carbon atoms and a nitro group, an alkoxy group having 1 to 4 carbon atoms and an amino group, or an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms, to benzene The present invention relates to benzoic acid or cinnamic acid esters bound to the nucleus and methods for producing them.
従来の技術:
高脂血症は動脈硬化、特に冠状動脈硬化症の重要な危険
因子であることがよく知られている。BACKGROUND OF THE INVENTION Hyperlipidemia is well known to be an important risk factor for arteriosclerosis, especially coronary arteriosclerosis.
1975年、Millerと旧1ler (G、J、M
iller、 N、I!、Mi−11er ; La
ncet : Jan、 4.16頁(1975) )
は血漿中の高比重リポ蛋白コレステロール(以下HDL
−Cと称する。)と体の中のコレステロールプールが負
の相関を示すことを認め、血中の総コレステロール(以
下TCと称する。)や他のリボ蛋白濃度との間には相関
が認められないことから、血中HDL−C濃度の低下に
よって動脈壁からのコレステロールのクリアランスが低
下することが動脈硬化を促進させるとの考えを提唱した
。この報告以後、数多くの疫学的研究〔例えばT、Go
rdon等: As、J、Med、、62巻、707頁
(1977) )により虚血性心疾患の発生とHDL−
C濃度との間に逆相関のあることが証明され、血中HD
L−C濃度の低下が、抗高脂血症剤の有無にかかわらず
、虚血性心疾患発生の一つの大きな危険因子であること
が確認された。1975, Miller and old 1ler (G, J, M
iller, N, I! , Mi-11er; La
ncet: Jan, p. 4.16 (1975))
is high-density lipoprotein cholesterol (HDL) in plasma.
-C. ) and the cholesterol pool in the body, and no correlation was observed between blood total cholesterol (hereinafter referred to as TC) and other riboprotein concentrations. He proposed the idea that a decrease in HDL-C concentration leads to a decrease in the clearance of cholesterol from the arterial wall, which promotes arteriosclerosis. Since this report, numerous epidemiological studies [e.g. T, Go
Rdon et al.: As, J. Med, Vol. 62, p. 707 (1977)) reported that the occurrence of ischemic heart disease and HDL-
It has been proven that there is an inverse correlation between C concentration and blood HD
It has been confirmed that a decrease in LC concentration is one of the major risk factors for the development of ischemic heart disease, regardless of the presence or absence of antihyperlipidemic agents.
従前から植物ステロールが血清コレステロールを低下さ
せることは公知である0例えばβ−シトステロールとジ
ヒドロ−β−シトステロールの混合物(米国、 Li
11部社商品名・Cytellin) ;ソイステロ
ール、植物ステロールとトコフェロールの混合物(日本
、森下製薬:商品名そりステロール)等は高脂血症治療
剤として市販されている。It has long been known that plant sterols lower serum cholesterol. For example, a mixture of β-sitosterol and dihydro-β-sitosterol (USA, Li
Soysterol, a mixture of plant sterol and tocopherol (Japan, Morishita Pharmaceutical Co., Ltd., trade name: Cytellin), etc. are commercially available as hyperlipidemia therapeutic agents.
一方、トリテルペンアルコールについては次の文献が発
表されている。On the other hand, the following literature has been published regarding triterpene alcohols.
特開昭57−18617号公報には、植物ステロール1
部にシクロアルテノール又は24−メチレンシクロアル
タノールを0.01〜0.1部併用すると相乗効果によ
り植物ステロール単独使用時よりも強い血清コレステロ
ール低下作用が認められている。JP-A-57-18617 discloses that plant sterol 1
When 0.01 to 0.1 part of cycloartenol or 24-methylenecycloartanol is used in combination with the plant sterol, a synergistic effect has been shown to have a stronger serum cholesterol lowering effect than when plant sterol is used alone.
特開昭58−116415号公報には、植物ステロール
100部に対し、シクロアルテノール、24−メチレン
シクロアルタノール又はシクロラウデノールを1〜20
部(特に5部程度)を併用すると相乗効果により植物ス
テロール単独使用時よりも相当に強い血清コレステロー
ル低下作用が認められたと記載されている。特にシクロ
アルテノール!:J:、[物ステロールの血清コレステ
ロール低下作用に対し相乗効果を示し、24−メチレン
シクロアルタノール及びシクロラウデノールは、シクロ
アルテノールよりもその相乗効果が劣ることを示してい
る。JP-A-58-116415 discloses that 1 to 20 parts of cycloartenol, 24-methylenecycloartanol, or cyclolaudenol is added to 100 parts of plant sterol.
It is stated that when phytosterols are used in combination (particularly about 5 parts), a considerably stronger serum cholesterol lowering effect was observed due to a synergistic effect than when plant sterols are used alone. Especially cycloartenol! :J:, [This shows a synergistic effect of sterols on the serum cholesterol-lowering effect, and 24-methylenecycloartanol and cyclolaudenol show a lower synergistic effect than cycloartenol.
特開昭59−27824号公報には、コレステロール0
.5%添加食に対し、シクロアルテノール又は24−メ
チレンシクロアルタノールを1%添加したト*、高コレ
ステロール摂取のコントロールに対しTCの低下率は前
者13.7%、後者10.2%(同公報第2表の結果に
より本発明者等が計算)と報告されている。Japanese Patent Application Laid-open No. 59-27824 discloses that cholesterol 0
.. When 1% cycloartenol or 24-methylene cycloartanol was added to the 5% supplemented diet*, the TC reduction rate was 13.7% for the former and 10.2% for the latter compared to the control with high cholesterol intake. Calculated by the present inventors based on the results in Table 2 of the publication).
然し、上記三線の公報中には血清中TOの低下作用につ
いて報告されているが、血清中のトリグリセライド(以
下TGと称する。)、総リン脂質(以下PLと称する。However, although the aforementioned Sanshin publication reports the effect of lowering serum TO, triglycerides (hereinafter referred to as TG) and total phospholipids (hereinafter referred to as PL) in serum are reported.
) 、HDL−C,^theroge−nic Ind
ex (TC−HDL−C/HDL−Cで求め、以下
AIと称する。我が国の医学者の内には、このAIをコ
レステロール比又は動脈硬化指数と称する方もおる。〕
及び過酸化脂質(以下LPOと称する。)に関しては何
等の記載がない。シクロアルテノール、24−メチレン
シクロアルタノール及びシクロラウデノールは、単独又
は植物ステロールとの共存下で血清TCを減少させたか
らと言って、これ以外の高脂血症の治療判定上の重要な
項目である血清脂質のTGSPL及びLPOに対しても
低下作用を有し、且つ最近、特に高脂血症の治療上重要
視されているHDL−Cを上昇させ、更にA]を低下さ
せる効果を有するか否かは不明である。又、かかる全般
的な薬理活性は類推不可能なことである。), HDL-C, ^theroge-nic Ind
ex (calculated as TC-HDL-C/HDL-C, hereinafter referred to as AI. Some Japanese medical scientists refer to this AI as the cholesterol ratio or arteriosclerosis index.)
There is no description regarding lipid peroxide (hereinafter referred to as LPO). Even though cycloartenol, 24-methylenecycloartanol, and cyclolaudenol reduced serum TC alone or in the coexistence with plant sterols, they are still important in determining the treatment of hyperlipidemia. It also has a lowering effect on the serum lipids TGSPL and LPO, which are items, and also has the effect of increasing HDL-C, which has recently been particularly important in the treatment of hyperlipidemia, and further reducing A]. It is unknown whether they have it or not. Moreover, such general pharmacological activity cannot be estimated.
又、現在、我が国で頭・頚部損傷治療剤の医薬品として
市販されているT−オリザノールは単品ではなく、各種
の植物ステロールとトリテルペンアルコールのフェルラ
酸エステルの混合物である。Furthermore, T-oryzanol, which is currently commercially available in Japan as a therapeutic agent for head and neck injuries, is not a single product, but a mixture of various plant sterols and ferulic acid esters of triterpene alcohols.
この成分比率の一例を示すと、カンペステロール14%
、スチグマステロール1%、β−シトステロール4%、
シフロア、ルタノール2%、シクロアルテノール35%
、24−メチレンシクロアルタノール44%の各フェル
ラ酸エステルの組成からなり、シクロブラノールフェル
ラ酸エステルはほとんど含有しない。An example of this ingredient ratio is campesterol 14%
, stigmasterol 1%, β-sitosterol 4%,
Shifuroa, 2% lutanol, 35% cycloartenol
, 24-methylenecycloartanol, and 44% of each ferulic acid ester, and contains almost no cyclobranol ferulic acid ester.
最近、高脂血症ラットのコレステロール代謝に及ぼすT
−オリザノールの影響について次の報告がある。葛谷文
男、吉峯徳、加藤庄志、藤田勝成、牛込裕代ら(Ger
iatric Medicine 1部巻、519〜
524頁(1980) )は、高コレステロール食飼育
ラットを用い、これを対照としてγ−オリザノールを0
.1.0.5及び1%添加の高コレステロール食摂取ラ
ットではTCは明らかに低下し、その低下は投与量依存
性であった。TCの低下率はPLの低下率を上回るもの
であり、又、TCの低下率はHDL−Cの低下率と同等
であり、AIに対して作用は認めなかった。TGは上昇
傾向を示し、LPOは明らかに低下作用を示したと報告
している。Recently, the effect of T on cholesterol metabolism in hyperlipidemic rats.
-There is the following report regarding the effects of oryzanol. Fumio Kuzutani, Noriyoshi Yoshimine, Shoji Kato, Katsunari Fujita, Hiroyo Ushigome and others (Ger
Iatric Medicine Volume 1, 519~
p. 524 (1980)) used rats fed a high-cholesterol diet and treated them with 0 γ-oryzanol as a control.
.. In rats fed high cholesterol diets supplemented with 1, 0.5 and 1%, TC was clearly decreased, and the decrease was dose dependent. The rate of decrease in TC exceeded the rate of decrease in PL, and the rate of decrease in TC was equivalent to the rate of decrease in HDL-C, and no effect on AI was observed. It is reported that TG showed an increasing tendency, and LPO clearly showed a decreasing effect.
三谷公瓦、木戸康博、清水精−1森田誠治ら〔動脈硬化
11巻、磁2、June 411〜416頁(198
3) )は、高コレステロール食摂取ラットに比較して
T−オリザノールを0.5.1.0及び2.0%添加し
た高コレステロール食摂取ラットでは、それぞれ血清T
C値は8.1.23.4及び30.9%の低下率を示し
た。一方血清TO値及び血清PL値に関しては有意な低
下を認めなかった。Mitani Kouga, Kido Yasuhiro, Shimizu Sei-1 Morita Seiji et al.
3)) Compared to rats fed a high-cholesterol diet, rats fed a high-cholesterol diet supplemented with 0.5, 1.0 and 2.0% T-oryzanol had lower serum T levels, respectively.
The C value showed a reduction rate of 8.1.23.4 and 30.9%. On the other hand, no significant decrease was observed in serum TO value and serum PL value.
井上修二、江用正人、佐藤忍ら〔動脈硬化 11巻、隘
2、June 41,7〜428頁(1983) )は
、視床下部性肥満ラットの高脂血症に対するγ−オリザ
ノールの影響について検討し、T−オリザノールは血中
TC低下作用を有するが、血中TOには有意な低下を認
めない。又血中PLSHDL−Cには影響を与えなかっ
たと報告している。Shuji Inoue, Masato Eyo, Shinobu Sato et al. [Arteriosclerosis Vol. 11, No. 2, June 41, pp. 7-428 (1983)] investigated the effects of γ-oryzanol on hyperlipidemia in hypothalamically obese rats. However, although T-oryzanol has an effect of lowering blood TC, no significant decrease is observed in blood TO. They also reported that it had no effect on blood PLSHDL-C.
一方、有機酸については、R,D、Sharma (^
the−rosclerosis 37巻、 463〜
46B頁(1980) )は、高コレステロール食摂取
ラットに比較して有機酸0.2%添加の高コレステロー
ル食摂取ラットではフェルラ酸(Perultc ac
id)とp−フマル酸(p−Cous+aric ac
id )はTCの低下率は前者10.8%、後者9.4
%で有意に低下した。TGの低下はフェルラ酸18.7
%、p−フマル酸19.8%と減少したが有意な減少で
はなかった。PLは両者ともほとんど低下が認められな
かった。バニリン酸(Vanillic acid )
、カフェ酸(Caffeic acid)、ケイヒ酸
(Cinnamic acid )にはTC,TG及び
LP共に低下減少は認められなかったと報告している。On the other hand, regarding organic acids, R, D, Sharma (^
the-rosclerosis volume 37, 463~
p. 46B (1980) found that ferulic acid (Perultac ac
id) and p-fumaric acid (p-Cous+aric ac
id), the TC decrease rate is 10.8% for the former and 9.4 for the latter.
% significantly decreased. Ferulic acid lowers TG by 18.7
%, p-fumaric acid decreased to 19.8%, but the decrease was not significant. Almost no decrease in PL was observed in both cases. Vanillic acid
reported that no decrease in TC, TG, or LP was observed for caffeic acid and cinnamic acid.
有機酸単独ではないが、α−メチルケイヒ酸誘導体の抗
高脂血症効果について、次の報告が発表されている。Although not an organic acid alone, the following report has been published regarding the antihyperlipidemic effect of α-methylcinnamic acid derivatives.
高島紘毅ら(Biochemical Phayvac
ology 27@、2631頁(1978) )は
、ラットにおけるα−モノ−p−ミリスチルオキシ−α
ゝ−メチルシンナモイルグリセロールの抗高脂血症効果
について報告した。Hiroki Takashima et al. (Biochemical Phyvac
Science 27@, p. 2631 (1978)) describes α-mono-p-myristyloxy-α in rats.
We reported on the antihyperlipidemic effect of -methylcinnamoylglycerol.
渡辺利部ら(Journal of Medicina
l Chemistry23巻、50頁(1980)
)は、p−アルコキシケイヒ酸とp−アルコキシ−α−
メチルケイヒ酸(但し、アルコキシのアルキル基はメチ
レン、ビニル及びC8〜C18:フェニル基);0−1
p−又はm−ミリスチルオキシケイヒ酸;m−メトキシ
−p−アルコキシ−α−メチルケイヒ酸(但し、アルコ
キシのアルキル基はC12とC14);1)−アルコキ
シケイヒ酸とp−アルコキシ−α−メチルケイヒ酸のエ
ステル誘導体〔アルコキシのアルキル基はメチレン、ビ
ニル、メチル、ブチル、C8〜C18;エステル基はク
ロルエチル、メタアクリルオキシエチル、モノグリセラ
イド、ジグリセライド等〕の金成法及びこれらの抗高脂
血症活性について詳細に報告した。更に渡辺利部ら(特
公昭51−45582号公報)はp−アルコキシ−α−
メチルケイヒ酸(但しアルコキシのアルキル基は08〜
C16)の製法を報告した。大田冨夫ら(特開昭57−
80370号公報)は、α−メチル−p−(ピリジル(
又はピリジルアルキル)オキシ〕−ケイヒ酸゛(又はケ
イヒ酸のC1〜C3のアルキルエステル)及びその製法
並びにこれらを含有する抗高脂血症剤について報告して
いる。Ribe Watanabe et al. (Journal of Medicina
l Chemistry vol. 23, p. 50 (1980)
) are p-alkoxycinnamic acid and p-alkoxy-α-
Methylcinnamic acid (however, the alkyl group of alkoxy is methylene, vinyl, and C8-C18: phenyl group); 0-1
p- or m-myristyloxycinnamic acid; m-methoxy-p-alkoxy-α-methylcinnamic acid (however, the alkyl groups of alkoxy are C12 and C14); 1)-alkoxycinnamic acid and p-alkoxy-α-methylcinnamic acid Detailed information on the preparation method of ester derivatives [alkoxy group is methylene, vinyl, methyl, butyl, C8 to C18; ester group is chloroethyl, methacryloxyethyl, monoglyceride, diglyceride, etc.] and their antihyperlipidemic activity. reported. Furthermore, Ribe Watanabe et al. (Special Publication No. 51-45582) p-alkoxy-α-
Methylcinnamic acid (however, the alkyl group of alkoxy is 08-
A method for producing C16) was reported. Tomio Ota et al.
80370) is α-methyl-p-(pyridyl (
or pyridylalkyl)oxy]-cinnamic acid (or a C1-C3 alkyl ester of cinnamic acid), a method for producing the same, and an antihyperlipidemic agent containing the same.
最近、ヘルミュト・グリルら(特開昭60−25953
号公報)はN−カルボキシメチル−4−(2−ヒドロキ
シ−4−フェニルブトキシ)ベンズアミド、4− (4
(4”−t−ブチルフェニル)−2−オキソブトキシ〕
安息香酸などのp−オキシ安息香酸誘導体、その製法及
び抗高脂血症剤について報告した。Recently, Helmuth Grill et al.
No. 4) is N-carboxymethyl-4-(2-hydroxy-4-phenylbutoxy)benzamide, 4-(4
(4”-t-butylphenyl)-2-oxobutoxy]
We reported on p-oxybenzoic acid derivatives such as benzoic acid, their production methods, and antihyperlipidemic agents.
発明が解決しようとする問題点:
本発明者らはシクロアルテノール、24−メチレンシク
ロアルタノール及びシクロブラノールの公知化合物につ
いての抗高脂血症効果の違試を行なった。抗高脂血症の
薬理試験方法は後述に示すB法(当初の体重100±1
gのWistar系雄ラットに飼料、水を自由摂取とし
た飼育期間4週間の方法−以下B法という。)で行なっ
た。なお、参考迄に示すと、抗高脂血症の薬理試験方法
のA法(当初の体重100±1gの一1star系雄ラ
ット−匹に対し、飼料の摂取量10g/日と制限した。Problems to be Solved by the Invention: The present inventors conducted a trial on the antihyperlipidemic effects of known compounds such as cycloartenol, 24-methylenecycloartanol, and cyclobranol. The pharmacological test method for antihyperlipidemia is Method B (initial body weight 100 ± 1
A method in which male Wistar rats (G) were reared for 4 weeks with free access to food and water - hereinafter referred to as Method B. ). For reference, method A of the pharmacological test method for antihyperlipidemia (feed intake was limited to 10 g/day for 1 star male rats with an initial body weight of 100±1 g).
但し、水は自由摂取とし、飼育期間2週間の方法−以下
A法という。)は先願(特許出願59−115306号
、出願日:昭和59年6月4日)で採用した方法であり
、これと区別のため、本発明ではB法という。又、血清
中の各脂質成分の測定方法は後述した。B法による公知
のトリテルペンアルコールの抗高脂血症試験結果は表−
1及び2に示した。However, water is allowed ad libitum and the rearing period is 2 weeks - hereinafter referred to as Method A. ) is the method adopted in the previous application (Patent Application No. 59-115306, filing date: June 4, 1982), and to distinguish it from this method, it is referred to as method B in the present invention. The method for measuring each lipid component in serum will be described later. The antihyperlipidemic test results of known triterpene alcohols using Method B are shown in Table-
1 and 2.
この表−1及び表−2かられかるように、高脂血症飼料
を投与したコントロール群に対し、シクロアルテノール
及びシクロブラノール投与群は有意(p < 0.01
)に血清中のTCの低下を認めた。As can be seen from Tables 1 and 2, the cycloartenol and cyclobranol administration group showed a significant difference (p < 0.01) compared to the control group administered hyperlipidemic feed.
), a decrease in serum TC was observed.
又、24−メチレンシクロアルタノール投与群も有意(
P < 0.05)なTCの低下を認めた。HDL−C
については、シクロアルテノールは有意(P<0.01
)に低下し、24−メチレンシクロアルタノールの低下
は僅少で有意な低下ではなかった。これに対し、シクロ
ブラノールは僅かな増加傾向を示すが有意な上昇ではな
かった。このHDL−Cについては前記文献に示すよう
に有意に増加することが望ましい。本発明化合物の抗高
脂血症剤創製の目的の1つは、血清中のTCを有意に低
下させると共にHDL−Cを有意に上昇させる点にある
。In addition, the 24-methylenecycloartanol administration group also had a significant effect (
A decrease in TC (P < 0.05) was observed. HDL-C
Cycloartenol was significant (P<0.01
), and the decrease in 24-methylenecycloartanol was slight and not significant. On the other hand, cyclobranol showed a slight increasing tendency, but the increase was not significant. It is desirable that this HDL-C increases significantly as shown in the above-mentioned literature. One of the objectives of creating an antihyperlipidemic agent using the compound of the present invention is to significantly lower TC and significantly increase HDL-C in serum.
前記に示すように、従前の文献結果と同じく、シクロア
ルテノール、シクロブラノール、24−メチレンシクロ
アルタノールなどの公知のトリテルペンアルコールの単
味は、血清中のTCを有意に低下させることを確認した
。然し、HDL−Cについては、本発明者らが実施した
A(特許出願昭59−115306号参照)及びB法の
両方法の飼育条件を異にする抗高脂血症試験方法によっ
ても有意な上昇は確認されなかった。AIについては、
3種のトリテルペンアルコールともに低下傾向を示した
。TG、PL及びLPOについては、3種のトリテルペ
ンアルコールは有意な変動を示さなかった。ただし、こ
れら3種のトリテルペンアルコールの比較では、シクロ
ブラノールはTC,AI、TG、PL、LPOの低下傾
向を示す一方、HDL−Cを上昇させ、シクロアルテノ
ール及び24−メチレンシクロアルタノールとは異なる
作用挙動を示した。即ち、シクロブラノールはシクロア
ルテノール及び24−メチレンシクロアルタノールより
すぐれた抗高脂血症効果を有することがわかった。As shown above, in line with previous literature results, it was confirmed that single doses of known triterpene alcohols such as cycloartenol, cyclobranol, and 24-methylenecycloartanol significantly lowered TC in serum. did. However, regarding HDL-C, the antihyperlipidemia test method conducted by the present inventors in which both Methods A (see patent application No. 115306/1982) and Method B, which differ in rearing conditions, showed no significant results. No increase was confirmed. Regarding AI,
All three types of triterpene alcohols showed a decreasing trend. For TG, PL and LPO, the three triterpene alcohols showed no significant variation. However, in a comparison of these three triterpene alcohols, cyclobranol showed a tendency to decrease TC, AI, TG, PL, and LPO, but it increased HDL-C, and compared with cycloartenol and 24-methylenecycloartanol. showed different action behavior. That is, cyclobranol was found to have a better antihyperlipidemic effect than cycloartenol and 24-methylenecycloartanol.
本発明者らは、トリテルペンアルコールの抗高脂血症効
果を改善するために詳細に検討した結果、すぐれた抗高
脂血症活性を持った多数の新規のトリテルペンアルコー
ル有機酸エステル化合物の存在を発見した。即ち、本発
明者らは血清中のTC1PLSTG含量を低下させる一
方でHDL−C含量を上昇させ、同時にAIを低下させ
、更に血清中のLPO含量も低下させる抗高脂血症剤の
創製を理想目標として研究した。次に6点の測定項目の
内、2乃至3点以上において出発原料の公知のトリテル
ペンアルコール及びT−オリザノールよりも抗高脂血症
効果の明らかな改善を示す抗高脂血症剤の創製について
鋭意検討した。その結果、本発明に示すトリテルペンア
ルコールの有機酸エステルがすぐれた抗高脂血症効果を
有することを見い出した。この事実は従来の公知のトリ
テルペンアルコール及び有機酸の単独又はγ−オリザノ
ールの性質からは想像することが困難なことである。As a result of detailed studies to improve the antihyperlipidemic effect of triterpene alcohols, the present inventors discovered the existence of a number of novel triterpene alcohol organic acid ester compounds with excellent antihyperlipidemic activity. discovered. That is, the present inventors ideally aim to create an antihyperlipidemic agent that lowers the TC1PLSTG content in serum while increasing the HDL-C content, simultaneously lowering AI, and further lowering the LPO content in the serum. I researched it as a goal. Next, we will discuss the creation of an antihyperlipidemic agent that exhibits clear improvement in antihyperlipidemic effects compared to known triterpene alcohols and T-oryzanol as starting materials in 2 to 3 or more of the 6 measurement items. I considered it carefully. As a result, it has been found that the organic acid ester of triterpene alcohol according to the present invention has excellent antihyperlipidemic effects. This fact is difficult to imagine from the conventionally known properties of triterpene alcohols and organic acids alone or of γ-oryzanol.
問題点を解決するための手段;
本発明の新規なトリテルペンアルコール有機酸エステル
は、シクロアルテノール、シクロブラノール、24−メ
チレンシクロアルタノール、ラノステロール、ラノステ
ノール、アグノステロール、シクロサドール、ジヒドロ
アグノステロール、シクロアルタノール、シクロアルタ
ノール、シクロユーカレノール、ユーホール、ブチロス
パーモール、チルカロール5、ユーホルボール又はダマ
ラジエノールの有機酸エステルである。これらの内、好
ましいのはシクロアルテノール、シクロブラノール、2
4−メチレンシクロアルタノールの有機酸エステルであ
る。その有機酸として好ましいのは、アミノ基、ニトロ
基、ヒドロキシ基、炭素数2〜5のアシルアミノ基、炭
素数1〜4のアルコキシ基又は炭素数2〜6のアルキル
カルボキシ基の一置換基をベンゼン核に結有するα一炭
素数1〜4のアルキルケイヒ酸;ヒドロキシ基と炭素数
1〜4のアルコキシ基、ヒドロキシ基と炭素数2〜6の
アルキルカルボキシ基、炭素数1〜4のアルコキシ基と
炭素数2〜6のアルキルカルボキシ基、炭素数1〜4の
アルコキシ基とニトロ基、炭素数1〜4のアルコキシ基
とアミノ基、炭素数1〜4のアルコキシ基と炭素数2〜
5のアシルアミノ基、炭素数1〜4のアルコキシ基の2
個、炭素数2〜6のアルキルカルボキシ基の2個又はヒ
ドロキシ基の2個の各二置換基をベンゼン核に結有する
α一炭素数1〜4のアルキルヶイヒ酸; 炭ff1M1
〜4のアルコキシ基とニトロ基、炭素数1〜4のアルコ
キシ基とアミノ基又は炭素数1〜4のアルコキシ基と炭
素数2〜5のアシルアミノ基の二置換基をベンゼン核に
結有するケイヒ酸又は安息香酸;炭素数4〜20の飽和
脂肪酸である。Means for solving the problems; The novel triterpene alcohol organic acid esters of the present invention include cycloartenol, cyclobranol, 24-methylenecycloartanol, lanosterol, lanosterol, agnosterol, cyclosadol, dihydroagnosterol, It is an organic acid ester of cycloartanol, cycloartanol, cycloeucalenol, euphor, butyrospermol, circalol 5, euphorbol or damaradienol. Among these, cycloartenol, cyclobranol, 2
It is an organic acid ester of 4-methylenecycloartanol. Preferred organic acids are amino groups, nitro groups, hydroxy groups, acylamino groups having 2 to 5 carbon atoms, alkoxy groups having 1 to 4 carbon atoms, or alkylcarboxy groups having 2 to 6 carbon atoms as a substituent in benzene. α-C1-C4 alkylcinnamic acid bonded to the nucleus; a hydroxy group and a C1-4 alkoxy group, a hydroxy group and a C2-6 alkylcarboxy group, a C1-4 alkoxy group Alkylcarboxy group having 2 to 6 carbon atoms, alkoxy group having 1 to 4 carbon atoms and nitro group, alkoxy group having 1 to 4 carbon atoms and amino group, alkoxy group having 1 to 4 carbon atoms and 2 to 4 carbon atoms
5 acylamino group, 2 of C 1-4 alkoxy group
α-alkylcarboxylic acid having 1 to 4 carbon atoms; carbon ff1M1 having two disubstituents of alkylcarboxy groups having 2 to 6 carbon atoms or two hydroxyl groups bonded to the benzene nucleus;
Cinnamate acid having a disubstituted group of ~4 alkoxy groups and a nitro group, a C1-4 alkoxy group and an amino group, or a C1-4 alkoxy group and a C2-5 acylamino group on a benzene nucleus or benzoic acid; a saturated fatty acid having 4 to 20 carbon atoms.
本発明化合物は安定な化合物である。実施例に示した製
法からも判明するようにpH0,5〜1.5の強酸性水
溶液で60〜70’Cに3時間加温攪拌しても加水分解
は全く受けない安定な化合物である。The compounds of the present invention are stable compounds. As is clear from the production method shown in the examples, it is a stable compound that does not undergo any hydrolysis even when heated and stirred at 60 to 70'C for 3 hours in a strongly acidic aqueous solution with a pH of 0.5 to 1.5.
本発明化合物において好ましい3種のトリテルペンアル
コールの有機酸エステルの構造式を以下に示す。The structural formulas of three preferred organic acid esters of triterpene alcohols in the compounds of the present invention are shown below.
(以下余白)
一般式1a、、Ib、IcにおいてRがHのとき、式1
aはシクロアルテノール、弐1bは24−メチレンシク
ロアルタノール、式Icはシクロブラノールである。こ
れら3種のトリテルペンアルコールは公知である。(Left below) When R is H in general formulas 1a, , Ib, and Ic, formula 1
a is cycloartenol, 21b is 24-methylenecycloartanol, and formula Ic is cyclobranol. These three types of triterpene alcohols are known.
本発明においてIa、Ib及びIcのRは前記に示した
各種の一塩基酸の有機酸の残基を表わす。In the present invention, R in Ia, Ib and Ic represents a residue of the various monobasic organic acids shown above.
これらの有機酸残基の内、04〜C20好ましくは06
〜016の飽和−塩基脂肪酸の残基以外の有機酸残基か
らなる本発明化合物を一般式■、■a〜d及びmeに示
す。Among these organic acid residues, 04 to C20, preferably 06
Compounds of the present invention comprising organic acid residues other than residues of saturated basic fatty acids of ~016 are shown in general formulas (1), (2) a to d, and me.
一般式
但し、R1はα−C1〜c4アルキル−α、β−不飽和
カルポニル基(−CH=C(R3)−Co−)を表わし
、R2はアミノ基(−NH2)、アシルアミノ基(−N
HCOR3)、ニトロ基(−NO2)、’ニーVo−t
’z基(−OH) 、炭素数1〜4のアルコキシ基(−
0R3)、又は炭素数2〜6のアルキルカルボキシ基(
−0COR4)を示す。R3は炭素数1〜4のアルキル
基、即ちメチル、エチル、プロピル、iso−プロピル
、ブチル、iso−ブチル、S−ブチル又はt−ブチル
である。R4は炭素数1〜5のアルキル基、即ち、前記
の炭素数1〜4のアルキル基の外にペンチル、130−
ペンチル、S−ペンチル、3−ペンチル又はt−ペンチ
ルかうなる。即ち、一般式(IF)はR2の一置換基が
ベンゼン核のオルト、メタ又はパラ位にそれぞれ結有す
るα一炭素数1〜4のアルキルヶイヒ酸のトリテルペン
アルコールエステルである。In the general formula, R1 represents an α-C1-C4 alkyl-α, β-unsaturated carbonyl group (-CH=C(R3)-Co-), and R2 represents an amino group (-NH2) or an acylamino group (-N
HCOR3), nitro group (-NO2), 'nee Vo-t
'z group (-OH), alkoxy group having 1 to 4 carbon atoms (-
0R3), or an alkylcarboxy group having 2 to 6 carbon atoms (
-0COR4). R3 is an alkyl group having 1 to 4 carbon atoms, ie methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, S-butyl or t-butyl. R4 is an alkyl group having 1 to 5 carbon atoms, that is, in addition to the above alkyl group having 1 to 4 carbon atoms, pentyl, 130-
Pentyl, S-pentyl, 3-pentyl or t-pentyl. That is, the general formula (IF) is a triterpene alcohol ester of an alkyl silicate having 1 to 4 carbon atoms, in which one substituent of R2 is bonded to the ortho, meta or para position of the benzene nucleus.
一般式
ただし、一般式m a w dのR1及びR3は前記と
同じ意味を表わす。General Formula However, R1 and R3 in the general formula m aw d represent the same meanings as above.
一般式
ただし、meのR5はα、β−不飽和カルボニル基(−
CH=CH−Co−)又はカルボニル基<−CO−>を
表わし、R3は前記と同じ意味を表わす。General formula: However, R5 of me is an α, β-unsaturated carbonyl group (-
CH=CH-Co-) or a carbonyl group <-CO->, and R3 has the same meaning as above.
一般式■aの化合物はベンゼン核にOH基とOR3基又
はOH基と0COR4基の異種の二置換基、一般式mb
の化合物はベンゼン核にOR3基と0COR4、NO2
、NH2又はNHCOR3基の異種の二置換基が結有す
るα−01〜4アルキルケイヒ酸のトリテルペンアルコ
ールエステルである。以下maとl1rbの化合物につ
いて詳細に説明する。The compound of general formula (a) has different disubstituted groups of OH group and OR3 group or OH group and 0COR4 group on the benzene nucleus, and general formula mb
The compound has OR3 groups, 0COR4, NO2 in the benzene nucleus.
, NH2 or NHCOR3 groups are triterpene alcohol esters of α-01-4 alkylcinnamic acid. The compounds ma and l1rb will be explained in detail below.
即ち、一般式maに示した化合物においてOH基がベン
ゼン核のオルト位(2位)に結合したとキニハ、OR3
又は0COR4基は3,4.5又は6位にそれぞれ結合
した化合物である。同様にOH基がベンゼン核のメタ位
(3位)に結合したときには、OR3基又は0COR4
基はベンゼン核の2.4.5又は6位にそれぞれ結合し
た化合物である。又、同様にOH基がベンゼン核のパラ
位(4位)に結合したときには、OR3基又は0COR
4基はベンゼン核の2又は3位にそれぞれ結合した化合
物である。(以下これらを一般式■aの化合物と略称す
る。)。これらmaの化合物群の個々の結合様式を下記
一般式ma1〜I[Ialoに示す。That is, in the compound shown in the general formula ma, the OH group is bonded to the ortho position (2 position) of the benzene nucleus, Kiniha, OR3
or a compound in which the 0COR4 group is bonded to the 3, 4.5 or 6 position, respectively. Similarly, when the OH group is bonded to the meta position (3rd position) of the benzene nucleus, OR3 group or 0COR4
The groups are compounds bonded to the 2, 4, 5 or 6 positions of the benzene nucleus, respectively. Similarly, when the OH group is bonded to the para-position (4-position) of the benzene nucleus, OR3 group or 0COR
The four groups are compounds each bonded to the 2nd or 3rd position of the benzene nucleus. (Hereinafter, these will be abbreviated as compounds of general formula (1)a.) The individual bonding modes of these ma compound groups are shown in the following general formulas ma1 to I[Ialo.
一般式
%式%)
0H
ただし一般式n[a1〜m a 10においてR1及び
R3は前記と同じ意味を示す。General formula % formula %) 0H However, in the general formula n[a1 to m a 10, R1 and R3 have the same meanings as above.
一般式mbの化合物群についての結合様式は、前記の一
般式maの化合物群のOH基がOR3基に代替され、且
つベンゼン核にOR3基と0COR4、NO2、NH2
又はNHCOR3基の異種二置換基を結合するα−01
〜4アルキルケイヒ酸のトリテルペンアルコールエステ
ルである。従って■b1は、I[alの化合物のOH基
の代わりにOR3基、又DIa1の化合物のOR3基又
は0COR4基の代わりに0COR4、NO2、NH2
又はNHCOR3基が代替結合した化合物である。The bonding mode for the compound group of the general formula mb is that the OH group of the compound group of the general formula ma is replaced with an OR3 group, and the benzene nucleus has an OR3 group and 0COR4, NO2, NH2
or α-01 binding a different disubstituted group of NHCOR3 group
It is a triterpene alcohol ester of ~4 alkylcinnamic acid. Therefore, ■b1 has an OR3 group instead of the OH group of the compound I[al, and 0COR4, NO2, NH2 instead of the OR3 group or 0COR4 group of the compound DIa1.
Or it is a compound in which three NHCOR groups are alternatively bonded.
以下mb2〜m b 10は同様であり、これらmb1
〜m b 1gの一般式を下記に示す。以下1[1bl
〜I[b toの化合物群における0COR4、NO2
、NH2又はNHCOR3基を総称しrXJと示す。The following mb2 to mb10 are the same, and these mb1
The general formula of ~m b 1g is shown below. Below 1[1bl
~I [0COR4, NO2 in the compound group of b to
, NH2 or NHCOR3 groups are collectively referred to as rXJ.
一般式
ただし一般式mb1〜m b 10においてRt及びR
3は前記と同じ意味を表わす。General formula However, in general formulas mb1 to mb10, Rt and R
3 represents the same meaning as above.
一般式mcの化合物は、ベンゼン核にOH基を2個、一
般式I[Idの化合物はベンゼン核にOR3基を2個結
有するα−01〜4のアルキルケイヒ酸のトリテルペン
アルコールエステルである。即ち一般式■cの化合物は
、ベンゼン核の2と3位、2と4位、2と5位、2と6
位、3と4位又は3と5位にOH基を2個結有し、下記
に示す6通りの結合物からなる。The compound of general formula mc is a triterpene alcohol ester of α-01 to 4 alkylcinnamic acid having two OH groups on the benzene nucleus, and the compound of general formula I[Id has two OR3 groups on the benzene nucleus. That is, the compound of general formula (c) has the 2nd and 3rd positions, the 2nd and 4th positions, the 2nd and 5th positions, and the 2nd and 6th positions of the benzene nucleus.
It has two OH groups at the 3rd and 4th positions, or the 3rd and 5th positions, and consists of the following six types of bonds.
一般式
又、一般式IIIdの化合物群の結合様式は、前記一般
式mc化合物のOH基2個の代わりにOR3基2個が代
替結合したものであり、m c 1〜mc6と同様にm
cti〜I[d5の61種の化合物が存在する。Furthermore, the bonding mode of the compound group of the general formula IIId is that two OR3 groups are substituted for the two OH groups of the general formula mc compound, and m
There are 61 compounds of cti to I[d5.
一般式I[eの化合物群においてNO2、NH2又はN
HCOR3基を総称しrYJと示したときの結合様式は
、前記mb1〜m b 1(、の一般式におけるR1基
の代わりにR5基、X基の代わりにY基がそれぞれ置換
結合したI[bl〜m b toと同じ10種の化合物
が存在する。In the group of compounds of general formula I[e, NO2, NH2 or N
When the HCOR3 groups are collectively referred to as rYJ, the bonding mode is I[bl There are 10 types of compounds that are the same as ~m b to.
以下、本発明化合物の製法について説明する。The method for producing the compound of the present invention will be explained below.
前記したγ−オリザノールはシクロアルテノール、24
−メチレンシクロアルタノール及びシクロブラノールの
好適な原料である。即ち、現在我が国で頭・頚部損傷治
療剤として市販されているγ−オリザノールは単品では
なく、各種のステロールとトリテルペンアルコールのフ
ェルラ酸エステルの混合物である。この成分比率の一例
を示すとカンペステロール14%、スチグマステロール
1%、β−シトステロール4%、シクロアルタノール2
%、シクロアルテノール35%、24−メチレンシクロ
アルタノール44%の各フェルラ酸エステルの混合組成
からなっている。The above-mentioned γ-oryzanol is cycloartenol, 24
- It is a suitable source of methylenecycloartanol and cyclobranol. That is, γ-oryzanol, which is currently commercially available in Japan as a therapeutic agent for head and neck injuries, is not a single product, but a mixture of various sterols and ferulic acid esters of triterpene alcohols. An example of this component ratio is campesterol 14%, stigmasterol 1%, β-sitosterol 4%, cycloartanol 2%.
%, cycloartenol 35%, and 24-methylenecycloartanol 44%.
シクロアルテノールの単離法:
即ち、T−オリザノールを遠藤、三栖、稲葉等〔油化学
18巻、63〜67頁(1969) )の方法を参考
として、アセトン−メタノール、アセトン、酢酸エチル
を用いて再結晶を繰り返し、シクロアルテノールフェル
ラ酸エステルを得、これをケン化分解することによりシ
クロアルテノール融点1ol〜102℃、比旋光度〔α
〕習・’ +49.7° (C1,01、CICl3
)を得た。このものはガスクロマトグラフィーで単一
ピークを示した。Isolation method of cycloartenol: That is, T-oryzanol was isolated using acetone-methanol, acetone, and ethyl acetate, with reference to the method of Endo, Misu, Inaba et al. Repeated recrystallization to obtain cycloartenol ferulic acid ester, which was saponified and decomposed to give cycloartenol with a melting point of 1 ol to 102°C and a specific optical rotation [α
] Xi・' +49.7° (C1,01, CICl3
) was obtained. This product showed a single peak in gas chromatography.
24−メチレンシクロアルタノールの単離法:前述の遠
藤ら〔油化学 18巻、63〜67頁(1969)〕の
方法に準じた。即ち、γ−オリザノールからシクロアル
テノールを分離した母液からの結晶をピリジン−無水酢
酸でアセチル化し、このアセチル化物をクロロホルム−
酢酸エチル−エタノール(4: 3 : 2)を用い再
結晶を繰り返し、脱アセチル化し、アセトン−メタノー
ル混合溶媒で再結晶し、24−メチレンシクロアルクノ
ールフェルラ酸エステルを得、これをケン化分解するこ
とにより24−メチレンシクロアルタノール融点123
〜124℃、比旋光度〔α〕智 +48.1° (C1
,00、C)IC13)を得た。このものはガスクロマ
トグラフィーで単一ピークを示した。Isolation method of 24-methylenecycloartanol: The method was based on the method of Endo et al. [Yuukagaku Vol. 18, pp. 63-67 (1969)]. That is, crystals from the mother liquor in which cycloartenol was separated from γ-oryzanol were acetylated with pyridine-acetic anhydride, and the acetylated product was purified with chloroform-acetic anhydride.
Repeated recrystallization using ethyl acetate-ethanol (4:3:2), deacetylation, recrystallization with acetone-methanol mixed solvent to obtain 24-methylenecycloalknolferulic acid ester, which was saponified and decomposed. Possibly 24-methylenecycloartanol melting point 123
~124℃, specific optical rotation [α] +48.1° (C1
,00,C)IC13) was obtained. This product showed a single peak in gas chromatography.
シクロブラノールの単離法:
γ−オリザノール1.1kg (シクロブラノール合量
0%)をアセトン8βに溶解し、ヨウ素40gを加え溶
解後1.5時間加熱還流した。放冷後、10%チオ硫酸
ナトリウム水溶液500−を加え30分攪拌したのち、
さらに水550−を加え析出した結晶をろ別した。これ
を2%チオ硫酸ナトリウム水溶液700−1続いて水4
2で洗浄し乾燥した。このT−オリザノールをガスクロ
マトグラフィーで分析の結果、シクロブラノールを約2
3%含有するγ−オリザノール1 kgを得た。この結
晶1 kgを4%カセイカリーエタノール溶液81に懸
濁し、3時間加熱還流した。放冷後、析出したγ−オリ
ザノールのカリウム塩をろ取し、続いてメタノール8I
tに懸濁し2時間加熱還流した。放冷後押出した黄色結
晶をろ取し乾燥後、γ−オリザノールのカリウム塩26
0gを得た。この結晶をカセイカリーエタノール溶液の
アルカリ濃度3%及び2%で前記処理を行い黄色結晶1
30gを得た。このものはシクロブラノールを88%含
有していた。引続き、黄色結晶130 gを2Nカセイ
カリーエタノール溶液2.61でケン化分解したのち残
渣をクロロホルム1゜21で抽出した。クロロホルム層
を乾燥後、減圧下に留去し粗シクロブラノール80g(
純度88%)を得た。この粗結晶80gをアセトン1.
61で再結晶を3回繰り返しシクロブラノールの結晶2
8gを得た。融点165〜166℃、比旋光度〔α〕管
+47.0° (C1,OQ、クロロホルム)。このも
のは、ガスクロマトグラフィーで単一のピークを示した
。Isolation method of cyclobranol: 1.1 kg of γ-oryzanol (total amount of cyclobranol 0%) was dissolved in 8β of acetone, 40 g of iodine was added, and after dissolution, the mixture was heated under reflux for 1.5 hours. After cooling, 10% sodium thiosulfate aqueous solution 500% was added and stirred for 30 minutes.
Furthermore, 550 g of water was added and the precipitated crystals were filtered out. Add this to 700-1 of a 2% sodium thiosulfate aqueous solution, followed by 4-4 of water.
2 and dried. As a result of gas chromatography analysis of this T-oryzanol, cyclobranol was found to be about 2
1 kg of γ-oryzanol containing 3% was obtained. 1 kg of this crystal was suspended in 4% caustic ethanol solution 81 and heated under reflux for 3 hours. After cooling, the precipitated potassium salt of γ-oryzanol was collected by filtration, and then methanol 8I
The mixture was suspended in water and heated under reflux for 2 hours. After cooling, the extruded yellow crystals were collected by filtration, dried, and potassium salt of γ-oryzanol 26
Obtained 0g. The crystals were treated as described above with caustic curry ethanol solution at alkali concentrations of 3% and 2%, and yellow crystals 1
30g was obtained. This contained 88% cyclobranol. Subsequently, 130 g of yellow crystals were saponified and decomposed with 2.6 g of a 2N caustic ethanol solution, and the residue was extracted with 1.2 g of chloroform. After drying the chloroform layer, it was distilled off under reduced pressure to obtain 80 g of crude cyclobranol (
A purity of 88%) was obtained. 80 g of this crude crystal was mixed with 1.0 g of acetone.
Repeat recrystallization three times at 61 to obtain cyclobranol crystal 2
8g was obtained. Melting point 165-166°C, specific rotation [α] tube +47.0° (C1, OQ, chloroform). This showed a single peak in gas chromatography.
本発明化合物のトリテルペンアルコール有機酸エステル
は一般のアルコールと有機酸との公知のエステル化反応
の利用により容易に得ることができる。即ち、硫酸、P
−)ルエンスルホン酸、三浦化硼素(BF3)などの触
媒を用いる脱水による有機酸とトリテルペンアルコール
のエステル化反応;硫酸、塩化亜鉛などの触媒の存在下
で有機酸無水物とトリテルペンアルコールの反応;有機
酸ハロゲナイド(有機酸ハロゲン化物ともいう。The triterpene alcohol organic acid ester of the compound of the present invention can be easily obtained by utilizing a known esterification reaction between a general alcohol and an organic acid. Namely, sulfuric acid, P
-) Esterification reaction of an organic acid and triterpene alcohol by dehydration using a catalyst such as luenesulfonic acid or boron Miura (BF3); reaction of an organic acid anhydride and triterpene alcohol in the presence of a catalyst such as sulfuric acid or zinc chloride; Organic acid halide (also called organic acid halide).
以下同じ意味である。)とトリテルペンアルコールとの
反応などが用いられる。これらの内、最も好ましいのは
有機酸ハロゲナイドとトリテルペンアルコールの反応に
よる方法である。即ち、06〜16の飽和脂肪酸の一塩
基酸;前記本発明化合物一般式■の有機酸の内、置換基
R2がNO2基、OR3基、・0COR4基又はNHC
OR3基の一置換基を結有するα−01〜4のアルキル
ケイヒ酸:前記一般式mbの化合物の有機酸でOR3基
と0COR4、NO2、Nl2又はNHCOR3基の計
2個;前記meの化合物の有機酸でOR3基とNO2、
Nl2又はNHCOR3基の計2個又はIIIdの化合
物の有機酸のようにOR3基の2個の置換基を結合する
ケイヒ酸、安息香酸又はα−C1〜4のアルキルケイヒ
酸を出発原料の有機酸とするときには、これらの有機酸
のC0OH基をハロゲン化試薬−にて酸ハロゲナイドと
したのち、この酸ハロゲナイドをトリテルペンアルコー
ル、脱ハロゲン化水素剤の存在下で溶媒中温度10〜1
00℃でエステル化反応させることにより目的の構造の
トリテルペンアルコール有機酸エステルが容易且つ高収
率で収得することができた。ハロゲン化試薬としては塩
化チオニル、塩化スルフリル、五塩化リン、オキシ塩化
リン、塩化ベンゾイル、塩化フタロイル、塩化水素又は
臭化水素などが好ましい。脱ハロゲン化水素剤としては
ピリジン、キノリン、トリメチルアミン、トリエチルア
ミン、トリプロピルアミン、トリブチルアミン、マグネ
シウム、ジメチルアニリンなどが用いられる。The following have the same meaning. ) and a triterpene alcohol. Among these, the most preferred method is the reaction of an organic acid halide with a triterpene alcohol. That is, a monobasic acid of a saturated fatty acid of 06 to 16; among the organic acids of the general formula (2) of the compound of the present invention, the substituent R2 is a NO2 group, an OR3 group, a .0COR4 group, or an NHC
α-01 to 4 alkylcinnamic acid having one substituent group of OR3 group: an organic acid of the compound of the general formula mb with a total of two OR3 groups and 0COR4, NO2, Nl2, or NHCOR3 group; of the compound of the above me OR3 group and NO2 with organic acid,
An organic acid starting from cinnamic acid, benzoic acid, or α-C1-4 alkylcinnamic acid that binds two substituents of the OR3 group, such as a total of two Nl2 or NHCOR3 groups or an organic acid of a IIId compound. In this case, the C0OH group of these organic acids is converted into an acid halide using a halogenating reagent, and then this acid halide is heated in a solvent at a temperature of 10 to 1
By carrying out the esterification reaction at 00°C, a triterpene alcohol organic acid ester having the desired structure could be obtained easily and in high yield. Preferred halogenating reagents include thionyl chloride, sulfuryl chloride, phosphorus pentachloride, phosphorus oxychloride, benzoyl chloride, phthaloyl chloride, hydrogen chloride, and hydrogen bromide. As the dehydrohalogenating agent, pyridine, quinoline, trimethylamine, triethylamine, tripropylamine, tributylamine, magnesium, dimethylaniline, etc. are used.
前、記一般式■の本発明化合物の有機酸の内、R2がo
IH基又はNl2基の一置換基を結有するα一炭素数1
〜4のアルキルケイヒ酸;前記11[aの本発明化合物
の有機酸のようにOH基とOR3基、OH基と0COR
3基の異種二置換基;■cの化合物の有機酸のようにO
H基の二置換基をベンゼン核に結有するα一炭素数1〜
4のアルキルケイヒ酸を出発原料とするときには、あら
かじめOH基又はNl2基をアシル化した有機酸を原料
とし、これを前記方法により酸ハロゲナイドとしたのち
、前記同様の操作法により目的構造のトリテルペンアル
コールの有機酸エステルを容易且つ高収率で収得する曇
とができる。しかる後、脱アシル化反応即ちアンモニア
、カセイアルカリ (カセイソーダ、カセイカリ)又は
無機酸(塩酸、硫酸、リン酸)の濃厚水溶液と加温処理
することにより、OH基又はNH2基をベンゼン核に結
有する本発明化合物の一般式■、■a又はmcの化合物
を容易に合成することができる。Of the organic acids of the compound of the present invention of general formula (3), R2 is o
α1 carbon number 1 having one substituent of IH group or Nl2 group
~4 alkylcinnamic acid; OH group and OR3 group, OH group and 0COR like the organic acid of the present invention compound of 11[a]
3 different disubstituents; ■O as in the organic acid of compound c
α1 carbon number 1 to 1 to bond the disubstituent of the H group to the benzene nucleus
When using the alkylcinnamic acid described in No. 4 as a starting material, use an organic acid in which the OH group or Nl2 group has been acylated in advance as a starting material, convert this into an acid halide by the method described above, and then convert it into a triterpene alcohol with the desired structure by the same procedure as described above. It is possible to easily obtain organic acid esters in high yields. After that, OH groups or NH2 groups are bonded to the benzene nucleus by deacylation reaction, that is, heating treatment with a concentrated aqueous solution of ammonia, caustic alkali (caustic soda, caustic potash), or inorganic acid (hydrochloric acid, sulfuric acid, phosphoric acid). Compounds of the general formula (1), (2)a or mc of the compounds of the present invention can be easily synthesized.
前記に示したアシル化は酢酸、プロピオン酸、酪酸又は
カプロン酸などの低級脂肪酸の酸無水物又は酸ハロゲナ
イドなどのアシル化剤を用いることにより容易に目的を
達成することができる。The above-mentioned acylation can be easily achieved by using an acylating agent such as an acid anhydride or acid halide of a lower fatty acid such as acetic acid, propionic acid, butyric acid or caproic acid.
又、本発明化合物一般式■、mb及びmeの内、NH2
基の1個、NH2基とOR3基又はNH2基と0COR
4基の2個を結有する本発明化合物群は、それぞれ対応
するNO2基をベンゼン核に結有するケイヒ酸、安息香
酸又はα−C1〜C4のアルキルケイヒ酸のトリテルペ
ンアルコールエステルを鉄又は亜鉛と酸(塩酸、硫酸、
酢酸)、スズ又は塩化スズと濃硫酸などの還元法により
NO2基のみが選択的に還元されてNH2基となる。こ
の金属と酸の還元法のときには、トリテルペンアルコー
ル基中に存在する不飽和基は還元されないので最良の還
元法である。In addition, among the compounds of the present invention whose general formulas are ①, mb and me, NH2
One of the groups, NH2 group and OR3 group or NH2 group and 0COR
The compound group of the present invention which has two of the four groups is a triterpene alcohol ester of cinnamic acid, benzoic acid, or α-C1 to C4 alkylcinnamic acid, each of which has a corresponding NO2 group attached to the benzene nucleus, and an acid with iron or zinc. (Hydrochloric acid, sulfuric acid,
Only NO2 groups are selectively reduced to NH2 groups using a reduction method such as acetic acid), tin or tin chloride, and concentrated sulfuric acid. This reduction method of metal and acid is the best reduction method because the unsaturated groups present in the triterpene alcohol group are not reduced.
次に、前記のアミノ署ヒ合物を通常の方法によりアシル
化すると、それぞれ対壺するところのNHCOR3基の
1個;NHCOR3基とOR3基又はNHCOR3基と
0COR4基の2個を結有する本発明化合物が容易に得
られる。Next, when the above-mentioned amino signed compound is acylated by a conventional method, one of the NHCOR3 groups to be paired with each other; the present invention which binds two of the NHCOR3 group and the OR3 group, or the NHCOR3 group and the 0COR4 group. The compound is easily obtained.
作 用:
本発明化合物の毒性及び抗高脂血症の薬理試験結果につ
いて、以下、詳細に説明する。Effect: The toxicity and antihyperlipidemic pharmacological test results of the compound of the present invention will be explained in detail below.
急性毒性試験:
体重30±2gのctay系雄マウス及び体重100±
2gのウィスター(Wistar)系雄うット各一群5
匹を用いて経口投与での急性毒性試験を行った。Acute toxicity test: ctay male mice weighing 30±2g and mice weighing 100±
5 each group of 2g Wistar male rats
An acute toxicity test using oral administration was conducted using rats.
例えば、急性毒性試験を実施した本発明化合物を下記に
示す。For example, compounds of the present invention for which acute toxicity tests were conducted are shown below.
実m例2(シクロアルテノール−4−ヒドロキシ−3−
メドキシーα−メチルケイヒ酸エステル)、実施例4(
シクロブラノール−4−ヒドロキシ−3−メトキシ−α
−メチルケイヒ酸エステル)、実m例6 (24−メチ
レンシクロアルタノール−4−ヒドロキシ−3−メトキ
シ−α−メチルケイヒ酸エステル)、
実施例8(シクロアルテノール−4−ヒドロキシ−3−
メトキシ−α−エチルケイヒ酸エステル)、実施例28
(シクロブラノール−3−エトキシ−4−ヒドロキシ−
α−メチルケイヒ酸エステル)、実施例18(シクロア
ルテノール−4−ヒドロキシ−α−エチルケイヒ酸エス
テル)、
実施例34(シクロアルテノール−4−ヒドロキシ−3
−プロポキシ−α−メチルケイヒ酸エステル)、実施例
55(シクロアルテノール−4−アミノ−3−メトキシ
安息香酸エステル)、
実施例61(シクロブラノール−5−アミノ−2−メト
キシ安息香酸エステル)、
実施例77(シクロアルテノール−4−アミノ−3−メ
トキシ−α−メチルケイヒ酸エステル)、実施例65(
シクロアルテノール−4−アミノ−3−メトキシケイヒ
酸エステル)、
実施例93(シクロアルテノール−p−アミノ−α−メ
チルケイヒ酸エステル)、
実施例71(シクロアルテノール−5−アミノ−2−ニ
トキシケイヒ酸エステル)、
実施例100(シクロプラノ−ルートアミノ−α−メチ
ルケイヒ酸エステル)、
実j4例79(24−メチレンシクロアルタノール−4
−アミノ−3−メトキシ−α−メチルケイヒ酸エステル
)、
実施例85(24−メチレンシクロアルタノール−5=
アミノ−2−プロポキシ−α−メチルケイヒ酸エステル
)、
実施例59(シクロアルテノール−5−アミノ−2−メ
トキシ安息香酸エステル)、
実施例58(シクロアルテノール−2−メトキシ−5−
二トロ安息香酸エステル)、
実施例66(シクロブラノール−4−アミノ−3−メト
キシケイヒ酸エステル)、
実施例83(シクロアルテノール−5−アミノ−2−プ
ロポキシ−α−メチルケイヒ酸エステル)、実施例10
1 (24−メチレンシクロアルタノール−m−アミ
ノ−α−メチルケイヒ酸エステル)、実施例1 (シク
ロアルテノール−3−メトキシ−4−プロピオニルオキ
シ−α−メチルケイヒ酸エステル)、
実施例5(24−メチレンシクロアルタノール−3−メ
トキシ−4−プロピオニルオキシ−α−メチルケイヒ酸
エステル)、
の23種及び対照薬のシクロアルテノール、24−メチ
レンシクロアルタノール、シクロブラノール及びT−オ
リザノールの服用量を0.1g/kgから6g/kgに
増加して前記のマウス(0,1から5g/kg)及びラ
ット(2から6g/kg)に咽喉さぐり棒で強制投与に
よって個々に投薬した。試験期間 −中動物は動物室温
度22〜23℃に維持し、投薬後14日間観察した。投
薬された服用量で死亡は全く認められなかった。投薬後
の中毒症及び行動を経時的に観察したが、正常動物群と
何等の相違は認められなかった。又、体重増加も正、常
動物群と差はなかった。試験後に実施した検視において
主要層管のいかなる部分にも何等巨視的障害は認められ
なかった。従って、本発明化合物は非常に低い毒性のた
めにL D so値を決定することができなかった。Practical example 2 (cycloartenol-4-hydroxy-3-
Medoxy α-methyl cinnamic acid ester), Example 4 (
Cyclobranol-4-hydroxy-3-methoxy-α
Example 6 (24-methylenecycloartanol-4-hydroxy-3-methoxy-α-methylcinnamic acid ester), Example 8 (cycloartenol-4-hydroxy-3-
methoxy-α-ethylcinnamic acid ester), Example 28
(Cyclobranol-3-ethoxy-4-hydroxy-
α-methyl cinnamic acid ester), Example 18 (cycloartenol-4-hydroxy-α-ethyl cinnamic acid ester), Example 34 (cycloartenol-4-hydroxy-3
-propoxy-α-methylcinnamic acid ester), Example 55 (cycloartenol-4-amino-3-methoxybenzoic acid ester), Example 61 (cyclobranol-5-amino-2-methoxybenzoic acid ester), Example 77 (cycloartenol-4-amino-3-methoxy-α-methylcinnamic acid ester), Example 65 (
cycloartenol-4-amino-3-methoxycinnamic acid ester), Example 93 (cycloartenol-p-amino-α-methyl cinnamic acid ester), Example 71 (cycloartenol-5-amino-2-nitoxycinnamic acid ester) (acid ester), Example 100 (cycloprano-root amino-α-methyl cinnamic acid ester), Example 79 (24-methylenecycloartanol-4
-amino-3-methoxy-α-methylcinnamic acid ester), Example 85 (24-methylenecycloartanol-5=
Example 59 (cycloartenol-5-amino-2-methoxybenzoic acid ester), Example 58 (cycloartenol-2-methoxy-5-
nitrobenzoic acid ester), Example 66 (cyclobranol-4-amino-3-methoxycinnamic acid ester), Example 83 (cycloartenol-5-amino-2-propoxy-α-methyl cinnamic acid ester), Example 10
1 (24-methylenecycloartanol-m-amino-α-methylcinnamic acid ester), Example 1 (cycloartenol-3-methoxy-4-propionyloxy-α-methylcinnamic acid ester), Example 5 (24- (methylenecycloartanol-3-methoxy-4-propionyloxy-α-methylcinnamic acid ester), and the control drugs cycloartenol, 24-methylenecycloartanol, cyclobranol, and T-oryzanol. The mice (0.1 to 5 g/kg) and rats (2 to 6 g/kg) were dosed individually by gavage with a throat probe in increasing doses from 0.1 to 6 g/kg. During the test period, animals were maintained at an animal room temperature of 22-23° C. and observed for 14 days after dosing. No deaths were observed at the doses administered. Toxicity and behavior after administration were observed over time, but no differences were observed from the normal animal group. In addition, the weight gain was also normal, and there was no difference from the normal animal group. A post-test necropsy did not reveal any macroscopic damage to any part of the main laminar canal. Therefore, it was not possible to determine L Dso values for the compounds of the present invention due to their very low toxicity.
抗高脂血症薬理試験のB方法:
1)動物:
体重100±1gのWistar系雄性ラットを使用し
た。Method B of antihyperlipidemic pharmacology test: 1) Animal: Male Wistar rats weighing 100±1 g were used.
2)飼料:
普通食は日本タレア社製粉末飼料(CE−2)とし、高
脂血症食は普通食飼料にコレステロール1%及びコール
酸0.5%を添加した。薬物はこの高脂血症食飼料に各
1%を添加してラットに投与した。2) Feed: The normal diet was a powdered feed (CE-2) manufactured by Nippon Talea, and the hyperlipidemic diet was a normal diet supplemented with 1% cholesterol and 0.5% cholic acid. The drugs were added to this hyperlipidemic diet at 1% each and administered to rats.
3)飼育条件:
1群8匹(ただし、高脂血症食コントロール群のみ一群
16匹)として各飼料で4週間飼育した。3) Rearing conditions: Groups of 8 animals (however, only the hyperlipidemic diet control group had 16 animals per group) were raised on each diet for 4 weeks.
1ケージにラット2匹を入れ、飼料及び水は自由摂取と
した。温度23±1℃及び湿度55±5%の恒温恒温で
4週間飼育した。実験開始後29日目(28日目の午後
4時から29日の午前8時までの16時間、水辺外は絶
食させた。)のラットをベントパルビタールナトリウム
〔商品名:ネンプタール(Nembutal) )を用
いた麻酔下で腹部下行大動脈より採血し、血清中のTC
,HDL−C,TG。Two rats were placed in each cage, and food and water were available ad libitum. The animals were kept at a constant temperature of 23±1°C and humidity of 55±5% for 4 weeks. On the 29th day after the start of the experiment (the rats were fasted from water for 16 hours from 4:00 pm on the 28th day to 8:00 am on the 29th day), rats were treated with bentoparbital sodium [trade name: Nembutal]. Blood was collected from the abdominal descending aorta under anesthesia using
, HDL-C, TG.
PL、LPOを下記の方法により測定した。PL and LPO were measured by the following methods.
血清TC値の測定法:
TCCキラ−K (製造販売元:日本商事株式会社)に
よった。本測定原理は血清中のエステルコレステロール
はコレステロールエステルヒドロラーゼにより遊離コレ
ステロールと脂肪酸に加水分解し、遊離コレステロール
のすべてをコレステロールオキシダーゼにより酸化させ
てΔ4−コレステノンと過酸化水素を生成せしめる。生
成した過酸化水素とパーオキシダーゼによりフェノール
と4−アミノアンチピリンを酸化縮合させ、生成した赤
色キノン色素を分光光度計500nmで比色定量して吸
光度を求めてTC値を測定する方法である。Measurement method of serum TC value: TCC Killer-K (Manufacturer: Nippon Shoji Co., Ltd.) was used. The principle of this measurement is that ester cholesterol in serum is hydrolyzed into free cholesterol and fatty acids by cholesterol ester hydrolase, and all of the free cholesterol is oxidized by cholesterol oxidase to produce Δ4-cholestenone and hydrogen peroxide. In this method, phenol and 4-aminoantipyrine are oxidatively condensed using the generated hydrogen peroxide and peroxidase, and the generated red quinone dye is colorimetrically determined using a spectrophotometer at 500 nm to determine the absorbance and TC value.
使用呈色試液の調製:
呈色試薬:1バイアル(成分:コレステロールエステラ
ーゼ25.000u、コレステロールオキシダーゼ25
u1パーオキシダーゼ3.554u 、 4−アミノア
ンチピリン20■含む)
緩衝液:成分100−中、フェノール33.3■、リン
酸二水素カリウム489.9■、無水リン酸−水素ナト
リウム908.5■を精製水に溶解。Preparation of color reagent used: Color reagent: 1 vial (components: cholesterol esterase 25.000 u, cholesterol oxidase 25
(Contains 3.554 μ of u1 peroxidase, 20 μ of 4-aminoantipyrine) Buffer: 33.3 μ of phenol, 489.9 μ of potassium dihydrogen phosphate, and 908.5 μ of sodium phosphate-hydrogen anhydride in 100 μ of ingredients. Dissolved in purified water.
標準液:成分100−中、コレステロール300■含む
。Standard solution: Contains 300 μm of cholesterol in 100% of components.
前記呈色試薬1バイアルを緩衝液160−に熔解したも
のを使用呈色試液という。A solution prepared by dissolving one vial of the coloring reagent in a buffer solution 160 is referred to as the coloring reagent used.
検体の血清0.021R1に使用呈色試液3.0−を加
え、よく混和し、37℃で15分間加温後、分光光度計
500nmで吸光度を測定した値をEAとする。別個に
標準液0.02艷に使用呈色試液3.0−を加え、よく
混和し、37℃で15分間加温後、分光光度計500n
mで吸光度を測定した値をESとする。このEA及びE
S共に使用呈色試液3.0艷の盲検を対照に測定する。Add 3.0 - of the coloring test solution used to 0.021 R1 of the serum of the specimen, mix well, and after heating at 37° C. for 15 minutes, measure the absorbance with a spectrophotometer at 500 nm. The value is defined as EA. Separately, add 3.0 - of the coloring test solution used to 0.02 - of the standard solution, mix well, heat at 37°C for 15 minutes, and then use a spectrophotometer at 500 nm.
The value obtained by measuring the absorbance at m is defined as ES. This EA and E
Measurement is performed using a blind test of 3.0 liters of the coloring test solution used for both S and S.
血清HDL−C値の測定法:
HDL−Cキラt−−N (製造販売元:日本商事株式
会社)によって測定した。即ち血清中の超低比重リポ蛋
白(VLDL) 、低比重リポ蛋白(LDL)をカルシ
ウムイオンの存在でヘパリンの作用により、沈澱物を形
成せしめて、遠心分離し、上清中に高比重リポ蛋白(H
DL)を溶存させる。Measurement method of serum HDL-C value: Measured by HDL-C Kira t--N (manufacturer: Nippon Shoji Co., Ltd.). That is, very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) in serum are formed into a precipitate by the action of heparin in the presence of calcium ions, and then centrifuged, high-density lipoproteins are dissolved in the supernatant. (H
DL) is dissolved.
この分画中のエステルコレステロールはコレステロール
エステルヒドロラーゼにより遊離コレステロールと脂肪
酸に加水分解し、すべての遊離コレステロールはコレス
テロールオキシダーゼにより酸化してΔ4−コレステノ
ンと過酸化水素を生成せしめる。生成した過酸化水素と
パーオキシダーゼによりフェノールと4−アミノアンチ
ピリンを酸化結合させて生成した赤色キノン色素を分光
光度計で500ns+における吸光度を測定することに
よりHDL−Cの合量を求めた。The ester cholesterol in this fraction is hydrolyzed to free cholesterol and fatty acids by cholesterol ester hydrolase, and all free cholesterol is oxidized by cholesterol oxidase to produce Δ4-cholestenone and hydrogen peroxide. The total amount of HDL-C was determined by measuring the absorbance at 500 ns+ of the red quinone dye produced by oxidative bonding of phenol and 4-aminoantipyrine using the produced hydrogen peroxide and peroxidase using a spectrophotometer.
血清PL値の測定法:
PLキン)−K (製造販売元:日本商事株式会社)に
より測定した。血清中のレシチン、スフィンゴミエリン
、リゾレシチンはホスホリパーゼDにより、コリン、ホ
スファチジン酸、N−アシルスフィンゴシルホスフェー
ト及びリゾホスファチジン酸にそれぞれ分解される。生
成したコリンはコリンオキシダーゼにより酸化され定量
的に過酸化水素とベタインを生成する。この過酸化水素
はパーオキシダーゼによりフェノールと4−アミノアン
チピリンを酸化縮合させて生成した赤色キノン色素を分
光光度針で500nmにおける吸光度を測定することに
よりPLの含量を求めた。Measuring method of serum PL value: Measured by PL Kin)-K (Manufacturer: Nippon Shoji Co., Ltd.). Lecithin, sphingomyelin, and lysolecithin in serum are decomposed by phospholipase D into choline, phosphatidic acid, N-acylsphingosyl phosphate, and lysophosphatidic acid, respectively. The produced choline is oxidized by choline oxidase to quantitatively produce hydrogen peroxide and betaine. The PL content of this hydrogen peroxide was determined by measuring the absorbance at 500 nm of a red quinone dye produced by oxidative condensation of phenol and 4-aminoantipyrine using peroxidase using a spectrophotometric needle.
血清TG値の測定法:
血清中のTGをアセチルアセトンを用いるトリグリセラ
イドテストキット(製造販売元:和光純薬工業株式会社
)により測定した。即ち、血清にイソプロピルアルコー
ルを加えて混合すると蛋白は沈澱し、血清中の脂質なら
びに糖などはイソプロピルアルコールに移行させて吸着
剤を加え、呈色妨害物質を吸着させ、遠心分離したのち
上清の一部に水酸化カリウムを加えるとトリグリセライ
ドは鹸化され、グリセリンを遊離する。次に緩衝液を加
え、pH6にしたのち、メタ過ヨウ素ナトリウム液を加
えてグリセリンを1分子のギ酸と2分子のホルムアルデ
ヒドに酸化させる。生成したホルムアルデヒドはアセチ
ルアセトン及び緩衝液中のアンモニアと反応して環状化
合物の3,5−ジアセチル−1,4−ジヒドロルチジン
(3+5−diacetyl−1+ 4−dihydr
olutidine)を生じ、この黄色色素を分光光度
針で410nmにおける吸光度を測定することによりト
リグリセライドの含量を求めた。Method for measuring serum TG value: TG in serum was measured using a triglyceride test kit (manufacturer: Wako Pure Chemical Industries, Ltd.) using acetylacetone. That is, when isopropyl alcohol is added to serum and mixed, proteins are precipitated, lipids and sugars in the serum are transferred to isopropyl alcohol, an adsorbent is added, substances that interfere with coloration are adsorbed, and after centrifugation, the supernatant is When potassium hydroxide is added to a portion, the triglyceride is saponified and glycerin is liberated. Next, a buffer solution is added to adjust the pH to 6, and then a sodium metaperiodate solution is added to oxidize the glycerin into one molecule of formic acid and two molecules of formaldehyde. The generated formaldehyde reacts with acetylacetone and ammonia in the buffer to form a cyclic compound, 3,5-diacetyl-1,4-dihydrortidine (3+5-diacetyl-1+ 4-dihydr).
The triglyceride content was determined by measuring the absorbance of this yellow pigment at 410 nm using a spectrophotometric needle.
血清LPO値の測定法:
八木式チオバルビッール酸法〔八木国人Bioch−e
n+、Med、 15巻、212頁(1976) 、八
木国人 ビタミン49巻、403頁(1975) )の
Lipoperoxideテストキット(製造販売元:
和光純薬工業株式会社)によって測定した。即ち、生理
食塩水1.0rnlに血清0.05−を加え、ゆるやか
に攪拌後、遠心分離(3,OOOrpm、 10分間)
し、上清0.5−にN/12硫酸4.OWI!を加え、
よく混合する。これに10%リンタングステン酸水溶液
0.5dを加え、よく攪拌し、室温に5分間放置したの
ち、遠心分離(3,000rpn+。Measuring method of serum LPO level: Yagi thiobarbic acid method [Kunito Yagi Bioch-e
n+, Med, Vol. 15, p. 212 (1976), Kunito Yagi, Vitamin Vol. 49, p. 403 (1975)) Lipoperoxide test kit (Manufacturer:
(Wako Pure Chemical Industries, Ltd.). That is, 0.05ml of serum was added to 1.0rnl of physiological saline, stirred gently, and then centrifuged (3,00 rpm, 10 minutes).
and add 4.0% N/12 sulfuric acid to the supernatant. OWI! Add
Mix well. Add 0.5 d of 10% phosphotungstic acid aqueous solution to this, stir well, leave at room temperature for 5 minutes, and centrifuge (3,000 rpm+).
10分間)する。得た沈澱物をN/12硫酸2.0−と
10%リンタングステン酸水溶液0.3−を加えて沈澱
をミキサーでよく懸濁させる。次に遠心分離(3,00
Orpm、 10分間)し、沈澱物に蒸留水4.0−を
加えてミキサーでよく懸濁させる。次にTBA試薬(5
0%酢酸溶液、2−チオバルビッール酸を含有する)
1.Omeを加えてよく混合し、遠心管上端にガラス
玉を置き、沸騰水浴中で60分間加熱したのち、流水中
で5分間冷却する。次にn−ブタノール5.0ml!を
加え共栓をつけ、20秒間ミキサーでよく混合し、抽出
して遠心分離(3,00Orpm、 10分間)し、上
層のn−ブタノール層について螢光測定を行う。試薬盲
検“を用いて螢光測定の零点を調整したのち、標準液(
1,1,3,3−テトラエトキシプロパン5 nmol
/me) 0.1−の螢光強度(F)ならびに検体の
螢光強度(f)を螢光光度針で励起波長515nm、螢
光波長553nmによって測定した。10 minutes). To the obtained precipitate are added 2.0 mm of N/12 sulfuric acid and 0.3 mm of a 10% aqueous phosphotungstic acid solution, and the precipitate is thoroughly suspended using a mixer. Next, centrifugation (3,000
Orpm for 10 minutes), add 4.0 mL of distilled water to the precipitate, and suspend well with a mixer. Next, TBA reagent (5
0% acetic acid solution, containing 2-thiobarbic acid)
1. Add Ome, mix well, place a glass ball on the top of the centrifuge tube, heat in a boiling water bath for 60 minutes, and then cool in running water for 5 minutes. Next, 5.0ml of n-butanol! Add the solution, put on a stopper, mix thoroughly with a mixer for 20 seconds, extract and centrifuge (3,000 rpm, 10 minutes), and measure the fluorescence of the upper n-butanol layer. After adjusting the zero point of fluorescence measurement using a reagent blind test, the standard solution (
1,1,3,3-tetraethoxypropane 5 nmol
/me) 0.1- and the fluorescence intensity (f) of the specimen were measured with a fluorometry needle at an excitation wavelength of 515 nm and a fluorescence wavelength of 553 nm.
即ち、本性においてはLPOとチオバルビツール酸との
反応生成物がマロンジアルデヒドとチオバルビッール酸
との反応生成物と同じである。従ってLPOの濃度は、
血清1−中のマロンジアルデヒド量として求めた。標準
液は定量的にマロンジアルデヒドを与える1、1,3.
3−テトラエトキシプロパン5 nmol/−の水溶液
であり、測定には標準液0.1−を使用するので1.1
.3.3−テトラエトキシプロパンは0.5nmolを
使用したことになり、従ってLPO含量は次式により算
出させる。That is, in nature, the reaction product of LPO and thiobarbituric acid is the same as the reaction product of malondialdehyde and thiobarbituric acid. Therefore, the concentration of LPO is
It was determined as the amount of malondialdehyde in serum 1-. Standard solutions give malondialdehyde quantitatively 1, 1, 3.
It is an aqueous solution of 5 nmol/- of 3-tetraethoxypropane, and since 0.1- of the standard solution is used for measurement, it is 1.1
.. 0.5 nmol of 3.3-tetraethoxypropane was used, so the LPO content was calculated by the following formula.
LPO含量(nmol/−血清)
抗高脂血症の薬理試験結果:
高コレステロール食又は普通食負荷ラットを用い、血清
脂質及び血清過酸化脂質に対する代表的本発明化合物即
ち、急性毒性と同じ化合物の活性作用について報告する
。LPO content (nmol/-serum) Antihyperlipidemia pharmacological test results: Using rats fed with high cholesterol diet or normal diet, typical compounds of the present invention on serum lipids and serum lipid peroxides, i.e., the same compound as acute toxicity. We will report on the active effects.
対照薬として用いたシクロアルテノール、24−メチレ
ンシクロアルタノール及びシクロブラノールの抗高脂血
症試験の結果は表−1及び表−2に示した。これらの効
果についての説明は前記した。The results of the antihyperlipidemia test of cycloartenol, 24-methylenecycloartanol, and cyclobranol used as control drugs are shown in Tables 1 and 2. These effects have been explained above.
又、B法による本発明化合物及び対照薬としてシクロア
ルテノール、シクロブラノール、24−メチレンシクロ
アルタノール及びγ−オリザノールの抗高脂血症効果を
表−3〜表−8に示した。Furthermore, the antihyperlipidemic effects of the compounds of the present invention and control drugs cycloartenol, cyclobranol, 24-methylenecycloartanol, and γ-oryzanol according to Method B are shown in Tables 3 to 8.
普通食を投与したコントロール群は、高脂血症飼料を投
与したコントロール群に対し、TC,PL及びLPOに
ついて例外なく有意(P < 0.001 )な低下を
示し、一方、HDL−Cは有意(P<0.001 )な
増加を示した。然し、TGについては低下傾向を示した
が、有意差は認められなかった。The control group fed a normal diet showed significant (P < 0.001) decreases in TC, PL, and LPO without exception, compared to the control group fed a hyperlipidemic diet, while HDL-C significantly decreased. (P<0.001). However, although TG showed a decreasing tendency, no significant difference was observed.
高脂血症飼料中に本発明化合物又は対照薬を添加した群
は、高脂血症飼料を投与したコントロール群に対し明ら
かに血清脂質成分の改善が認められた。特に、本発明化
合物群は対照葉群より明らかに血清脂質のTC,HDL
−C,PL、LPOの2以上の成分を改善した。In the group to which the compound of the present invention or the control drug was added to the hyperlipidemic feed, a clear improvement in serum lipid components was observed compared to the control group to which the hyperlipidemic feed was administered. In particular, the compound group of the present invention significantly lowered serum lipids such as TC and HDL than the control leaf group.
- Two or more components of C, PL, and LPO were improved.
即ち、TCについては、対照薬のトリテルペンアルコー
ル及びT−オリザノールは高脂血症飼料を投与したコン
トロール群に対し、有意(p<0.01)な低下を認め
た。これに対し、本発明化合物の実施例2.4.6.7
7.93.100.79.85.59.66.83及び
101は、有意(P < 0.001 )な低下を認め
、又、実施例8.28.18.34.55.61.65
.71.58.1及び5の化合物は有意(P < 0.
01)な低下を認めた。That is, regarding TC, the control drugs triterpene alcohol and T-oryzanol showed a significant (p<0.01) decrease compared to the control group administered with hyperlipidemic feed. In contrast, Example 2.4.6.7 of the compound of the present invention
7.93.100.79.85.59.66.83 and 101 showed a significant (P < 0.001) decrease, and Example 8.28.18.34.55.61.65
.. Compounds 71.58.1 and 5 were significant (P<0.
01) was observed.
HDL−Cについては、対照薬のシクロアルテノールが
有意(P<0.01)な低下を示したが、シクロブラノ
ール、24−メチレンシクロアルタノール及びγ−オリ
ザノールは僅少な増加乃至減少傾向を示したが、有意差
は認められなかった。これに対し、本発明化合物の実施
例2.4.6.28.34.55.61.77.65.
93、100及び101は有意(P < 0.001
)な上昇を認め、実施例8.18.71.79.85.
59.66.83.1及び5の化合物は有意(P <
0.01)な上昇を認め、実施例58の化合物は有意(
P < 0.05)な上昇を認めた。特に注目すべきこ
とは、実施例4.6.28.55.61.58.66.
83及び101の化合物は普通食投与群よりも顕著な上
昇を認めたことである。Regarding HDL-C, the control drug cycloartenol showed a significant (P<0.01) decrease, but cyclobranol, 24-methylenecycloartanol, and γ-oryzanol showed a slight tendency to increase or decrease. However, no significant difference was observed. In contrast, Example 2.4.6.28.34.55.61.77.65 of the compound of the present invention.
93, 100 and 101 are significant (P < 0.001
) was observed, and Example 8.18.71.79.85.
Compounds 59.66.83.1 and 5 were significant (P <
The compound of Example 58 showed a significant increase (0.01).
A significant increase (P < 0.05) was observed. Of particular note is Example 4.6.28.55.61.58.66.
Compounds 83 and 101 showed a more significant increase than the normal food administration group.
AIについては、対照薬及び本発明化合物ともに低下傾
向を示すが、特に本発明化合物は顕著な低下を示した。Regarding AI, both the control drug and the compound of the present invention showed a decreasing tendency, but the compound of the present invention showed a particularly remarkable decrease.
TGについては、対照薬及び本発明化合物ともに僅少乃
至ある程度の低下傾向を示したが、有意差は認められな
かった。Regarding TG, both the control drug and the compound of the present invention showed a slight to some degree of decreasing tendency, but no significant difference was observed.
PLについては、対照薬は僅少な低下傾向を示したが、
有意な低下ではなかった。これに対し、本発明化合物の
実施例2.4.6.28.34.59.83及び101
の化合物は有意(P<0.001)な低下を示し、実施
例8.18.77.93.100.79.85.58.
66.1及び5の化合物は有意(P < 0.01)な
低下を示し、実施例55.61.65及び71の化合物
は有意(P < 0.05)な低下を認めた。Regarding PL, the control drug showed a slight tendency to decrease;
It was not a significant decrease. In contrast, Examples 2.4.6.28.34.59.83 and 101 of the compounds of the present invention
Compounds of Example 8.18.77.93.100.79.85.58 showed a significant (P<0.001) reduction.
Compounds 66.1 and 5 showed a significant (P<0.01) decrease, and compounds of Examples 55.61.65 and 71 showed a significant (P<0.05) decrease.
LPOについては、対照薬のγ−オリザノールは有意(
p < 0.01)な低下を示し、3種のトリテルペン
アルコールは有意な低下ではないが、明らかな低下傾向
を示した。これに対し、本発明化合物の実施例2.4.
6.8.28.18.34.77.93.100、71
.79.85.59.66.83及び101は有意(P
< 0.001 )な低下を認め、実施例55.61
.65.58.1及び5の化合物は有意(P < 0.
01)な低下を認めた。For LPO, the control drug γ-oryzanol showed a significant (
p < 0.01), and the three types of triterpene alcohols showed a clear decreasing trend, although the decrease was not significant. In contrast, Example 2.4 of the compound of the present invention.
6.8.28.18.34.77.93.100, 71
.. 79.85.59.66.83 and 101 are significant (P
<0.001) was observed, and Example 55.61
.. Compounds 65.58.1 and 5 were significant (P<0.
01) was observed.
前記に示すように、本発明化合物は多くの場合、HDL
−Cが明らかに増加する一方、TC,AI、PL、LP
Oについて明らかな低下傾向が認められた。即ち、本発
明化合物は遊離のトリテルペンアルコール単味投与に比
較して、抗高脂血症活性が相乗的効果であることは明ら
かである。As indicated above, the compounds of the present invention often have HDL
-C clearly increases, while TC, AI, PL, LP
A clear downward trend in O was observed. That is, it is clear that the antihyperlipidemic activity of the compound of the present invention is synergistic compared to administration of free triterpene alcohol alone.
本抗高脂血症試験におけるラットの体重増加例を表−9
及び10に示した。普通食投与群の体重増加は、高脂血
症食を投与したコントロール群に対し有意(P < 0
.001 )な上昇を示した。対照薬及び本発明化合物
を高脂血症食に添加した投与群は、高脂血症食投与群よ
りも若干僅少な増加傾向を示したが、有意差は認められ
なかった。Table 9 shows examples of weight gain of rats in this antihyperlipidemia test.
and 10. The weight gain of the normal diet group was significantly higher than that of the control group administered the hyperlipidemic diet (P < 0
.. 001). The group in which the control drug and the compound of the present invention were added to the hyperlipidemic diet showed a slightly smaller tendency to increase than the group administered with the hyperlipidemic diet, but no significant difference was observed.
(以下余白)
本発明化合物を添加した飼料の消費量から略算すると、
本発明化合物をラット1匹当り最大時210■を投与し
たことになる。例えばシクロアルテノール−4−ヒドロ
キシ−3−メトキシ−α−メチルケイヒ酸エステル(実
施例2)、シクロブラノール−3−エトキシ−4−ヒド
ロキシ−α−メチルケイヒ酸エステル(実施例28)、
シクロブラノール−5−アミノ−2−メトキシ安息香酸
エステル(実施例61)、シクロアルテノール−p−ア
ミノ−α−メチルケイヒ酸エステル(実施例93)及び
シクロブラノール−m−アミノ−α−メチルケイヒ酸エ
ステル(実施例100)の各210■中に結合する遊離
状の4−ヒドロキシ−3−メトキシ−α−メチルケイヒ
酸は70.8■、3−エトキシ−4−ヒトロキシーα−
メチルケイヒ酸は72.5■、5−アミノ−2−メトキ
シ安息香酸は59.4■、p−アミノ−α−メチルケイ
ヒ酸は63.4■、m−アミノ−α−メチルケイヒ酸は
62.0■である。(Left below) Approximately calculated from the consumption of feed to which the compound of the present invention has been added:
This means that a maximum of 210 μ of the compound of the present invention was administered per rat. For example, cycloartenol-4-hydroxy-3-methoxy-α-methylcinnamic acid ester (Example 2), cyclobranol-3-ethoxy-4-hydroxy-α-methylcinnamic acid ester (Example 28),
Cyclobranol-5-amino-2-methoxybenzoic acid ester (Example 61), cycloartenol-p-amino-α-methylcinnamic acid ester (Example 93) and cyclobranol-m-amino-α-methylcinnamic acid ester The free 4-hydroxy-3-methoxy-α-methylcinnamic acid bound in each 210μ of the acid ester (Example 100) is 70.8μ, 3-ethoxy-4-hydroxyα-
Methylcinnamic acid is 72.5■, 5-amino-2-methoxybenzoic acid is 59.4■, p-amino-α-methylcinnamic acid is 63.4■, m-amino-α-methylcinnamic acid is 62.0■ It is.
これらの各遊離有機酸を高脂血症飼料中に添加した飼料
を本杭高脂血症試験B法同様に投与して効果をみたが、
これらの有機酸は前記の62.0〜72.5■の投与量
では抗高脂血症効果は全く認められなかった。即ち、本
発明化合物の効果はトリテルペンアルコール有機酸エス
テルが加水分解されて遊離した有機酸に起因するもので
ないことが証明された。Feed containing each of these free organic acids added to the hyperlipidemic feed was administered in the same manner as in the present Hyperlipidemia Test Method B, and the effects were examined.
No antihyperlipidemic effect was observed with these organic acids at doses of 62.0 to 72.5 cm. That is, it was proved that the effect of the compound of the present invention is not due to the organic acid liberated by hydrolysis of the triterpene alcohol organic acid ester.
本発明化合物の内、抗高脂血症剤として最も好ましいも
のは、ヒドロキシ基又はアミノ基の1個をベンゼン核に
結有するα一炭素数1〜4のケイヒ酸;炭素数1〜4の
アルコキシ基とヒドロキシ基又は炭素数1〜4のアルコ
キシ基とアミノ基の2個をベンゼン核に結有するα一炭
素数1〜4のケイヒ酸、ケイヒ酸又は安息香酸のトリテ
ルペンアルコールのエステルである。Among the compounds of the present invention, the most preferred as antihyperlipidemic agents are α-1 to 4-carbon cinnamic acid having one hydroxyl group or amino group attached to the benzene nucleus; It is an ester of a triterpene alcohol of cinnamic acid, cinnamic acid, or benzoic acid having 1 to 4 carbon atoms, which has two groups, a hydroxy group or an alkoxy group having 1 to 4 carbon atoms, and an amino group, attached to a benzene nucleus.
本発明の化合物群は臨床治療用として投与するときの形
態は経口剤又は非経口剤のいずれでもよいが、特に経口
投与が好ましい。本発明化合物の経口用の剤形としては
、適当な医薬担体と混合して錠剤、顆粒剤、散剤(粉剤
)、コーティング剤、糖衣錠、カプセル剤、乳剤などの
製剤が用いられる。医薬担体としては、例えば賦形剤と
して乳糖、白糖、マニトール、ブドウ糖、デン粉、ソル
ビトール、グリシン、リン酸カリウム、微結晶セルロー
スなど;結合剤としてデン粉、ゼラチン、アラビアゴム
、ブドウ糖、白糖、ソルビトール、マニトール、トラガ
ント、ヒドロキシプロピルセルロース、ヒドロキシプロ
ポキシメチルセルロース、カルボキシメチルセルロース
、2−メチル−5−ビニルピリジン−メタアクリル酸−
アクリル酸メチルエステル共重合体、ポリビニルピロリ
ドン、アルギン酸ナトリウムなど;滑沢剤としてステア
リン酸、硬化油、ステアリン酸マグネシウム、ステアリ
ン酸カルシウム、ポリオキシエチレンモノステアレート
、タルク、酸化ケイ素、ポリエチレングリコールなど;
崩壊剤としてバレイショデン粉、界面活性剤などを含む
デン粉;湿潤剤としてラウリル硫酸ナトリウム等があげ
られる。更に非経口的に投与する場合には、筋肉注射薬
、層剤としても用いることができる。特に層剤の基剤と
してカカオ脂、ウイテプソール(Wi tepsol)
、サバナール(Subanal ) 、ポリエチレン
グリコール、ポリプロピレングリコール、グリセロゼラ
チン、ゼラチンカプセルなどが用いられる。その他、メ
チルパラヒドロキシベンゾエート、プロピルパラヒドロ
キシベンゾエート、ブチルパラヒドロキシベンゾエート
、ブチルヒドロキシアニソールなど公知の安全な防腐剤
、その他の安全な色素を配合して用いる。The compounds of the present invention may be administered in the form of oral or parenteral administration for clinical treatment, but oral administration is particularly preferred. Oral dosage forms of the compounds of the present invention include tablets, granules, powders, coatings, sugar-coated tablets, capsules, emulsions, and the like, mixed with suitable pharmaceutical carriers. Examples of pharmaceutical carriers include excipients such as lactose, sucrose, mannitol, glucose, starch, sorbitol, glycine, potassium phosphate, and microcrystalline cellulose; binders such as starch, gelatin, gum acacia, glucose, sucrose, and sorbitol. , mannitol, tragacanth, hydroxypropylcellulose, hydroxypropoxymethylcellulose, carboxymethylcellulose, 2-methyl-5-vinylpyridine-methacrylic acid-
Acrylic acid methyl ester copolymer, polyvinylpyrrolidone, sodium alginate, etc.; Lubricants such as stearic acid, hydrogenated oil, magnesium stearate, calcium stearate, polyoxyethylene monostearate, talc, silicon oxide, polyethylene glycol, etc.;
Examples of disintegrants include potato starch and starch containing surfactants; examples of wetting agents include sodium lauryl sulfate. Furthermore, when administered parenterally, it can also be used as an intramuscular injection drug or a layered preparation. In particular, cocoa butter and Wi tepsol are used as bases for layering agents.
, Subanal, polyethylene glycol, polypropylene glycol, glycerogelatin, gelatin capsules, etc. are used. In addition, known safe preservatives such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, butyl hydroxyanisole, and other safe dyes are used.
本発明の化合物の投与量は、投与方法、患者の年齢、体
重、状態及び疾患の種類によっても変動するが、通常ヒ
トに一日当り0.01gから5g程度が好ましい。最も
好ましいのは0.02gから1.5gである。Although the dosage of the compound of the present invention varies depending on the method of administration, age, weight, condition, and type of disease of the patient, it is usually preferably about 0.01 g to 5 g per day for humans. Most preferred is 0.02g to 1.5g.
本発明に示す新規なトリテルペンアルコール有機酸エス
テルは、好ましいトリテルペンアルコール有機酸エステ
ルの代表として前記したシクロアルテノール、シクロブ
ラノール及び24−メチレンシクロアルタノール有機酸
エステルを用いたものであり、それら以外のラノステロ
ール、ラノステノール、アグノステロール、シクロサド
ール(3β−ヒドロキシ−24−メチレン−9,19−
シクロ−9β−ジノスター23−エン)、ジヒドロエル
ゴステロール、シクロアルタノール、シクロアルタノー
ル、シクロユー力しノール、ユーホール、ブチロスパー
モール、チルカロール、ユーホルボール、ダマラジエノ
ールなどのトリテルペンアルコールの本発明に示す構造
の有機酸エステルも含む。これらは、抗高脂血症剤とし
て好ましい。又トリテルペンアルコールと構造類似のス
テロール類、例えばジヒドロ−β−シトステロール、ジ
ヒドロ−T−シトステロール、カンペステロール、β−
シトステロール、γ−シトステロール、スチグマステロ
ール、24−メチレンコレステロール、エビステロール
、22−ジヒドロエルゴステロールなどの本発明に示す
有機酸のエステル類は抗高脂血症剤として同じ効果を示
すことが期待できる。本発明化合物は単味で用いること
が最も好ましく、又、2種以上の混合物として用いるこ
ともできる。The novel triterpene alcohol organic acid ester shown in the present invention uses the above-mentioned cycloartenol, cyclobranol, and 24-methylenecycloartanol organic acid ester as representative of preferred triterpene alcohol organic acid esters, and uses other than these. lanosterol, lanstenol, agnosterol, cyclosadol (3β-hydroxy-24-methylene-9,19-
Triterpene alcohols such as cyclo-9β-dinoster-23-ene), dihydroergosterol, cycloartanol, cycloartanol, cyclo-ergosterol, euphol, butyrospermol, tirkarol, euphorbol, and damaradienol are shown in the present invention. Also includes organic acid esters of structure. These are preferred as antihyperlipidemic agents. Also, sterols with similar structures to triterpene alcohols, such as dihydro-β-sitosterol, dihydro-T-sitosterol, campesterol, β-
The esters of organic acids shown in the present invention, such as sitosterol, γ-sitosterol, stigmasterol, 24-methylenecholesterol, evisterol, and 22-dihydroergosterol, are expected to exhibit the same effects as antihyperlipidemic agents. . The compounds of the present invention are most preferably used alone, and can also be used as a mixture of two or more.
(以下余白)
実施例1 シクロアルテノール−3−メトキシ−4−プ
ロピオニルオキシ−α−メチル
ケイヒ酸エステルの製法
3−メトキシ−4−プロピオニルオキシ−α−メチルケ
イヒ酸72.0g (0,272モル)にトルエン40
0−1塩化チオニル40.Ome(2当量)、ジメチル
ホルムアミド0.5dを加え60℃にて1.5時間反応
させた。反応液を減圧濃縮後ジオキサン100Tdを加
え0℃で攪拌し、そこへピリジン300−に熔解させた
シクロアルテノール80.0g (0,187モル)を
加え、さらに60℃にて3時間加熱攪拌した。反応終了
後、溶媒を減圧留去し、得られた残渣を800 Wll
のクロロホルムに溶解後、飽和重曹水500艷で洗浄し
た。水層をクロロホルム500m1iずつを用いてさら
に2回抽出し、得られた全クロロホルム層を乾燥後、減
圧濃縮し、シリカゲルカラムクロマトグラフィー〔溶媒
ヘキサン−塩化メチレン、(5: 1) )にて精製す
ることによりシクロアルテノール−3−メトキシ−4−
プロピオニルオキシ−α−メチルケイヒ酸エステル11
0gを得た。(Left below) Example 1 Method for producing cycloartenol-3-methoxy-4-propionyloxy-α-methylcinnamic acid 72.0 g (0,272 mol) of 3-methoxy-4-propionyloxy-α-methylcinnamic acid toluene 40
0-1 thionyl chloride 40. Ome (2 equivalents) and 0.5 d of dimethylformamide were added and reacted at 60° C. for 1.5 hours. After concentrating the reaction solution under reduced pressure, dioxane 100Td was added and stirred at 0°C. 80.0 g (0,187 mol) of cycloartenol dissolved in pyridine 300- was added thereto, and the mixture was further heated and stirred at 60°C for 3 hours. . After the reaction was completed, the solvent was distilled off under reduced pressure, and the resulting residue was heated at 800 Wll.
After dissolving in chloroform, the solution was washed with 500 bottles of saturated sodium bicarbonate solution. The aqueous layer is further extracted twice using 500ml of chloroform each time, and the entire chloroform layer obtained is dried, concentrated under reduced pressure, and purified by silica gel column chromatography [solvent: hexane-methylene chloride, (5:1)]. Possibly cycloartenol-3-methoxy-4-
Propionyloxy-α-methylcinnamate ester 11
Obtained 0g.
収率87.1%、融点130〜131℃比旋光度〔α〕
り +41.1° (C1,00,CI(C13)元
素分析結果 C3□Hbり05
(分子量672.95として)
計算値(%) :C78,53H9,59実測値(%
) :C7B、59 H9,52IRI/、KBr
(an″″1):2920.2850.1765.
1710、1630.1600.1510.1240.
1140.1110゜PMR(CDC13) δ: 0
.39 (IH,%ABq、4.2Hz )、0.60
(IB、 %ABq、4.2Hz > 、0.60〜
2.20 (2711゜m ) 、0.90 (6H,
s) 、0.98 (6H,s) 、1.27 (3H
,t、7.2Hz) 、1.58 (3H,bs) 、
1.88 (3H,bs)、2.12 (3H,d、1
.2Hz) 、2.62 (2H,q、7.2Hz)
、3.80(3H,s) 、4.50〜5.30 (2
H,n+) 、6.80〜7.70 (4II+m)。Yield 87.1%, melting point 130-131℃ Specific rotation [α]
+41.1° (C1,00, CI (C13) elemental analysis result C3□Hbri05 (assuming molecular weight 672.95) Calculated value (%): C78,53H9,59 actual value (%
) :C7B, 59 H9, 52IRI/, KBr
(an″″1):2920.2850.1765.
1710, 1630.1600.1510.1240.
1140.1110°PMR (CDC13) δ: 0
.. 39 (IH, %ABq, 4.2Hz), 0.60
(IB, %ABq, 4.2Hz > , 0.60~
2.20 (2711゜m), 0.90 (6H,
s), 0.98 (6H, s), 1.27 (3H
, t, 7.2Hz), 1.58 (3H, bs),
1.88 (3H, bs), 2.12 (3H, d, 1
.. 2Hz), 2.62 (2H,q,7.2Hz)
, 3.80 (3H, s) , 4.50~5.30 (2
H, n+), 6.80-7.70 (4II+m).
実施例2 シクロアルテノール−4−ヒドロキシ−3−
メトキシ−α−メチルケイヒ酸
エステル(別名ニジクロアルテノール
−α−メチルフェルラ酸エステル)の
製法
実施例1の方法により得たシクロアルテノール−3−メ
トキシ−4−プロピオニルオキシ−α−メチルケイヒ酸
エステル84.0g−(0,125モル)を1000−
のジオキサンに熔解後、25%アンモニア水200rI
I!を加え50℃で2時間加熱攪拌した。反応終了後、
溶媒を減圧留去し、得られた残渣を500T11のクロ
ロホルムに溶解し、飽和食塩水500−にて洗浄した。Example 2 Cycloartenol-4-hydroxy-3-
Method for producing methoxy-α-methyl cinnamic acid ester (also known as dichloroartenol-α-methylferulic acid ester) Cycloartenol-3-methoxy-4-propionyloxy-α-methyl cinnamic acid ester 84 obtained by the method of Example 1 .0g-(0,125 mol) to 1000-
After dissolving in dioxane, add 200 rI of 25% ammonia water.
I! was added, and the mixture was heated and stirred at 50°C for 2 hours. After the reaction is complete,
The solvent was distilled off under reduced pressure, and the resulting residue was dissolved in 500T11 chloroform and washed with 500% saturated brine.
水層をさらに300−のクロロホルムにて2回抽出し、
全クロロホルム層を集め乾燥後、減圧濃縮し、残渣を塩
化メチレン−メタノール(1: 4)にて再結晶するこ
とによりシクロアルテノール−4−ヒドロキシ−3−メ
トキシ−α−メチルケイヒ酸エステル(シクロアルテノ
ール−α−メチルフェルラ酸エステル)を73.0B得
た。The aqueous layer was further extracted twice with 300-ml chloroform,
All the chloroform layers were collected, dried, concentrated under reduced pressure, and the residue was recrystallized from methylene chloride-methanol (1:4) to obtain cycloartenol-4-hydroxy-3-methoxy-α-methylcinnamate (cycloaltenol-4-hydroxy-3-methoxy-α-methylcinnamate). 73.0B of tenol-α-methylferulic acid ester) was obtained.
収率94.8%、融点143〜144℃比旋光度〔α)
; +44.1° (C1,00,CHCl3 ”
)元素分析結果 CQ/ H6004
(分子量616.93として)
計算値(%) jc 79.82 H9,80実
測値(%’) jc 79.88 H9,811
RW、KBr (cm−1) :3400.290
0.2850゜1695.1690.1625.160
0.1510.1250.1110゜P M R(CD
C13) δ: 0.38 (1B、 !/GAB
q、4.2Hz )、0.59 (III、 !4A
Bq、4.2Hz ) 、0.60〜2.30 (2
7H。Yield 94.8%, melting point 143-144℃ Specific rotation [α]
; +44.1° (C1,00, CHCl3 ”
) Elemental analysis results CQ/ H6004 (as molecular weight 616.93) Calculated value (%) jc 79.82 H9,80 actual value (%') jc 79.88 H9,811
RW, KBr (cm-1): 3400.290
0.2850°1695.1690.1625.160
0.1510.1250.1110゜P M R (CD
C13) δ: 0.38 (1B, !/GAB
q, 4.2Hz), 0.59 (III, !4A
Bq, 4.2Hz), 0.60-2.30 (2
7H.
ta ) 、0.88 (6H,s) 、0.97
(6H,s) 、1.60 (3H。ta), 0.88 (6H,s), 0.97
(6H,s), 1.60 (3H.
bs) 、1.66 (3H,bs) 、2.12
(3H,d、1.2Hz) 、3.88 (3H,
s) 、4.50〜5.30 (2H,m) 、5.8
0 (IH。bs), 1.66 (3H, bs), 2.12
(3H, d, 1.2Hz), 3.88 (3H,
s), 4.50-5.30 (2H, m), 5.8
0 (IH.
bs) 、6.70〜7.70 (4H,m) 。bs), 6.70-7.70 (4H, m).
実施例3 シクロブラノール−3−メトキシ−4−プロ
ピオニルオキシ−α−メチルケ
イヒ酸エステルの製法
3−メトキシ−4−プロピオニルオキシ−α−メチルケ
イヒ酸15.59 g (0,059モル)をトルエン
50m1に懸濁し1、塩化チオニル20m (4,6当
量)とジメチルホルムアミド5滴を加え60℃にて2時
間攪拌した。反応後、減圧下に溶媒を留去し、残渣を再
びトルエン150−と無水ピリジン3o−に懸濁させ、
シクロブラノール20g (0,045モル)を加え6
0℃にて2時間攪拌した。反応終了後、減圧下に溶媒を
留去し、残渣をクロロホルム300mt’で抽出した。Example 3 Preparation of cyclobranol-3-methoxy-4-propionyloxy-α-methylcinnamic acid ester 15.59 g (0,059 mol) of 3-methoxy-4-propionyloxy-α-methylcinnamic acid was added to 50 ml of toluene. 20 m (4.6 equivalents) of thionyl chloride and 5 drops of dimethylformamide were added to the suspension and stirred at 60°C for 2 hours. After the reaction, the solvent was distilled off under reduced pressure, and the residue was suspended again in toluene 150- and anhydrous pyridine 3-
Add 20 g (0,045 mol) of cyclobranol to 6
The mixture was stirred at 0°C for 2 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was extracted with 300 mt' of chloroform.
クロロホルム層を水洗後、乾燥し減圧留去した。残渣を
エタノール50rII!で洗浄し、次にアセトン−水(
19:1)から再結晶し、シクロブラノール−3−メト
キシ−4−プロピオニルオキシ−α−メチルケイヒ酸エ
ステル24.69 gを得た。The chloroform layer was washed with water, dried and evaporated under reduced pressure. Add 50rII of ethanol to the residue! and then acetone-water (
19:1) to obtain 24.69 g of cyclobranol-3-methoxy-4-propionyloxy-α-methylcinnamate.
収率79.2%、融点146〜147℃比旋光度(α)
、 +39.2” (C1,00,CHCl3)
元素分析結果 c、、 H6605
(分子量686.98として)
計算値(%”) :C78,67H9,68実測値(
%) :C7B、75 H9,62IRν、K B
r (elm−’) : 3400.2590.
2850.1760.1710.1630.1600.
1240.1150.1120゜PMR(CDC13)
δ: 0.37 (LH,〃ABq、4.8Hz )、
0.62 (18,’A^Bq、4.8Hz ) 、0
.70〜2.22 (27H。Yield 79.2%, melting point 146-147℃ Specific rotation (α)
, +39.2” (C1,00,CHCl3)
Elemental analysis results c,, H6605 (as molecular weight 686.98) Calculated value (%”): C78,67H9,68 actual value (
%): C7B, 75 H9, 62IRν, K B
r (elm-'): 3400.2590.
2850.1760.1710.1630.1600.
1240.1150.1120゜PMR (CDC13)
δ: 0.37 (LH, ABq, 4.8Hz),
0.62 (18,'A^Bq, 4.8Hz), 0
.. 70-2.22 (27H.
m ) 、0.92 (6H,s) 、0.99 (6
H,s) 、1.29 (3H,t、7.2Hz) 、
1.64 (9H,s) 、2.14 (3H,d、1
.2Hz)、2.63 (2H,q、7.21冒z)
、 3.84 (3H,s) 、 4.48〜
4.88(III、m) 、6.80〜7.08 (3
H,m) 、7.59 (11Lq、1.2Hz) 。m), 0.92 (6H,s), 0.99 (6
H,s), 1.29 (3H,t, 7.2Hz),
1.64 (9H, s), 2.14 (3H, d, 1
.. 2Hz), 2.63 (2H, q, 7.21 z)
, 3.84 (3H,s) , 4.48~
4.88 (III, m), 6.80-7.08 (3
H, m), 7.59 (11Lq, 1.2Hz).
実施例4 シクロブラノール−4−ヒドロキシ−3−メ
トキシ−α−メチルケイヒ酸エ
ステルの製法
実施例3の方法にて得たシクロブラノール−3−メトキ
シ−4−プロピオニルオキシ−α−メチルケイヒ酸エス
テル24.69g (0,036モル)をジオキサン4
00+wlに溶解し、25%アンモニア水40m1を滴
下後、50℃にて2時間攪拌した。反応終了後、減圧下
に溶媒を留去し、残渣をエタノールで洗浄し、次にアセ
トン−水(19:1)から再結晶し、シクロブラノール
−4−ヒドロキシ−3−メトキシ−α−メチルケイヒ酸
エステル21.72gを得た。Example 4 Preparation of cyclobranol-4-hydroxy-3-methoxy-α-methylcinnamic acid ester Cyclobranol-3-methoxy-4-propionyloxy-α-methylcinnamic acid ester obtained by the method of Example 3 24 .69g (0,036 mol) of dioxane 4
00+wl, 40 ml of 25% aqueous ammonia was added dropwise, and the mixture was stirred at 50° C. for 2 hours. After the reaction, the solvent was distilled off under reduced pressure, the residue was washed with ethanol, and then recrystallized from acetone-water (19:1) to give cyclobranol-4-hydroxy-3-methoxy-α-methylcinnabar. 21.72 g of acid ester was obtained.
収率95.8%、融点185〜186℃比旋光度〔α〕
智 +43.7° (C1,00、cnct3 )元素
分析結果 Ca2 Hb> 04
(分子量630.92として)
計算値(%’) :C79,95H9,91実測値(
%):C79,90H9,98I?、K B r (
cs−’) : 3380.2920.2850.1
693.1600.1510.1285.1250.1
120PMR(CDC13’) δ: 0.36 (
IIl、 !4ABq、4.8Hz )、0.61
(ill、 〃ABq、4.8Hz ) 、0.7
6〜2.30 (2711゜s ) 、0.91 (
6H,s) 、0.99 (6H,s) 、1.6
3 (9H。Yield 95.8%, melting point 185-186℃ Specific rotation [α]
+43.7° (C1,00, cnct3) Elemental analysis result Ca2 Hb> 04 (assuming molecular weight 630.92) Calculated value (%'): C79,95H9,91 Actual value (
%): C79,90H9,98I? , K B r (
cs-'): 3380.2920.2850.1
693.1600.1510.1285.1250.1
120PMR (CDC13') δ: 0.36 (
IIl, ! 4ABq, 4.8Hz), 0.61
(ill, ABq, 4.8Hz), 0.7
6-2.30 (2711°s), 0.91 (
6H,s), 0.99 (6H,s), 1.6
3 (9H.
s ) 、2.14 (311,d、1.2Hz
) 、3.90 (311,s) 、4.48〜4
.84 (LH,a+) 、5.84 (IIL
bs) 、6.80〜6.98 (311,m)
、7.55 (IH,q、1.2Hz) 。s), 2.14 (311,d, 1.2Hz
), 3.90 (311,s), 4.48~4
.. 84 (LH, a+), 5.84 (IIL
bs), 6.80-6.98 (311, m)
, 7.55 (IH, q, 1.2Hz).
実施例524−メチレンシクロアルタノール−3−メト
キシ−4−プロピオニルオ
キシ−α−メチルケイヒ酸の製法
3−メトキシ−4−プロピオニルオキシ−α−メチルケ
イヒ酸0.8g (0,003モル)をトルエン2−に
懸濁し、塩化チオニル0.5m (2,2当量)とジメ
チルホルムアミド2滴を加え60℃にて2時間攪拌した
0反応後、減圧下に溶媒を留去し残渣を再びトルエン2
−と無水ピリジン1m1に懸濁させ、24−メチレンシ
クロアルタノール1 g (0,0023モル)を加え
60℃にて2時間攪拌した。反応終了後、減圧下に溶媒
を留去し残渣をクロロホルム20mで抽出した。クロロ
ホルム層を洗浄後、乾燥し、減圧留去した。残渣をエタ
ノール5WI!で洗浄した後、アセトン−メタノール(
1: 1)から再結晶し、24−メチレンシクロアルタ
ノール−3−メトキシ−4−プロピオニルオキシ−α−
メチルケイヒ酸エステル1 、35gを得た。Example 52 Preparation of 4-methylenecycloartanol-3-methoxy-4-propionyloxy-α-methylcinnamate 0.5 m (2.2 equivalents) of thionyl chloride and 2 drops of dimethylformamide were added and stirred for 2 hours at 60°C. After the reaction, the solvent was distilled off under reduced pressure, and the residue was dissolved again in toluene (2.2 eq.).
- was suspended in 1 ml of anhydrous pyridine, 1 g (0,0023 mol) of 24-methylenecycloartanol was added, and the mixture was stirred at 60°C for 2 hours. After the reaction was completed, the solvent was distilled off under reduced pressure and the residue was extracted with 20ml of chloroform. The chloroform layer was washed, dried, and evaporated under reduced pressure. Ethanol the residue 5WI! After washing with acetone-methanol (
1: Recrystallized from 1) to give 24-methylenecycloartanol-3-methoxy-4-propionyloxy-α-
35 g of methylcinnamic acid ester 1 was obtained.
収率86.6%、融点134〜135℃比旋光度 〔α
); + 41.2° (C1,00,CHCl3
)元素分析値 CfvH赫05
(分子量686.98として)
計算値(%) ;C7B、67 H9,68実測値
(%) ;C7B、75 H9,62IRν、K
B r (am−’) : 3400.2920.
2850.1760.1700.1240.1115゜
PMR(CDCl2 )δ: 0.36 (IH,〃A
Bq、4.2Hz )、0.61 (!4ABq、4.
2Hz ) 、0.70〜2.22 <348 、a+
)、0.88 (6H,S) 、0.96 (6H,S
) 、1.26 (3H,t、?、211z) 、2.
11 (3H,d、1.2Hz) 、2.60 (2H
,q、7.2Hz)、3.80 (31(、S) 、4
.44〜4.86 (IH,a+) 、4.86〜5.
26(2B、s) 、6.’76〜7.OB (3Lw
+) 、7.55 (ILq、 1.2Hz ) 。Yield 86.6%, melting point 134-135℃ Specific rotation [α
); + 41.2° (C1,00,CHCl3
) Elemental analysis value CfvHak05 (as molecular weight 686.98) Calculated value (%); C7B, 67 H9,68 Actual value (%); C7B, 75 H9,62IRν, K
B r (am-'): 3400.2920.
2850.1760.1700.1240.1115゜PMR (CDCl2) δ: 0.36 (IH,〃A
Bq, 4.2Hz), 0.61 (!4ABq, 4.
2Hz), 0.70-2.22 <348, a+
), 0.88 (6H,S), 0.96 (6H,S
) , 1.26 (3H, t, ?, 211z) , 2.
11 (3H, d, 1.2Hz), 2.60 (2H
,q,7.2Hz),3.80(31(,S),4
.. 44-4.86 (IH, a+), 4.86-5.
26 (2B, s), 6. '76-7. OB (3Lw
+), 7.55 (ILq, 1.2Hz).
実施例624−メチレンシクロアルタノール−4−ヒド
ロキシ−3−メトキシ−α−メ
チルケイヒ酸エステルの製法
実施例5の方法で得た24−メチレンシクロアルタノー
ル−3−メトキシ−4−プロピオニルオキシ−α−メチ
ルケイヒ酸エステル1.35g (0,002モル)を
ジオキサン20meに溶解し、25%アンモニア水2−
を滴下後、50℃にて2時間攪拌した。反応終了後、減
圧下に溶媒を留去し残渣をエタノールで洗浄し、次ぎに
エタノールから再結晶し、24−メチレンシクロアルタ
ノール−4−ヒドロキシ−3−メトキシ−α−メチルケ
イヒ酸エステル1.02gを得た。Example 6 Preparation of 24-methylenecycloartanol-4-hydroxy-3-methoxy-α-methylcinnamate 24-methylenecycloartanol-3-methoxy-4-propionyloxy-α- obtained by the method of Example 5 1.35 g (0,002 mol) of methyl cinnamic acid ester was dissolved in dioxane 20me, and 25% ammonia water 2-
After dropping, the mixture was stirred at 50°C for 2 hours. After the reaction, the solvent was distilled off under reduced pressure, the residue was washed with ethanol, and then recrystallized from ethanol to obtain 1.02 g of 24-methylenecycloartanol-4-hydroxy-3-methoxy-α-methylcinnamate. I got it.
収率82.2%、融点144〜145℃比旋光度〔α〕
智 +44.8° (C1,0O1CIC13)元素分
析結果 Ca3 H6204
(分子量630.92として)
計算値(%”) :C79,95H9,91実測値(
%”) :C79,99H9,84IRj/、K B
r (an−’) : 3400.2900.2
850゜1690.1600.1510.1250.1
110゜PMR(CDC13) δ : 0.37
(IL %ABq、4.2Hz >、0.61 (1
B、 !4ABq、4.2Hz ) 、0.70〜
2.21 (34H。Yield 82.2%, melting point 144-145℃ Specific rotation [α]
Satoshi +44.8° (C1,0O1CIC13) Elemental analysis result Ca3 H6204 (as molecular weight 630.92) Calculated value (%”): C79,95H9,91 Actual value (
%"): C79,99H9,84IRj/, K B
r (an-'): 3400.2900.2
850°1690.1600.1510.1250.1
110°PMR (CDC13) δ: 0.37
(IL %ABq, 4.2Hz >, 0.61 (1
B,! 4ABq, 4.2Hz), 0.70~
2.21 (34H.
m ) 、0.89 (6H,s) 、0.98
(6H,s) 、2.14 <3H,d、1.2Hz
> 、3.88 (3H,s) 、4.50〜4.
88 (IH,m) 、4.88〜5.28 (2H
,n+) 1.5.80 (LH,bs ) 、6
.82〜7.10 (3H,m) 、?、59 (1
)1.q、1.2Hz) 。m), 0.89 (6H,s), 0.98
(6H,s), 2.14 <3H,d, 1.2Hz
>, 3.88 (3H, s), 4.50-4.
88 (IH, m), 4.88-5.28 (2H
, n+) 1.5.80 (LH, bs), 6
.. 82~7.10 (3H, m),? , 59 (1
)1. q, 1.2Hz).
実施例7 シクロアルテノール−4−ブチリルオキシ−
3−メトキシ−α−エチルケイ
ヒ酸エステルの製法
4−ブチリルオキシ−3−メトキシ−α−エチルケイヒ
酸18.0g (0,062モル)のベンゼン4〇−溶
液を0℃に冷やし、塩化チオニル15.0m (3,3
当量)を滴下した。この混合物を60℃にて2時間加熱
した。反応後過剰の塩化チオニル及び溶媒を減圧下に留
去し、ピリジン10rI11及びジオキサン4〇−を加
え、0℃に冷やしながらシクロアルテノール17.5g
(0,041モル)を含むピリジン3〇−溶液を滴下
した。この混合物を20℃にて一夜攪拌した。Example 7 Cycloartenol-4-butyryloxy-
Preparation of 3-methoxy-α-ethylcinnamic acid ester A solution of 18.0 g (0,062 mol) of 4-butyryloxy-3-methoxy-α-ethylcinnamic acid in benzene was cooled to 0°C, and 15.0 m of thionyl chloride ( 3,3
equivalent amount) was added dropwise. This mixture was heated at 60°C for 2 hours. After the reaction, excess thionyl chloride and the solvent were distilled off under reduced pressure, 10rI11 of pyridine and 40-dioxane were added, and 17.5 g of cycloartenol was added while cooling to 0°C.
A solution of pyridine 30 containing (0,041 mol) was added dropwise. This mixture was stirred at 20°C overnight.
反応後溶媒を減圧下に留去し、残渣をクロロホルム20
0rII!で抽出し、クロロホルム層を減圧下に濃縮し
、得られた粗結晶をアセトン−メタノール(1: 1)
より再結晶し、シクロアルテノール−4−ブチリルオキ
シ−3−メトキシ−α−エチルケイヒ酸エステルを収量
22.4gで得り。After the reaction, the solvent was distilled off under reduced pressure, and the residue was dissolved in chloroform 20
0rII! The chloroform layer was concentrated under reduced pressure, and the obtained crude crystals were mixed with acetone-methanol (1:1).
Recrystallization was performed to obtain 22.4 g of cycloartenol-4-butyryloxy-3-methoxy-α-ethylcinnamate.
収率77.9%、融点118.5〜119.5℃比旋光
度〔α〕甘 +35.7° (C1,0O1C1(C1
3)元素分析結果 C44HI、t O5
(分子量701.00として)
計算値(%’) :C78,8L H9,78実測
値(%”) :C78,72H9,86IRν、K
B r (ca+−1) : 3400.2920
.2800.1700、1600.1510.1230
.1120゜PMR(CDC13)δ: 0.36 (
IH,MABq、4.2Hz )、0.52〜2.26
(29H,m ) 、0.61 (IH,HABq、
4.2Hz) 、0.90 (6H,s) 、0.96
(61(、s) 、1.04 (3H,t、7.2H
z) 、1.18 (3H,t、7.2Hz) 、1.
60 (3H,s)、1.66 (3H,s) 、2.
26〜2.82 (4H,m) 、3.79 (3H,
s)、4.50〜4.88 <111.m) 、4.8
8〜5.28 CILm)、6.70〜7.12 (3
H,m) 、7.48〜7.68 (LH,m) 。Yield 77.9%, melting point 118.5-119.5°C Specific optical rotation [α] Sweet +35.7° (C1,0O1C1(C1
3) Elemental analysis results C44HI, t O5 (assuming molecular weight 701.00) Calculated value (%'): C78,8L H9,78 actual value (%''): C78,72H9,86IRν, K
B r (ca+-1): 3400.2920
.. 2800.1700, 1600.1510.1230
.. 1120°PMR (CDC13) δ: 0.36 (
IH, MABq, 4.2Hz), 0.52-2.26
(29H, m), 0.61 (IH, HABq,
4.2Hz), 0.90 (6H,s), 0.96
(61 (, s) , 1.04 (3H, t, 7.2H
z), 1.18 (3H, t, 7.2Hz), 1.
60 (3H, s), 1.66 (3H, s), 2.
26-2.82 (4H, m), 3.79 (3H,
s), 4.50-4.88 <111. m), 4.8
8-5.28 CILm), 6.70-7.12 (3
H, m), 7.48-7.68 (LH, m).
実施例8 シクロアルテノール−4−ヒドロキシ−3−
メトキシ−α−エチルケイヒ酸
エステルの製法
実施例7の方法にて得たシクロアルテノール−4−ブチ
リルオキシ−3−メトキシ−α−エチルケイヒ酸エステ
ル22.0g (0,0314モル)をジオキサン20
0rR1に溶解させ、25%濃アンモニア水2〇−を滴
下した。この混合物を50℃で5時間加熱した。Example 8 Cycloartenol-4-hydroxy-3-
Preparation of methoxy-α-ethylcinnamic acid ester 22.0 g (0,0314 mol) of cycloartenol-4-butyryloxy-3-methoxy-α-ethylcinnamic acid ester obtained by the method of Example 7 was added to 20 g of dioxane.
It was dissolved in 0rR1, and 20 - 25% concentrated ammonia water was added dropwise. This mixture was heated at 50°C for 5 hours.
反応後、溶媒を減圧下に留去し、残渣をクロロホルム2
00dで抽出し、クロロホルム層を減圧下に濃縮し、得
られた粗結晶をアセトン−メタノール(1: 1)より
再結晶し、シクロアルテノール−4−ヒドロキシ−3−
メトキシ−α−エチルケイヒ酸エステルを収量17.2
gでflり。After the reaction, the solvent was distilled off under reduced pressure, and the residue was dissolved in chloroform 2
The chloroform layer was concentrated under reduced pressure, and the obtained crude crystals were recrystallized from acetone-methanol (1:1) to give cycloartenol-4-hydroxy-3-
Yield of methoxy-α-ethylcinnamate ester: 17.2
Flirt with g.
収率86.8%、融点136〜137℃比旋光度〔α〕
智 +41.5° (C1,00、C)IC13)元素
分析結果 CのH6ン04
(分子量630.92として)
計算値(%”) :C79,95H9,96実測値(
%) :C79,90H9,83IRν、K B r
(cm−’) : 3400.2B30.170
0.1595.1510.1240.1120゜PMR
(CDC13) δ: 0.35 (IH,AABq
、4.2Hz )、0.50〜2.18 (27■1)
、0−60 (IH9!4ABq+4.2Hz) 、
0.89 (6H,s) 、0.95 (6H,s)
、1.19 (3H,t、7.21(z) 、157
(3H,s) 、1.65 (31(、s) 、2.5
6(2H,bq、7.2Hz > 、3.87 (3H
,s) 、4.4’?’y4.85(IH,n) 、4
.85〜5.24 (IH,m) 、5.76 (IH
,bs)、6.96〜7.09 (3H,m) 、7.
24〜7.64 (18,m) 。Yield 86.8%, melting point 136-137℃ Specific rotation [α]
+41.5° (C1,00,C)IC13) Elemental analysis result H6-04 of C (as molecular weight 630.92) Calculated value (%"): C79,95H9,96 Actual value (
%): C79,90H9,83IRν, KBr
(cm-'): 3400.2B30.170
0.1595.1510.1240.1120゜PMR
(CDC13) δ: 0.35 (IH, AABq
, 4.2Hz), 0.50-2.18 (27■1)
, 0-60 (IH9!4ABq+4.2Hz) ,
0.89 (6H,s), 0.95 (6H,s)
, 1.19 (3H,t, 7.21(z) , 157
(3H,s), 1.65 (31(,s), 2.5
6 (2H, bq, 7.2Hz > , 3.87 (3H
,s) ,4.4'? 'y4.85(IH,n), 4
.. 85-5.24 (IH, m), 5.76 (IH
, bs), 6.96-7.09 (3H, m), 7.
24-7.64 (18, m).
実施例9 シクロブラノール−4−ブチリルオキシ−3
−メトキシ−α−エチルケイヒ
酸エステルの製法
4−ブチリルオキシ−3−メトキシ−α−エチルケイヒ
酸18.0g (0,062モル)をベンゼン4〇−に
溶解した溶液を0℃に冷やし、塩化チオニル15、Om
e (3,3当量)を滴下した。この混合物を60℃に
て2時間加熱攪拌後、過剰の塩化チオニル及び溶媒を減
圧下に留去し、ピリジン4〇−及びジオキサン40−を
加え、0℃に冷やしながらシクロブラノール18.1g
(0,041モル)を加えた。この混合物を20℃に
て一夜攪拌した。反応後溶媒を減圧下に留去し、残渣を
クロロホルム200−で抽出し、クロロホルム層を減圧
下に濃縮し、得られた粗結晶をアセトン−エタノール(
1: 1)より再結晶し、シクロブラノール−4−ブチ
リルオキシ−3−メトキシ−α−エチルケイヒ酸エステ
ルを収量22.3gで得た。Example 9 Cyclobranol-4-butyryloxy-3
-Production of methoxy-α-ethylcinnamic acid ester A solution of 18.0 g (0,062 mol) of 4-butyryloxy-3-methoxy-α-ethylcinnamic acid dissolved in 40-benzene was cooled to 0°C, and thionyl chloride 15, Om
e (3.3 eq.) was added dropwise. After heating and stirring this mixture at 60°C for 2 hours, excess thionyl chloride and the solvent were distilled off under reduced pressure, 40-pyridine and 40-dioxane were added, and while cooling to 0°C, 18.1 g of cyclobranol was added.
(0,041 mol) was added. This mixture was stirred at 20°C overnight. After the reaction, the solvent was distilled off under reduced pressure, the residue was extracted with 200% chloroform, the chloroform layer was concentrated under reduced pressure, and the resulting crude crystals were extracted with acetone-ethanol (
1:1) to obtain 22.3 g of cyclobranol-4-butyryloxy-3-methoxy-α-ethylcinnamate.
収率76.0%、融点138〜139℃比旋光度〔α〕
智 +33.7° (C1,00,C:HCl3 )元
素分析結果 CψH7a05
(分子量715.03として)
計算値(%) :C78,94H9,87実測値(%
”) :C78,89H9,88■Rν、K B r
(am−’) : 3400.2920.2B5
0゜1760、1710.1625.1510.123
0.1120゜PMR(CDC13)δ: 0.36
(1■+ V、ABq、4.8Hz )、0.52〜2
.22 (29H,m ) 、0.61 (IH,%^
Bq、4.8Hz) 、0.92 (6H,s) 、0
.97 (6H,s) 、1.03 (3H,t、7.
2Hz) 、1.18 (3H,t、7.2Hz) 、
1.60 (9Q、s)、2.22〜2.82 (4H
,m) 、3.81 (3H,s) 、4.48〜4.
90(1)1.ll+)、6.70〜7.18 (3H
,o+) 、7.40〜7.64 (IH+m)
実施例10 シクロブラノール−4−ヒドロキシ−3
−メトキシ−α−エチルケイヒ酸エ
ステルの製法
実施例9の方法にて得たシクロブラノール−4−ブチリ
ルオキシ−3−メトキシ−α−エチルケイヒ酸エステル
21.3g (0,0298モル)をジオキサン200
−に溶解させ、25%濃アンモニア水201111を滴
下した。この混合物を50℃で5時間加熱攪拌後、溶媒
を減圧下に留去し、残渣をクロロホルム20〇−で抽出
した。クロロホルム層を減圧下に濃縮し、得られた粗結
晶をエタノールより再結晶し、シクロブラノール−4−
ヒドロキシ−3−メトキシ−α−エチルケイヒ酸エステ
ルを収量17.1gで得た。Yield 76.0%, melting point 138-139℃ Specific rotation [α]
+33.7° (C1,00,C:HCl3) Elemental analysis result CψH7a05 (as molecular weight 715.03) Calculated value (%): C78,94H9,87 Actual value (%)
”) :C78,89H9,88■Rν,K B r
(am-'): 3400.2920.2B5
0°1760, 1710.1625.1510.123
0.1120゜PMR (CDC13) δ: 0.36
(1■+V, ABq, 4.8Hz), 0.52~2
.. 22 (29H, m), 0.61 (IH,%^
Bq, 4.8Hz), 0.92 (6H,s), 0
.. 97 (6H, s), 1.03 (3H, t, 7.
2Hz), 1.18 (3H, t, 7.2Hz),
1.60 (9Q, s), 2.22~2.82 (4H
, m), 3.81 (3H, s), 4.48-4.
90(1)1. ll+), 6.70-7.18 (3H
,o+) ,7.40-7.64 (IH+m) Example 10 Cyclobranol-4-hydroxy-3
-Production of methoxy-α-ethylcinnamic acid ester 21.3 g (0,0298 mol) of cyclobranol-4-butyryloxy-3-methoxy-α-ethylcinnamic acid ester obtained by the method of Example 9 was added to 200 g of dioxane.
-, and 25% concentrated ammonia water 201111 was added dropwise. After heating and stirring the mixture at 50°C for 5 hours, the solvent was distilled off under reduced pressure, and the residue was extracted with 200 °C of chloroform. The chloroform layer was concentrated under reduced pressure, and the obtained crude crystals were recrystallized from ethanol to give cyclobranol-4-
Hydroxy-3-methoxy-α-ethylcinnamic acid ester was obtained in a yield of 17.1 g.
収率88.9%、融点156〜157℃比旋光度〔α〕
智 +37,7° (C1,00、CHCl3 )元素
分析結果 C幻H6qO4
(分子量644.94として)
計算値(%”) :C80,07H10,00実測値
(%):C80゜13 H10,12IRν、KBr
(cm−’) : 3400.2930.169
6.1235.1130゜
PMR(CDC13) δ: 0.38 (IH,M
ABq、4.8Hz )、0.52〜2.22 (27
H,m ) 、0.62 (IH,zABq、4.8
Hz) 、0.91 (61(、s) 、0.97
(6H,s) 、1.21 (3H,t、7.2H
z) 、1.62 (98,s) 、2.57 (
2H,bq、7.2Hz )、3.98 (3H,s)
、4.48〜4.86 (11,m) 、5.7
8 (LH、bs) 、6.70〜?、OO(31,
m) 、7.53 (LH,m) 。Yield 88.9%, melting point 156-157℃ Specific rotation [α]
+37,7° (C1,00, CHCl3) Elemental analysis result C illusion H6qO4 (as molecular weight 644.94) Calculated value (%”): C80,07H10,00 Actual value (%): C80°13 H10,12IRν, KBr
(cm-'): 3400.2930.169
6.1235.1130°PMR (CDC13) δ: 0.38 (IH, M
ABq, 4.8Hz), 0.52-2.22 (27
H, m), 0.62 (IH, zABq, 4.8
Hz), 0.91 (61(,s), 0.97
(6H, s) , 1.21 (3H, t, 7.2H
z), 1.62 (98,s), 2.57 (
2H, bq, 7.2Hz), 3.98 (3H, s)
, 4.48-4.86 (11, m) , 5.7
8 (LH, bs), 6.70~? ,OO(31,
m), 7.53 (LH, m).
実施例11 シクロアルテノール−4−プロピオニル
オキシ−α−メチルケイヒ酸エステ
ルの製法
4−プロピオニルオキシ−α−メチルケイヒ酸17.6
g (0,075モル)をベンゼン40rnRに熔解し
た溶液を0℃に冷やし、それに塩化チオニル18.1m
e(3,3当量)及びジメチルホルムアルデヒド0.5
−を滴下した。この混合物を60℃にて2時間加熱攪拌
後、過剰の塩化チオニル及び溶媒を減圧下に留去し、ジ
オキサン40me及びピリジン10il11!を加え、
0℃に冷やしながらシクロアルテノール21.3g(0
,050モル)を溶解したピリジン4〇−溶液を滴下し
た。この混合物を20℃にて一夜攪拌した。反応後溶媒
を減圧下に留去し、残渣をクロロホルム200dで抽出
し、クロロホルム層を減圧下に濃縮し、得られた粗結晶
をアセトン−エタノール(1:2)より再結晶し、シク
ロアルテノール−4−プロピオニルオキシ−α−メチル
ケイヒ酸エステルを収量27.0gで得た。Example 11 Preparation of cycloartenol-4-propionyloxy-α-methylcinnamic acid ester 4-propionyloxy-α-methylcinnamic acid 17.6
A solution of g (0,075 mol) in benzene 40rnR was cooled to 0°C, and 18.1m thionyl chloride was added to it.
e (3,3 equivalents) and dimethyl formaldehyde 0.5
- was added dropwise. After heating and stirring this mixture at 60° C. for 2 hours, excess thionyl chloride and the solvent were distilled off under reduced pressure, and 40 me of dioxane and 10 il of pyridine were added! Add
While cooling to 0℃, add 21.3g of cycloartenol (0.
, 050 mol) was added dropwise to the solution. This mixture was stirred at 20°C overnight. After the reaction, the solvent was distilled off under reduced pressure, the residue was extracted with 200 d of chloroform, the chloroform layer was concentrated under reduced pressure, the obtained crude crystals were recrystallized from acetone-ethanol (1:2), and cycloartenol -4-propionyloxy-α-methylcinnamic acid ester was obtained in a yield of 27.0 g.
収率83.9%、融点87〜88℃
比旋光度(α)、 + 45.9° (C1,00
、CHCl3 )元素分析結果 C1a H6204
(分子量642.93として)
計算値(%) :C80,33H9,72実測値(%
) :C80,31H9,79IRν、K B r
(am−’) : 3400.2920.2850
.1760、1700.1260.1215.1115
゜PMR(CDC13)δ: 0.36 (1)1.
%ABq、4.2■2)、0.52〜2.20 (27
H,m ) 、0.61 (IH,!4ABq、4.2
Hz) 、0.89 (6H,s) 、0.97 (6
11,s) 、1.25 (3H,t、7.2Hz)
、1.57 (3H,s) 、1.65 (31(、s
) 、2.10(3H,d、1.2Hz) 、2.58
(2TI、q、7.2Hz) 、4.28〜4.84
0LH,++) 、4.92〜5.240LH,m)
、6.92〜7.09(2B、m) 、7.11
〜7.50 (2H,m) 、7.50〜7.70 (
11+ta) 一
実施例12 シクロアルテノール−4−ヒドロキシ−
α−メチルケイヒ酸エステルの製法
実施例11の方法で得たシクロアルテノール−4−プロ
ピオニルオキシ−α−メチルケイヒ酸エステル27.0
g (0,042モル)をジオキサン200−に熔解さ
せ、25%アンモニア水20−を滴下した。この混合物
を50℃で2時間加熱した。反応後、溶媒を減圧下に留
去し、残渣をクロロホルム200−で抽出し、クロロホ
ルム層を減圧下に濃縮し、得られた粗結晶をエタノール
より再結晶し、シクロアルテノール−4−ヒドロキシ−
α−メチルケイヒ酸エステルを収量20.5gで得た。Yield 83.9%, melting point 87-88℃ Specific rotation (α), + 45.9° (C1,00
, CHCl3) Elemental analysis results C1a H6204 (as molecular weight 642.93) Calculated value (%): C80,33H9,72 Actual value (%)
) :C80,31H9,79IRν,KBr
(am-'): 3400.2920.2850
.. 1760, 1700.1260.1215.1115
°PMR (CDC13) δ: 0.36 (1)1.
%ABq, 4.2■2), 0.52-2.20 (27
H,m), 0.61 (IH,!4ABq,4.2
Hz), 0.89 (6H,s), 0.97 (6
11,s), 1.25 (3H,t, 7.2Hz)
, 1.57 (3H,s) , 1.65 (31(,s
) , 2.10 (3H, d, 1.2Hz) , 2.58
(2TI, q, 7.2Hz), 4.28-4.84
0LH, ++), 4.92-5.240LH, m)
, 6.92-7.09 (2B, m) , 7.11
~7.50 (2H, m), 7.50~7.70 (
11+ta) Example 12 Cycloartenol-4-hydroxy-
Cycloartenol-4-propionyloxy-α-methylcinnamic acid ester obtained by the method of Example 11 27.0
g (0,042 mol) was dissolved in 200 mm of dioxane, and 20 mm of 25% aqueous ammonia was added dropwise. This mixture was heated at 50°C for 2 hours. After the reaction, the solvent was distilled off under reduced pressure, the residue was extracted with 200% chloroform, the chloroform layer was concentrated under reduced pressure, the obtained crude crystals were recrystallized from ethanol, and cycloartenol-4-hydroxy-
α-Methylcinnamic acid ester was obtained in a yield of 20.5 g.
収率83.1%、融点190〜191℃比旋光度(α)
、 +45.8° (C1,00,C)IC13)
元素分析結果 CQDH1903
(分子量586.86として)
計算値(%”) :C8186H9,96実測値(%
) :C81,77H9,99IRν、KBr (
a11″″1):3400.2992.2985.17
00.1675.1600.1510,1260.12
00.1170.1120゜
P M R(CDC13) δ : 0.36
(10,54ABq、4.2Hz )、0.52〜
2.24 (27H,m ) 、0.61 (IH,’
A八へQ、4.2Hz) 、0.90 (6Ls)
、0.98 (6La) 、1.61 (3H,s
)、1.64 (3H,s) 、2.13 (3H,
d、1.2Hz) 、4.50〜4.88 (IH
,s) 、 4.88〜5.24 (LH,m)
、 5.88〜6.60(IH,++)、8.68〜
7.12 (2H,m) 、7.12〜7.50(1
11、m) 、7.50〜7.68 (LH,a+)
。Yield 83.1%, melting point 190-191℃ Specific rotation (α)
, +45.8° (C1,00,C)IC13)
Elemental analysis results CQDH1903 (as molecular weight 586.86) Calculated value (%”): C8186H9,96 actual value (%
): C81,77H9,99IRν, KBr (
a11″″1):3400.2992.2985.17
00.1675.1600.1510,1260.12
00.1170.1120゜P M R (CDC13) δ: 0.36
(10,54ABq, 4.2Hz), 0.52~
2.24 (27H,m), 0.61 (IH,'
A8 to Q, 4.2Hz), 0.90 (6Ls)
, 0.98 (6La) , 1.61 (3H,s
), 1.64 (3H,s), 2.13 (3H,
d, 1.2Hz), 4.50-4.88 (IH
,s), 4.88~5.24 (LH,m)
, 5.88~6.60 (IH, ++), 8.68~
7.12 (2H, m), 7.12~7.50 (1
11, m), 7.50-7.68 (LH, a+)
.
実施例13 シクロブラノール−4−プロピオニルオ
キシ−α−メチルケイヒ酸エステル
の製法
4−プロピオニルオキシ−α−メチルケイヒ酸17.6
g (0,075モル)をベンゼン40r11に熔解し
、その溶液を0℃に冷却しながら、塩化チオニル18.
1me (3,3当量)及びジメチルホルムアルデヒド
0.5rIlを滴下した。この混合物を60℃にて2時
間加熱攪拌後、過剰の塩化チオニル及び溶媒を減圧下に
留去し、ジオキサン2〇−及びピリジン40mを加え、
0℃に冷却しながらシクロブラノール22.0g (0
,050モル)を加えた。この混合物を20℃にて一夜
攪拌した。反応後溶媒を減圧下に留去し、クロロホルム
200−で抽出し、クロロホルム層を減圧下に濃縮し、
得られた粗結晶をアセトン−メタノール(1: 1)よ
り再結晶し、シクログラ。ノールー4−プロピオニルオ
キシ−α−メチルケイヒ酸エステルを収量26.3gで
得た。Example 13 Preparation of cyclobranol-4-propionyloxy-α-methylcinnamic acid ester 4-propionyloxy-α-methylcinnamic acid 17.6
g (0,075 mol) in benzene 40r11 and while cooling the solution to 0°C, 18.g thionyl chloride was added.
1me (3.3 equivalents) and 0.5rIl dimethyl formaldehyde were added dropwise. After heating and stirring this mixture at 60°C for 2 hours, excess thionyl chloride and the solvent were distilled off under reduced pressure, and 20 m of dioxane and 40 m of pyridine were added.
Cyclobranol 22.0g (0
,050 mol) was added. This mixture was stirred at 20°C overnight. After the reaction, the solvent was distilled off under reduced pressure, extracted with 200% chloroform, and the chloroform layer was concentrated under reduced pressure.
The obtained crude crystals were recrystallized from acetone-methanol (1:1) to obtain cyclogra. Nor-4-propionyloxy-α-methylcinnamic acid ester was obtained in a yield of 26.3 g.
収率80.0%、融点107〜108℃比旋光度〔α)
+34.7° (C1,0OSCIC13)ρ
元素分析結果 C1C1Hbt104
(分子量656.95として)
計算値(%’) :C80,44H9,82実測値(
%”) :CBo、39 H9,77IRJ/、K
Br (elm−’) : 3400.2920.
2850.1B60.1710.1630.1260.
1200.1165.1120゜PMR(CDC13)
δ: 0.36 (III、 %ABq、4.8Hz
)、0.61 (IH,%ABq、4.8112)
、0.74〜2.32 (2711゜−) 、0.89
(6H,s) 、0.96 (6H,s) 、1.2
6 (3H,t、7.2H2) 、1.61 (9H
,s) 、2.10 (3H,d、1.2Hz)
、2.58 (2H,q、7.21(z) 、4.4
6〜4.86 (IH,s+) 、6.90〜7.5
2 (4H,m) 、 7.52〜7.70 (I
H,m) 。Yield 80.0%, melting point 107-108℃ Specific rotation [α]
+34.7° (C1,0OSCIC13)ρ Elemental analysis result C1C1Hbt104 (assuming molecular weight 656.95) Calculated value (%'): C80,44H9,82 actual value (
%"): CBo, 39 H9, 77IRJ/, K
Br (elm-'): 3400.2920.
2850.1B60.1710.1630.1260.
1200.1165.1120゜PMR (CDC13)
δ: 0.36 (III, %ABq, 4.8Hz
), 0.61 (IH, %ABq, 4.8112)
, 0.74-2.32 (2711°-) , 0.89
(6H,s), 0.96 (6H,s), 1.2
6 (3H, t, 7.2H2), 1.61 (9H
,s) ,2.10 (3H,d, 1.2Hz)
, 2.58 (2H, q, 7.21 (z) , 4.4
6-4.86 (IH, s+), 6.90-7.5
2 (4H, m), 7.52~7.70 (I
H, m).
実施例14 シクロブラノール−4−ヒドロキシ−α
−メチルケイヒ酸エステルの製法
実施例13の方法で得たシクロブラノール−4−プロピ
オニルオキシ−α−メチルケイヒ酸エステル26.3g
(0,040モル)をジオキサン200dに溶解させ
、25%アンモニア水20m1!を滴下した。この混合
物を50℃で2時間加熱攪拌後、溶媒を減圧下に留去し
た。残渣をクロロホルム200−で抽出し、クロロホル
ム層を減圧下に濃縮し、得られた粗結晶をアセトン−メ
タノール(1: 1)より再結晶し、シクロブラノール
−4−ヒドロキシ−α−メチルケイヒ酸エステルを収量
20.7gで得た。Example 14 Cyclobranol-4-hydroxy-α
-Production of methyl cinnamic acid ester 26.3 g of cyclobranol-4-propionyloxy-α-methyl cinnamic acid ester obtained by the method of Example 13
(0,040 mol) was dissolved in 200 d of dioxane, and 20 ml of 25% ammonia water! was dripped. After heating and stirring this mixture at 50° C. for 2 hours, the solvent was distilled off under reduced pressure. The residue was extracted with 200% chloroform, the chloroform layer was concentrated under reduced pressure, and the resulting crude crystals were recrystallized from acetone-methanol (1:1) to give cyclobranol-4-hydroxy-α-methylcinnamate ester. was obtained in a yield of 20.7 g.
収率83.1%、融蕉203〜204℃比旋光度〔α)
; +46.Oo (C1,00、ClICl3 )
元素分析結果 Ct、tlHbo03
(分子量600.89として)
計算値(%) :C81,95H10,0?実測値(
%) :C81,99H10,07■Rν、KBr(
C11′″り:3400.2920.2850.178
0、 1605.1510.1265.1200.11
70.1125゜PMR(CDC13’) δ: 0
.36 (IIl、 WABq+4.8Hz )、0
.61 (1B、 !4ABq、4.8Hz )
、0.80〜2.33 (271゜re ) 、0.
90 (6H,s) 、0.98 (611,s)
、1.60 (9H,s)、2.12 (3H,d、
1.2Hz) 、4.08〜4.88 (111,s
+) 、5.56〜5.80 (IH,n+) 、
6.70〜6.92 (2B、s+) 、7.12〜
7.44 (2H,m) 、7.58 (IH,q、
1.2Hz) 。Yield 83.1%, melting temperature 203-204℃ Specific rotation [α]
; +46. Oo (C1,00, ClICl3)
Elemental analysis results Ct, tlHbo03 (assuming molecular weight 600.89) Calculated value (%): C81,95H10,0? Actual measurement value (
%) :C81,99H10,07 ■Rν, KBr(
C11''ri: 3400.2920.2850.178
0, 1605.1510.1265.1200.11
70.1125゜PMR (CDC13') δ: 0
.. 36 (IIl, WABq+4.8Hz), 0
.. 61 (1B, !4ABq, 4.8Hz)
, 0.80-2.33 (271°re), 0.
90 (6H,s), 0.98 (611,s)
, 1.60 (9H,s), 2.12 (3H,d,
1.2Hz), 4.08~4.88 (111,s
+), 5.56-5.80 (IH, n+),
6.70~6.92 (2B, s+), 7.12~
7.44 (2H, m), 7.58 (IH, q,
1.2Hz).
実施例15 24−メチレンシクロアルタノール−4−
プロピオニルオキシ−α−メチルケ
イヒ酸エステルの製法
実施例13の方法にてシクロブラノールの代りに24−
メチレンシクロアルタノールを用いた以外は、同じ操作
法により24−メチレンシクロアルタノール−α−メチ
ルケイヒ酸エステル25.8gを得た。Example 15 24-methylenecycloartanol-4-
Process for producing propionyloxy-α-methylcinnamic acid ester In the method of Example 13, 24-
25.8 g of 24-methylenecycloartanol-α-methylcinnamic acid ester was obtained by the same procedure except that methylenecycloartanol was used.
収率78.5%、融点94〜95℃
Iり
比旋光度〔α) +44.2° (C1,00、C
ICl3 )元素分析結果 C穀H咋o4
(分子量656.95として)
計算値(%) :C80,44H9,82実測値(%
) :C80,48H9,78実施例1624−メチ
レンシクロアルタノール−4−ヒドロキシ−α−メチル
ケイヒ酸エ
ステルの製法
実施例15の方法で得た24−メチレンシクロアルタノ
ール−4−プロピオニルオキシ−α−メチルケイヒ酸エ
ステル24.0g (0,036モル)をジオキサン2
00−に溶解させ、25%アンモニア水20−を滴下し
た。この混合物を50℃で2時間加熱攪拌後、溶媒を減
圧下に留去し、残渣をクロロホルム200がで抽出し、
クロロホルム層を減圧下に濃縮し、得られた粗結晶をア
セトン−メタノール(1: 1)から再結晶し24−メ
チレンシクロアルタノール−4−ヒドロキシ−α−メチ
ルケイヒ酸エステルを収量19.4gで得た。Yield 78.5%, melting point 94-95°C Specific optical rotation [α) +44.2° (C1,00, C
ICl3) Elemental analysis results C-grain H-o4 (assuming molecular weight 656.95) Calculated value (%): C80,44H9,82 Actual value (%)
): C80,48H9,78 Example 16 24-Methylenecycloartanol-4-hydroxy-α-methylcinnamic acid ester 24-methylenecycloartanol-4-propionyloxy-α-methylcinnamate obtained by the method of Example 15 24.0 g (0,036 mol) of acid ester was added to dioxane 2
00-, and 20-25% aqueous ammonia was added dropwise. After heating and stirring this mixture at 50°C for 2 hours, the solvent was distilled off under reduced pressure, and the residue was extracted with 200% chloroform.
The chloroform layer was concentrated under reduced pressure, and the resulting crude crystals were recrystallized from acetone-methanol (1:1) to obtain 24-methylenecycloartanol-4-hydroxy-α-methylcinnamate in a yield of 19.4 g. Ta.
収率89.6%、融点195〜196℃比旋光度〔α)
、 + 43.8° (C1,00、CICl3
)元素分析結果 CSt/ Hbo 03(分子量60
0.89として)
計算値(%) :C81,95H10,0?実測値(
%) :C81,90H10,14実施例17 シ
クロアルテノール−4−ブチリルオキシ−α−エチルケ
イヒ酸エステルの
製法
4−ブチリルオキシ−α−エチルケイヒ酸3.50g
(0,0133モル)をベンゼン71111に溶解した
溶液を0℃に冷却し、これに塩化チオニル4.8me(
5当量)を滴下した。この混合物を60℃にて2時間加
熱攪拌後、過剰の塩化チオニル及び溶媒を減圧下に留去
し、ピリジン10m1を加え、0℃に冷却しながらシク
ロアルテノール2.85g (0,0067モル)を含
むピリジンLon1!溶液を滴下した。この混合物を2
0℃にて一夜攪拌した。反応後溶媒を減圧下に留去し、
残渣をクロロホルム40−で抽出し、クロロホルム層を
減圧下に濃縮し、得られた粗結晶をアセトン−エタノー
ル(1: 1)より再結晶し、シクロアルテノール−4
−ブチリルオキシ−α−エチルケイヒ酸エステルを収量
3.63gで得た。Yield 89.6%, melting point 195-196℃ Specific rotation [α]
, +43.8° (C1,00, CICl3
) Elemental analysis results CSt/Hbo 03 (molecular weight 60
As 0.89) Calculated value (%): C81,95H10,0? Actual measurement value (
%): C81,90H10,14 Example 17 Preparation of cycloartenol-4-butyryloxy-α-ethylcinnamic acid ester 3.50 g of 4-butyryloxy-α-ethylcinnamic acid
A solution of (0,0133 mol) dissolved in benzene 71111 was cooled to 0°C, and thionyl chloride 4.8 me (
5 equivalents) was added dropwise. After heating and stirring this mixture at 60°C for 2 hours, excess thionyl chloride and the solvent were distilled off under reduced pressure, 10ml of pyridine was added, and 2.85g (0,0067 mol) of cycloartenol was added while cooling to 0°C. Containing pyridine Lon1! The solution was added dropwise. Add this mixture to 2
Stirred overnight at 0°C. After the reaction, the solvent was distilled off under reduced pressure,
The residue was extracted with chloroform-40, the chloroform layer was concentrated under reduced pressure, and the obtained crude crystals were recrystallized from acetone-ethanol (1:1) to give cycloartenol-4.
-Butyryloxy-α-ethylcinnamic acid ester was obtained in a yield of 3.63 g.
収率80.7%、融点88〜89℃
比旋光度〔α〕菅 +41.2° (C1,00、Cl
ICl3 )元素分析結果 C’fHLb O4
(分子量670.98として)
計算値(%) :Cso、ss H9,92実測値
(%) :C80,64H9,84IRj/、KBr
(e1m″’1) : 3400.2940.2
860.1760.1710.1240.1200.1
170.1125゜PMR(CDC13) δ: 0.
36 (IH,!4ABq、4.2Hz )、0.52
〜2.22 (298,01) 、0.61 (lit
、 54ABq、4.2Hz) 、0.90 (6H,
s) 、0.96 (6)1.s) 、1.03 (3
H,t、7.2Hz) 、1.18 (3H,t、7.
2Hz) 、1.58 (3H,s)、1.66 (3
H,s) 、2.22〜2.80 (4H,m) 、4
.42〜4.88(IH,s+) 、4.88〜5.2
4 (IH,m) 、6.89〜7.18 (2H、m
) 、7.18〜7.46 (2H,s) 、7.46
〜7.64 (18,l11) 。Yield 80.7%, melting point 88-89°C Specific rotation [α] +41.2° (C1,00, Cl
ICl3) Elemental analysis results C'fHLb O4 (as molecular weight 670.98) Calculated value (%): Cso, ss H9,92 actual value (%): C80,64H9,84IRj/, KBr
(e1m'''1): 3400.2940.2
860.1760.1710.1240.1200.1
170.1125°PMR (CDC13) δ: 0.
36 (IH, !4ABq, 4.2Hz), 0.52
~2.22 (298,01), 0.61 (lit
, 54ABq, 4.2Hz) , 0.90 (6H,
s), 0.96 (6)1. s) , 1.03 (3
H, t, 7.2Hz), 1.18 (3H, t, 7.
2Hz), 1.58 (3H,s), 1.66 (3
H,s), 2.22-2.80 (4H,m), 4
.. 42-4.88 (IH, s+), 4.88-5.2
4 (IH, m), 6.89-7.18 (2H, m
), 7.18-7.46 (2H,s), 7.46
~7.64 (18,l11).
実施例18 シクロアルテノール−4−ヒドロキシ−
α−エチルケイし酸エステルの製法
実施例17の方法で得たシクロアルテノール−4−ブチ
リルオキシ−α−エチルケイヒ酸エステル2、OOg
(0,003モル)をジオキサン20m1に溶解させ、
25%アンモニア水2−を滴下した。この混合物を50
℃で5時間加熱した。反応後、溶媒を減圧下に留去し、
残渣をクロロホルム20−で抽出し、クロロホルム層を
減圧下に濃縮し、得られた粗結晶をアセトンより再結晶
し、シクロアルテノール−4−ヒドロキシ−α−エチル
ケイヒ酸エステルを収量 1.68gで得た。Example 18 Cycloartenol-4-hydroxy-
Production of α-ethyl silicate ester Cycloartenol-4-butyryloxy-α-ethyl cinnamic acid ester 2 obtained by the method of Example 17, OOg
(0,003 mol) was dissolved in 20 ml of dioxane,
25% ammonia water 2- was added dropwise. 50% of this mixture
Heated at ℃ for 5 hours. After the reaction, the solvent was distilled off under reduced pressure,
The residue was extracted with 20-chloroform, the chloroform layer was concentrated under reduced pressure, and the obtained crude crystals were recrystallized from acetone to obtain cycloartenol-4-hydroxy-α-ethylcinnamate in a yield of 1.68 g. Ta.
収率93.2%、融点162.5〜163℃比旋光度〔
α〕智 +46.1° (C1,00、CICl3 ’
)元素分析結果 C,// Hbo O3(分子量60
0.89として)
計算値(%’) :C81,95H10,0?実測値
(%) :C81,88H10,12IRν、KBr
(cm−1) : 3300.2920.280
0.1760.1710.1625.1500.128
0.1240.1200゜1165.1120゜
P M R(CDCl3 ) δ: 0.36 (IH
,%ABq、4.2Hz )、0.52〜2.22 (
27)1.m ) 、0.61 (IH,%ABq、4
.2Hz) 、0.90 (6H,s) 、0.96
(6H,s) 、1.19 (3H,t、7.2Hz)
、 1.60 (38,s) 、1.67 (3H,
s) 、2.57(2H,bq、7.2Hz ) 、4
.47〜4.88 (IH,m) 、4.92〜5.3
2 (IH,m) 、6.43〜6.67 (18,
m) 、6.68〜7.04(2H,m) 、7.
12〜7.48 (2H,m) 、7.52〜7.6
9 (ill+m)一
実施例19 シクロブラノール−4−ブチリルオキシ
−α−エチルケイヒ酸エステルの製
法
4−ブチリルオキシ−α−エチルケイヒ酸5.25g
(0,02モル)をベンゼン10m1’に熔解し、その
溶液を0℃に冷却しながら、塩化チオニル7.3−(5
当量)を滴下した。この混合物を60℃にて2時間加熱
攪拌後、過剰の塩化チオニル及び溶媒を減圧下に留去し
、残渣にピリジン40−を加え、0℃に冷却しながらシ
クロブラノール4.41g (0,001モル)を加え
た。この混合物を20℃にて一夜攪拌した。反応後溶媒
を減圧下に留去し、残渣をクロロホルム60−で抽出し
、クロロホルム層を減圧下に濃縮し、得られた粗結晶を
アセトン−エタノール(1: 1)より再結晶し、シク
ロブラノール−4−ブチリルオキシ−α−エチルケイヒ
酸エステルを収量4.80gで得た。Yield 93.2%, melting point 162.5-163℃, specific optical rotation [
α] Wisdom +46.1° (C1,00, CICl3'
) Elemental analysis results C, // Hbo O3 (molecular weight 60
As 0.89) Calculated value (%'): C81,95H10,0? Actual value (%): C81, 88H10, 12IRν, KBr
(cm-1): 3300.2920.280
0.1760.1710.1625.1500.128
0.1240.1200゜1165.1120゜P M R (CDCl3) δ: 0.36 (IH
, %ABq, 4.2Hz), 0.52-2.22 (
27)1. m ), 0.61 (IH, %ABq, 4
.. 2Hz), 0.90 (6H,s), 0.96
(6H,s), 1.19 (3H,t, 7.2Hz)
, 1.60 (38,s) , 1.67 (3H,
s), 2.57 (2H, bq, 7.2Hz), 4
.. 47-4.88 (IH, m), 4.92-5.3
2 (IH, m), 6.43-6.67 (18,
m), 6.68-7.04 (2H, m), 7.
12-7.48 (2H, m), 7.52-7.6
9 (ill+m) Example 19 Preparation of cyclobranol-4-butyryloxy-α-ethylcinnamic acid ester 5.25 g of 4-butyryloxy-α-ethylcinnamic acid
(0.02 mol) was dissolved in 10 ml of benzene, and while cooling the solution to 0°C, thionyl chloride 7.3-(5
equivalent amount) was added dropwise. After heating and stirring this mixture at 60°C for 2 hours, excess thionyl chloride and the solvent were distilled off under reduced pressure, 40-pyridine was added to the residue, and while cooling to 0°C, 4.41 g of cyclobranol (0, 001 mol) was added. This mixture was stirred at 20°C overnight. After the reaction, the solvent was distilled off under reduced pressure, the residue was extracted with 60-chloroform, the chloroform layer was concentrated under reduced pressure, the obtained crude crystals were recrystallized from acetone-ethanol (1:1), and cyclobranched. Nol-4-butyryloxy-α-ethylcinnamic acid ester was obtained in a yield of 4.80 g.
収率70.1%、融点117.5〜118℃比旋光度〔
α〕智 +38.6° (C1,00、CHCl3 )
元素分析結果 C俤H&904
(分子量685.00として)
計算値(%) :C80,65H10,01実測値(
%) :C80,59H10,06IRν、KBr
(am−’) : 3400.2900.2B50
゜1770.1710.1625.1510.1230
.1120゜PMR(CDC13)δ: 0.36 (
IH−、!4ABq、4.8Hz )、0.52〜2.
24 (29H,m ) 、0.61 (iff、 %
ABq、4.8fiz) 、0.90 (611,s)
、0.96 (6H,s) 、1.03 (3H,t
、7.211z) 、1.18 (3H,t、7.2H
z) 、1.59 (9H,s)、2.24〜2.82
(41,m) 、4.48〜4.84 (111,m
) 、6.90〜7.18 (28,m) 、7.18
〜7.48 (2H,m) 、7.48〜7.68 (
IH,m) 。Yield 70.1%, melting point 117.5-118℃ Specific optical rotation [
α] Wisdom +38.6° (C1,00, CHCl3)
Elemental analysis results C H&904 (assuming molecular weight 685.00) Calculated value (%): C80,65H10,01 actual value (
%): C80,59H10,06IRν, KBr
(am-'): 3400.2900.2B50
゜1770.1710.1625.1510.1230
.. 1120°PMR (CDC13) δ: 0.36 (
IH-,! 4ABq, 4.8Hz), 0.52-2.
24 (29H, m), 0.61 (if, %
ABq, 4.8fiz), 0.90 (611,s)
, 0.96 (6H, s) , 1.03 (3H, t
, 7.211z) , 1.18 (3H, t, 7.2H
z), 1.59 (9H, s), 2.24-2.82
(41, m), 4.48~4.84 (111, m
), 6.90-7.18 (28, m), 7.18
~7.48 (2H, m), 7.48~7.68 (
IH, m).
実施例20 シクロブラノール−4−ヒドロキシ−α
−エチルケイヒ酸エステルの製法
実施例19の方法にて得たシクロブラノール−4−ブチ
リルオキシ−α−エチルケイヒ酸エステル4.11g
(0,0060モル)をジオキサン30−に溶解させ、
25%濃アンモニア水31n1を滴下した。この混合物
を50℃で5時間加熱した。反応後溶媒を減圧下に留去
し、残渣をクロロホルム40−で抽出し、クロロホルム
層を減圧下に濃縮し、得られた粗結晶をアセトンより再
結晶し、シクロブラノール−4−ヒドロキシ−α−エチ
ルケイヒ酸エステルを収量3.39gで得た。Example 20 Cyclobranol-4-hydroxy-α
-Production of ethylcinnamic acid ester 4.11 g of cyclobranol-4-butyryloxy-α-ethylcinnamic acid ester obtained by the method of Example 19
(0,0060 mol) is dissolved in dioxane 30-,
31n1 of 25% concentrated ammonia water was added dropwise. This mixture was heated at 50°C for 5 hours. After the reaction, the solvent was distilled off under reduced pressure, the residue was extracted with 40-chloroform, the chloroform layer was concentrated under reduced pressure, the obtained crude crystals were recrystallized from acetone, and cyclobranol-4-hydroxy-α -Ethylcinnamic acid ester was obtained in a yield of 3.39 g.
収率91.9%、融点202〜203℃比旋光度〔α〕
智 +44.0° (C1,00、ClICl3 ”)
元素分析結果 C傘2 H6203
(分子量614.92として)
計算値(%’) :C82,03H10,16実測値
(%”) :C81,97H10,18IRν、KB
r (cm−’) : 3350.2920.28
60.1680.1600.1510.1275.12
45.1200.1170.1130゜
PMR(cl)cl3 ) δ: 0.36 (LH,
’AABq、4.8Hz )、0.52〜2.24 (
27H,m ) 、0.61 (1B、 %ABq、4
.8tlz) 、0.90 (68,s) 、0.97
(6H,s)、1.19 (38,t、7.2Hz)
、1.61 (9H,s) 、2.57 (2H,b
q、7.2Hz )、4.52〜4.84 (LH,m
) 、6.43〜6.64 (IH,m> 、6.
64〜7.02 (2Lm) 、7.12〜7.48
(2H,m) 、7.48〜7.67 (LH,m
) 。Yield 91.9%, melting point 202-203℃ Specific rotation [α]
Wisdom +44.0° (C1,00, ClICl3”)
Elemental analysis results C Umbrella 2 H6203 (as molecular weight 614.92) Calculated value (%'): C82,03H10,16 Actual value (%''): C81,97H10,18IRν, KB
r (cm-'): 3350.2920.28
60.1680.1600.1510.1275.12
45.1200.1170.1130゜PMR(cl)cl3) δ: 0.36 (LH,
'AABq, 4.8Hz), 0.52~2.24 (
27H,m), 0.61 (1B, %ABq, 4
.. 8tlz), 0.90 (68,s), 0.97
(6H,s), 1.19 (38,t, 7.2Hz)
, 1.61 (9H,s) ,2.57 (2H,b
q, 7.2Hz), 4.52-4.84 (LH, m
), 6.43-6.64 (IH, m>, 6.
64~7.02 (2Lm), 7.12~7.48
(2H, m), 7.48~7.67 (LH, m
).
実施例21 シクロアルテノール−3−メトキシ−4
−バレリルオキシ−α−プロピルケ
イヒ酸エステルの製法
原料として3−メトキシ−4−バレリルオキシ−α−プ
ロピルケイヒ酸17゜9g (0,056モル)を用い
た以外は実施例7と同じ操作法によりシクロアルテノー
ル−3−メトキシ−4−バレリルオキシ−α−プロピル
ケイヒ酸エステルを収量23.2gで得た。Example 21 Cycloartenol-3-methoxy-4
-Production of valeryloxy-α-propylcinnamic acid ester Cycloalcoal was prepared using the same procedure as in Example 7, except that 17.9 g (0,056 mol) of 3-methoxy-4-valeryloxy-α-propylcinnamic acid was used as the raw material. Tenol-3-methoxy-4-valeryloxy-α-propylcinnamic acid ester was obtained in a yield of 23.2 g.
収率77.6%、融点113〜114℃比旋光度〔α〕
智 +34.2° (C1,00、CHCl3 )元素
分析結果 C仝9Hりλo5
(分子量729.06として)
計算値(%) :C79,07H9,95実測値(%
):C79,13H9,88実施例22 シクロアル
テノール−4−ヒドロキシ−3−メトキシ−α−プロピ
ルケイヒ
酸エステルの製法
原料として実施例21の方法で得たシクロアルテノール
−3−メトキシ−4−バレリルオキシ−α−プロピルケ
イヒ酸エステル23.3g (0,032モル)を用い
た以外は実施例8と同じ操作法によりシクロアルテノー
ル−4−ヒドロキシ−4−メトキシ−α−プロピルケイ
ヒ酸エステルを収量18.1gで得た。Yield 77.6%, melting point 113-114℃ Specific rotation [α]
+34.2° (C1,00, CHCl3) Elemental analysis result C9H λo5 (assuming molecular weight 729.06) Calculated value (%): C79,07H9,95 Actual value (%)
): C79,13H9,88 Example 22 Process for producing cycloartenol-4-hydroxy-3-methoxy-α-propylcinnamate Cycloartenol-3-methoxy-4- obtained by the method of Example 21 as a raw material Cycloartenol-4-hydroxy-4-methoxy-α-propylcinnamic acid ester was obtained by the same procedure as in Example 8 except that 23.3 g (0,032 mol) of valeryloxy-α-propylcinnamic acid ester was used. Obtained in 18.1 g.
収率87.6%、融点122〜123℃比旋光度〔α〕
智 +41.2° (C1,0O1CHC13)元素分
析結果 C93H6S/ 04
(分子量644.94として)
計算値(%) :C80,07H10,00実測値(
%) :C80,14H9,97実jll123
シクロアルテノール−4−カプリルオキシ−3−メトキ
シ−α−ブチルケイ
ヒ酸エステルの製法
原料として4−カプリルオキシ−3−メトキシ−α−ブ
チルケイヒ酸19.2g (0,0551モル)を用い
た以外は実施例7と同じ操作法によりシクロアルテノー
ル−4−カプリルオキシ−3−メトキシ−α−ブチルケ
イヒ酸エステルを収量22.7gで得た。Yield 87.6%, melting point 122-123℃ Specific rotation [α]
Satoshi +41.2° (C1,0O1CHC13) Elemental analysis result C93H6S/ 04 (assuming molecular weight 644.94) Calculated value (%): C80,07H10,00 Actual value (
%) :C80,14H9,97 fruit jll123
Process for producing cycloartenol-4-capryloxy-3-methoxy-α-butylcinnamic acid ester Except for using 19.2 g (0,0551 mol) of 4-capryloxy-3-methoxy-α-butylcinnamic acid as the raw material. Using the same procedure as in Example 7, cycloartenol-4-capryloxy-3-methoxy-α-butylcinnamate was obtained in a yield of 22.7 g.
収率54.4%、融点100〜101℃比旋光度〔α〕
智 +33.5° (C1,00、CHCl3 )元素
分析結果 Cpo H7bOs
(分子量757.11として)
計算値(%’) :C79,31H10,12実測値
(%”) :C79,38H10,05実施例24
シクロアルテノール−4−ヒドロキシ−3−メトキシ
−α−ブチルケイヒ酸
エステルの製法
原料としてシクロアルテノール−4−カプリルオキシ−
3−メトキシ−α−ブチルケイヒ酸24.4g (0,
032モル)を用いた以外は実施例8と同じ操作法によ
りシクロアルテノール−4−ヒドロキシ−3−メトキシ
−α−ブチルケイヒ酸エステルを収量17.8gで得た
。Yield 54.4%, melting point 100-101℃ Specific rotation [α]
Satoshi +33.5° (C1,00, CHCl3) Elemental analysis result Cpo H7bOs (as molecular weight 757.11) Calculated value (%'): C79,31H10,12 Actual value (%''): C79,38H10,05 Example 24
Cycloartenol-4-capryloxy- as a raw material for the production of cycloartenol-4-hydroxy-3-methoxy-α-butylcinnamate ester
3-methoxy-α-butylcinnamic acid 24.4g (0,
Cycloartenol-4-hydroxy-3-methoxy-α-butylcinnamic acid ester was obtained in a yield of 17.8 g by the same procedure as in Example 8, except that 032 mol) was used.
収率84.4%、融点110〜111℃比旋光度〔α〕
智 +40.6° (C1,00、CICl3 )元素
分析結果 C<tシH46o4
(分子量672.99として)
計算値(%’) :C80,19H10,10実測値
(%) =CBo、24 H10,05実施例25
シクロブラノール−4−ヒドロキシ−3−メトキシ
−α−ブチルケイヒ酸エ
ステルの製法
原料としてシクロブラノール−4−カプリルオキシ−3
−メトキシ−α−ブチルケイヒ酸26.2g(0,03
4モル)を用いた以外は実施例8と同じ操作法によりシ
クロブラノール−4−ヒドロキシ−3−メトキシ−α−
ブチルケイヒ酸エステルを収量18.4gで得た。Yield 84.4%, melting point 110-111℃ Specific rotation [α]
+40.6° (C1,00, CICl3) Elemental analysis result C<tshiH46o4 (assuming molecular weight 672.99) Calculated value (%'): C80,19H10,10 Actual value (%) =CBo, 24 H10, 05 Example 25
Cyclobranol-4-capryloxy-3 as a raw material for the production of cyclobranol-4-hydroxy-3-methoxy-α-butylcinnamic acid ester
-Methoxy-α-butylcinnamic acid 26.2 g (0.03
Cyclobranol-4-hydroxy-3-methoxy-α-
Butyl cinnamic acid ester was obtained in a yield of 18.4 g.
収率80.4%、融点132〜133°C比旋光度〔α
〕習 +37.0” (C1,00,CHCl3 )
元素分析結果 CqHb904
(分子量672.99として)
計算値(%):C80,31H10,18実測値(%)
:C80,39H10,04実施例2624−メチ
レンシクロアルタノール−4−ヒドロキシー3−メトキ
シーα−ブ
チルケイヒ酸エステルの製法
原料として24−メチレンシクロアルタノール−4−カ
プリルオキシ−3−メトキシ−α−ブチルケイヒ酸26
.2g (0,034モル)を用いた以外は実施例8と
同じ操作法により24−メチレンシクロアルタノール−
4−ヒドロキシ−3−メトキシ−α−ブチルケイヒ酸エ
ステルを収量18.1gで得た。Yield 80.4%, melting point 132-133°C specific optical rotation [α
] Xi +37.0” (C1,00, CHCl3)
Elemental analysis results CqHb904 (as molecular weight 672.99) Calculated value (%): C80,31H10,18 actual value (%)
:C80,39H10,04 Example 2624-Methylenecycloartanol-4-hydroxy-3-methoxy-α-butylcinnamic acid ester 24-methylenecycloartanol-4-capryloxy-3-methoxy-α-butylcinnamic acid as raw material 26
.. 24-methylenecycloartanol-24-methylenecycloartanol-
4-Hydroxy-3-methoxy-α-butylcinnamic acid ester was obtained in a yield of 18.1 g.
収率79.1%、融点124〜125℃比旋光度〔α〕
智 +39.8° (C1,00、CHCl3 )元素
分析結果 CげH6804
(分子量672.99として)
計算値(%) :C80,31H10,18実測値(
%):C80,25H10,22実施例27 シクロ
アルテノール−3−エトキシ−4−ヒドロキシ−α−メ
チルケイヒ猷
エステルの製法
原料としてシクロアルテノール−3−エトキシ−4−プ
ロピオニルオキシ−α−メチルケイヒ酸エステル22.
0g (0,032モル)を用いた以外は実施例8と同
じ操作法によりシクロアルテノール−3−エトキシ−4
−ヒドロキシ−α−メチルケイヒ酸エステルを収量15
.8gで得た。Yield 79.1%, melting point 124-125℃ Specific rotation [α]
+39.8° (C1,00, CHCl3) Elemental analysis result C+H6804 (as molecular weight 672.99) Calculated value (%): C80,31H10,18 Actual value (
%): C80,25H10,22 Example 27 Cycloartenol-3-ethoxy-4-hydroxy-α-methylcinnamate ester as raw material Cycloartenol-3-ethoxy-4-propionyloxy-α-methylcinnamate ester 22.
Cycloartenol-3-ethoxy-4 was prepared using the same procedure as in Example 8 except that 0 g (0,032 mol) was used.
-Hydroxy-α-methyl cinnamic acid ester yield: 15
.. Obtained in 8g.
収率78.2%、融点132〜133℃比旋光度〔α〕
智 +43.9° (C1,00、CHCl3 )元素
分析結果 C似HA204
(分子量630.92として)
計算値(%”) :C79,95H9,91実測値(
%”) :C79,90H9,99実施例28 シ
クロブラノール−3−エトキシ−4=ヒドロキシ−α−
メチルケイヒ酸エ
ステルの製法
原料としてシクロブラノール−3−エトキシ−4−プロ
ピオニルオキシ−α−メチルケイヒ酸エステル21.7
g <0.031モル)を用いた以外は実施例8と同じ
操作法によりシクロブラノール−3−エトキシ−4−ヒ
ドロキシ−α−メチルケイヒ酸エステルを収量16.1
gで得た。Yield 78.2%, melting point 132-133℃ Specific rotation [α]
+43.9° (C1,00, CHCl3) Elemental analysis result C-like HA204 (assuming molecular weight 630.92) Calculated value (%”): C79,95H9,91 Actual value (
%”): C79,90H9,99 Example 28 Cyclobranol-3-ethoxy-4=hydroxy-α-
Cyclobranol-3-ethoxy-4-propionyloxy-α-methylcinnamic acid ester as a raw material 21.7
Cyclobranol-3-ethoxy-4-hydroxy-α-methylcinnamic acid ester was obtained in a yield of 16.1 mol by the same procedure as in Example 8, except that 0.031 mol) was used.
Obtained in g.
収率80.5%、融点174〜175℃比旋光度〔α〕
智 +42.4° (C1,00,CICl3 ”)元
素分析結果 CJHb5104
(分子量644.94として)
計算値(%) :CBo、07 H10,00実測
値(%”) :CBo、18 H10,05実施例
2924−メチレンシクロアルタノール−3−エトキシ
−4−ヒドロキシ−α−メ
チルケイヒ酸エステルの製法
原料として24−メチレンシクロアルタノール−3−エ
トキシ−4−プロピオニルオキシ−α−メチルケイヒ酸
エステル22.2g (0,0317モル)ヲ用いた以
外は実施例8と同じ操作法により24−メチレンシクロ
アルタノール−3−エトキシ−4−ヒドロキシ−α−メ
チルケイヒ酸エステルを収量16.7gで得た。Yield 80.5%, melting point 174-175℃ Specific rotation [α]
+42.4° (C1,00,CICl3'') Elemental analysis result CJHb5104 (as molecular weight 644.94) Calculated value (%): CBo, 07 H10,00 actual value (%''): CBo, 18 H10,05 implementation Example 29 22.2 g of 24-methylenecycloartanol-3-ethoxy-4-hydroxy-α-methylcinnamate 24-methylenecycloartanol-3-ethoxy-4-propionyloxy-α-methylcinnamate as raw material ( 24-methylenecycloartanol-3-ethoxy-4-hydroxy-α-methylcinnamic acid ester was obtained in a yield of 16.7 g by the same procedure as in Example 8, except that 0.0317 mol) was used.
収率81.6%、融点134〜135℃比旋光度〔α〕
智 +40.2° (C1,00、ClICl3 )元
素分析結果 Co3H6604
(分子量644.94として)
計算値(%) :C80,07H10,00実測値(
%) :C80,13H9,92実施例30 シク
ロアルテノール−3−エトキシ−4−ヒドロキシーα−
エチルケイヒ酸
エステルの製法
原料としてシクロアルテノール−4−ブチリルオキシ−
3−エトキシ−α−メチルケイヒ酸エステル21.5g
(0,030モル)を用いた以外は実施例8と同じ操
作法によりシクロアルテノール−3−エトキシ−4ヒド
ロキシ−α−エチルケイヒ酸エステルを収量15.4g
で得た。Yield 81.6%, melting point 134-135℃ Specific rotation [α]
+40.2° (C1,00, ClICl3) Elemental analysis result Co3H6604 (as molecular weight 644.94) Calculated value (%): C80,07H10,00 Actual value (
%): C80,13H9,92 Example 30 Cycloartenol-3-ethoxy-4-hydroxy-α-
Cycloartenol-4-butyryloxy- as a raw material for the production of ethylcinnamic acid ester
21.5 g of 3-ethoxy-α-methyl cinnamic acid ester
Cycloartenol-3-ethoxy-4hydroxy-α-ethylcinnamate was obtained in a yield of 15.4 g using the same procedure as in Example 8, except that (0,030 mol) was used.
I got it.
収率79.6%、融点124〜125℃比旋光度〔α〕
智 +41.2° (C1,00、ClICl3 )元
素分析結果 Cy3 Hb’l O4(分子量644.
94として)
計算値(%”) :C80,07H10,00実測値
(%) :C80,04H10,08実施例31
シクロアルテノール−3−エトキシ−4−ヒドロキシ−
α−プロピルケイヒ
酸エステルの製法
原料としてシクロアルテノール−3−エトキシ−4−バ
レリルオキシ−α−プロピルケイヒ酸工ステル26.O
g (0,035モル)を用いた以外は実施例8と同じ
操作法によりシクロアルテノール−3−エトキシ−4−
ヒドロキシ−α−プロピルケイヒ酸エステル16.8g
を得た。Yield 79.6%, melting point 124-125℃ Specific rotation [α]
+41.2° (C1,00, ClICl3) Elemental analysis results Cy3 Hb'l O4 (molecular weight 644.
94) Calculated value (%”): C80,07H10,00 Actual value (%): C80,04H10,08 Example 31
Cycloartenol-3-ethoxy-4-hydroxy-
Process for producing α-propylcinnamic acid ester Cycloartenol-3-ethoxy-4-valeryloxy-α-propylcinnamic acid ester 26. O
Cycloartenol-3-ethoxy-4-
Hydroxy-α-propylcinnamate ester 16.8g
I got it.
収率72.8%、融点111〜112℃比旋光度〔α〕
智 +40.7” (C1,00、CICl3 )元
素分析結果 Cq%t Hbb O4(分子量658.
97として)
計算値(%) :C80,19HIG、10実測値(
%) :C8Q、26 H10,02実施例32
シクロブラノール−3−エトキシ−4−ヒドロキシ−
α−プロピルケイヒ酸
エステルの製法
原料としてシクロブラノール−3−エトキシ−4−バレ
リルオキシ−α−プロピルケイヒ酸エステル24.2g
(0,032モル)を用いた以外は実施例8と同じ操
作法によりシクロブラノール−3−エトキシ−4−ヒド
ロキシ−α−プロピルケイヒ酸エステル16.7gを得
た。Yield 72.8%, melting point 111-112℃ Specific rotation [α]
+40.7" (C1,00, CICl3) Elemental analysis results Cq%t Hbb O4 (molecular weight 658.
97) Calculated value (%): C80, 19HIG, 10 actual measurement value (
%): C8Q, 26 H10,02 Example 32
Cyclobranol-3-ethoxy-4-hydroxy-
Cyclobranol-3-ethoxy-4-valeryloxy-α-propylcinnamic acid ester 24.2g as a raw material for the production of α-propylcinnamic acid ester
16.7 g of cyclobranol-3-ethoxy-4-hydroxy-α-propylcinnamic acid ester was obtained by the same procedure as in Example 8 except that (0,032 mol) was used.
収率72.8%、融点134〜135℃比旋光度〔α〕
智 +37゜1’ (C1,00、CICl3 )元
素分析結果 Cttt H6904
(分子量672.99として)
計算値(%) :C80,3L H10,18実測
値(%) :C8(1,25I(10,24実施例3
3 シクロアルテノール−3−エトキシ−4−ヒドロ
キシ−α−ブチルケイヒ酸
エステルの製法
原料としてシクロアルテノール−4−カプリルオキシ−
3−エトキシ−α−ブチルケイヒ酸エステル23.1
g (0,030モル)を用いた以外は実施例8と同じ
操作法によりシクロアルテノール−3−エトキシ−4−
ヒドロキシ−α−ブチルケイヒ酸エステル16.2gを
得た。Yield 72.8%, melting point 134-135℃ Specific rotation [α]
+37゜1' (C1,00, CICl3) Elemental analysis result Cttt H6904 (assuming molecular weight 672.99) Calculated value (%): C80,3L H10,18 actual value (%): C8 (1,25I (10, 24 Example 3
3 Cycloartenol-4-capryloxy- as a raw material for the production of cycloartenol-3-ethoxy-4-hydroxy-α-butylcinnamate ester
3-Ethoxy-α-butylcinnamate ester 23.1
Cycloartenol-3-ethoxy-4-
16.2 g of hydroxy-α-butylcinnamic acid ester was obtained.
収率80.2%、融点99〜100℃
比旋光度〔α〕智 +40.0° (C1,00、CI
Cl3 ”)元素分析結果 C<tsHb訃04
(分子量672.99として)
計算値(%) :C80,3L H10,18実測
値(%) :CBo、2L H10,22実施例3
4 シクロアルテノール−4−ヒドロキシ−3−プロ
ポキシ−α−メチルケイヒ
酸エステルの製法
原料としてシクロアルテノール−4−プロピオニルオキ
シ−3−プロポキシ−α−メチルケイヒ酸エステル23
.1g (0,033モル)を用いた以外は実施例8と
同じ操作法によりシクロアルテノール−4−ヒトμキシ
ー3−プロポキシーα−メチルケイヒ酸エステル17.
2gを得た。Yield 80.2%, melting point 99-100°C Specific rotation [α] +40.0° (C1,00, CI
Cl3'') Elemental analysis results C<tsHb 04 (assuming molecular weight 672.99) Calculated value (%): C80,3L H10,18 Actual value (%): CBo, 2L H10,22 Example 3
4 Cycloartenol-4-propionyloxy-3-propoxy-α-methylcinnamic acid ester as a raw material for the production of cycloartenol-4-hydroxy-3-propoxy-α-methylcinnamic acid ester 23
.. Cycloartenol-4-human μxy 3-propoxy α-methylcinnamic acid ester 17.
2g was obtained.
収率80.8%、融点138〜139℃比旋光度(α〕
智 +43.7° (C1,00、CHCl3 )元素
分析結果 C,、aH6,04
(分子量644.94として)
計算値(%) :C80,07H10,00実測値(
%’) :CBo、19 H10,04実施例35
シクロアルテノール−4−ヒドロキシ−3−ブトキ
シ−α−メチルケイヒ酸
エステルの製法
原料としてシクロアルテノール−4−プロピオニルオキ
シ−3−ブトキシ−α−メチルケイヒ酸エステル22.
9g (0,032モル)を用いた以外は実施例8と同
じ操作法によりシクロアルテノール−4−ヒドロキシ−
3−ブトキシ−α−メチルケイヒ酸エステル16.5g
を得た。Yield 80.8%, melting point 138-139℃ Specific rotation (α)
+43.7° (C1,00, CHCl3) Elemental analysis result C,, aH6,04 (as molecular weight 644.94) Calculated value (%): C80,07H10,00 Actual value (
%'): CBo, 19 H10,04 Example 35
Cycloartenol-4-propionyloxy-3-butoxy-α-methylcinnamic acid ester as a raw material for the production of cycloartenol-4-hydroxy-3-butoxy-α-methylcinnamic acid ester 22.
Cycloartenol-4-hydroxy-
3-butoxy-α-methylcinnamate ester 16.5g
I got it.
収率78.2%、融点126〜127℃比旋光度〔α〕
智 +39.7° (C1,00、CICl3 )元素
分析結果 CシタH66o4
(分子量658.97として)
計算値(%) :C80,19H10,10実測値(
%”) :C80,24H10,03実施例3624
−メチレンシクロアルタノール−4−ブチリルオキシ−
3−メトキシ−α
−エチルケイヒ酸エステルの製法
原料として24−メチレンシクロアルタノール18.1
g (0,041モル)を用いた以外は実施例9と同じ
操作法により24−メチレンシクロアルタノール−4−
ブチリルオキシ−3−メトキシ−α−エチルヶイヒ酸エ
ステル22.8gを得た。Yield 78.2%, melting point 126-127℃ Specific rotation [α]
+39.7° (C1,00, CICl3) Elemental analysis result Cita H66o4 (as molecular weight 658.97) Calculated value (%): C80,19H10,10 Actual value (
%"): C80,24H10,03 Example 3624
-methylenecycloartanol-4-butyryloxy-
24-methylenecycloartanol 18.1 as a raw material for the production of 3-methoxy-α-ethylcinnamic acid ester
24-methylenecycloartanol-4-
22.8 g of butyryloxy-3-methoxy-α-ethyl biarsenic acid ester was obtained.
収率77.8%、融点127〜128℃比旋光度〔α〕
智 +35.1° (C1,0O1C)IC13)元素
分析結果 C<t7 H7605
(分子量715.03として)
計算値(%) :C78,94H9,87実測値(%
) :C78,90H9,79実施例3724−メチ
レンシクロアルタノール−4−ヒドロキシ−3−メトキ
シ−α−エ
チルケイヒ酸エステルの製法
原料として24−メチレンシクロアルタノール−4−ブ
チリルオキシ−3−メトキシ−α−エチルケイ、ヒ酸エ
ステル21.5g (0,0301モル)を用いた以外
は実施例10と同じ操作法により24−メチレンシクロ
アルタノール−4−ヒドロキシ−3−メトキシ−α−エ
チルケイヒ酸エステル17.3g ヲ得た。Yield 77.8%, melting point 127-128℃ Specific rotation [α]
Satoshi +35.1° (C1,0O1C)IC13) Elemental analysis result C<t7 H7605 (as molecular weight 715.03) Calculated value (%): C78,94H9,87 Actual value (%)
): C78,90H9,79 Example 3724-Methylenecycloartanol-4-hydroxy-3-methoxy-α-ethylcinnamic acid ester 24-methylenecycloartanol-4-butyryloxy-3-methoxy-α- as a raw material 17.3 g of 24-methylenecycloartanol-4-hydroxy-3-methoxy-α-ethyl cinnamic acid ester was prepared using the same procedure as in Example 10 except that 21.5 g (0,0301 mol) of ethyl cinnamic acid ester was used. I got it.
収率89.1%、融点137〜138℃比旋光度〔α〕
智 +40.7° (C1,0O1CHC13)元素分
析結果 C,3H6り04
(分子量644.94として)
計算値(%) :C80,07H10,00実測値(
%) :C80,1L H9,93実施例38
シクロブラノール−4−ヒドロキシ−3−プロポキシ−
α−エチルケイヒ酸
エステルの製法
原料としてシクロブラノール−4−ブチリルオキシ−3
−プロポキシ−α−エチルヶイヒ酸エステル22.1g
(0,0297モル)を用いた以外は実施例8と同じ
操作法によりシクロブラノール−4−ヒドロキシ−3−
プロポキシ−α−エチルヶイヒ酸エステル17.8gを
得た。Yield 89.1%, melting point 137-138℃ Specific rotation [α]
+40.7° (C1,0O1CHC13) Elemental analysis result C,3H6ri04 (as molecular weight 644.94) Calculated value (%): C80,07H10,00 Actual value (
%): C80,1L H9,93 Example 38
Cyclobranol-4-hydroxy-3-propoxy-
Cyclobranol-4-butyryloxy-3 as a raw material for the production of α-ethylcinnamic acid ester
-Propoxy-α-ethyl biarsenic acid ester 22.1g
Cyclobranol-4-hydroxy-3-
17.8 g of propoxy-α-ethyl biarsenic acid ester was obtained.
収率89.1%、融点140〜141℃比旋光度(α)
! +36.8° (C1,00,CHCl3 )
元素分析結果 C4rH6204
(分子量672.99として)
計算値(%) :C80,31H10,1B実測値(
%) :C80,36H10,12実)lJ39 2
4−メチレンシクロアルタノール−4−ヒドロキシ−3
−プロポキシ−α−
プロピルケイヒ酸エステルの製法
原料として24−メチレンシクロアルタノール−3−プ
ロポキシ−4−バレリルオキシ−α−プロピルケイヒ酸
エステル23.5g (0,0305モル)ヲ用いた以
外は実施例8と同じ操作法により24−メチレンシクロ
アルタノール−4−ヒドロキシ−3=プロポキシ−α−
プロピルケイヒ酸エステル17.2gを得た。Yield 89.1%, melting point 140-141℃ Specific rotation (α)
! +36.8° (C1,00, CHCl3)
Elemental analysis result C4rH6204 (as molecular weight 672.99) Calculated value (%): C80,31H10,1B actual value (
%) :C80,36H10,12 fruit) lJ39 2
4-methylenecycloartanol-4-hydroxy-3
-Production method of propoxy-α-propylcinnamic acid ester Example except that 23.5 g (0,0305 mol) of 24-methylenecycloartanol-3-propoxy-4-valeryloxy-α-propylcinnamic acid ester was used as the raw material. 24-methylenecycloartanol-4-hydroxy-3=propoxy-α-
17.2 g of propylcinnamic acid ester was obtained.
収率8261%、融点120〜121℃比旋光度〔α〕
甘 千39.1° (C1,0OSCIC13)元素分
析結果 C<t(、H7o04
(分子量687.02として)
計算値(%):C80,41H10,27実測値(%)
:C80,32H10,34実施例40〜42
シクロアルテノール、シクロブラノール又は24−メチ
レンシクロア
ルタノール−3−プロピオニルオ
キシ−α−メチルケイ上酸エステ
ルの製法
シクロアルテノール(21,3g) 、シクロブラノー
ル(22,0g)又は24−メチレンシクロアルタノー
ル(22,0g)の各0.050モルと3−プロピオニ
ルオキシ−α−メチルケイヒ酸17.6g (0,0
75モル)を用いた以外は、実施例11と同じ操作法に
より、それぞれ表記の目的化合物を得た。これらの収率
(%)、融点(℃)、比旋光度(〔α〕智(C1,00
、CHCl3 ) )は次のとおりであった。Yield 8261%, melting point 120-121℃ Specific rotation [α]
Sweet 39.1° (C1,0OSCIC13) Elemental analysis result C<t(, H7o04 (as molecular weight 687.02) Calculated value (%): C80,41H10,27 Actual value (%)
:C80,32H10,34 Examples 40-42
Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-3-propionyloxy-α-methylcinnamate Cycloartenol (21.3g), cyclobranol (22.0g) or 24-methylenecyclo 0.050 mol each of altanol (22,0 g) and 17.6 g of 3-propionyloxy-α-methylcinnamic acid (0,0
75 mol) was used, but the same procedure as in Example 11 was used to obtain the desired target compounds. The yield (%), melting point (℃), specific optical rotation ([α] (C1,00
, CHCl3)) were as follows.
実施例43〜45 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロア
ルクノール−3−ヒドロキシ−α
−メチルケイヒ酸エステルの製法
前記実施例40〜42の化合物をそれぞれ0.042モ
ルを用い、実施例12と同じ操作法により、表記の目的
化合物を得た。これらの収率(%)、融点(℃)、比旋
光度(〔α〕智(C1,00SCHC13) )は次の
とおりであった。Examples 43 to 45 Preparation of cycloartenol, cyclobranol or 24-methylenecycloalknol-3-hydroxy-α-methylcinnamic acid ester Using 0.042 mol of each of the compounds of Examples 40 to 42, Example The title compound was obtained by the same procedure as in Example 12. The yield (%), melting point (°C), and specific optical rotation ([α](C1,00SCHC13)) of these were as follows.
実施例46〜48 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロア
ルタノール−3−ブチリルオキシ
一α−エチルケイヒ酸エステルの
製法
3−ブチリルオキシ−α−エチルケイヒ酸3.50g
(0,0135モル)とシクロアルテノール2.85g
、シクロブラノール2.95g又は24−メチレンシク
ロアルタノール2.95gの各0.0067モルを用い
た以外は、実施例17と同じ操作法により、それぞれ表
記の目的化合物を得た。これらの収率(%)、融点(℃
)、比旋光度((α) v(C1,0O1CIC13)
)は次のとおりであった。Examples 46-48 Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-3-butyryloxy-α-ethylcinnamic acid ester 3.50 g of 3-butyryloxy-α-ethylcinnamic acid
(0,0135 mol) and cycloartenol 2.85 g
, 2.95 g of cyclobranol, or 2.95 g of 24-methylenecycloartanol, each of which was used in an amount of 0.0067 mol, was carried out in the same manner as in Example 17 to obtain the target compounds described. These yields (%), melting points (℃
), specific optical rotation ((α) v(C1,0O1CIC13)
) were as follows.
実施例49〜51 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロア
ルタノール−3−ヒドロキシ−α
一エチルケイヒ酸エステルの製法
前記実施例46〜48の化合物をそれぞれ0.003モ
ルを用いた以外は実施例18と同じ操作法により、表記
の目的化合物を得た。これらの収率(%)、融点(℃)
、比旋光度(〔α〕智(CL、0O1CHC13))は
次のとおりである。Examples 49-51 Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-3-hydroxy-α monoethylcinnamate except that 0.003 mol of each of the compounds of Examples 46-48 was used. By the same procedure as in Example 18, the title compound was obtained. These yields (%), melting points (℃)
, the specific optical rotation ([α] (CL, 0O1CHC13)) is as follows.
実施例52〜53 シクロアルテノール又はシクロブ
ラノール−2−ヒドロキシ−α−
メチルケイヒ酸エステルの製法
シクロアルテノール21.3g又はシクロブラノール2
2.0gの各0.050モルと2−プロピオニルオキシ
−α−メチルケイヒ酸17.6g (0,075モル)
を用いた以外は、実施例11と同じ操作法により、シク
ロアルテノール又はシクロブラノール−2−プロピオニ
ルオキシ−α−メチルケイヒ酸エステルをそれぞれ27
.5g (収率85.5%)及び27.5g (収率8
2.8%)を得た。これらを各24.5g用い実施例1
2と同じ操作法によりシクロアルテノール又はシクロ7
’−7ノールー2−ヒドロキシ−α−メチルケイヒ酸エ
ステルを得た。これらの収率(%)、融点(℃)、比旋
光度(〔α〕習(C1,00、CHCl3 ))は次の
とおりである。Examples 52-53 Process for producing cycloartenol or cyclobranol-2-hydroxy-α-methylcinnamate 21.3 g of cycloartenol or cyclobranol 2
2.0 g of each 0.050 mol and 17.6 g (0,075 mol) of 2-propionyloxy-α-methylcinnamic acid.
Cycloartenol or cyclobranol-2-propionyloxy-α-methylcinnamic acid ester was prepared at 27% by the same procedure as in Example 11, except that
.. 5g (yield 85.5%) and 27.5g (yield 8
2.8%). Example 1 using 24.5g each of these
Cycloartenol or cyclo7 by the same procedure as 2.
'-7 nor-2-hydroxy-α-methyl cinnamic acid ester was obtained. The yield (%), melting point (°C), and specific optical rotation ([α] (C1,00, CHCl3)) of these are as follows.
(以下余白)
実施例54 シクロアルテノール−3−メトキシ−4
−二トロ安息香酸エステルの製法
3−メトキシ−4−ニトロ安息香酸15.Og(0,0
76モル)に塩化チオニル34r!I!(6当量)とジ
メチルホルムアミド0.5ml!を加え、60℃にて2
時間加熱攪拌した。反応液を減圧濃縮後ジオキサン75
TIiを加え0℃で攪拌し、そこヘビリジン11〇−に
溶解・させたシクロアルテノール25.0g (0,0
59モル)を加え、70℃にて20分間攪拌した。反応
終了後、溶媒を減圧留去し、得られた残渣をクロロホル
ムに溶解し、飽和重曹水で洗浄後、乾燥した。(Left below) Example 54 Cycloartenol-3-methoxy-4
-Production of nitrobenzoic acid ester 3-methoxy-4-nitrobenzoic acid 15. Og(0,0
76 mol) to thionyl chloride 34r! I! (6 equivalents) and 0.5 ml of dimethylformamide! 2 at 60℃
The mixture was heated and stirred for hours. After concentrating the reaction solution under reduced pressure, dioxane 75
TIi was added and stirred at 0°C, and 25.0 g of cycloartenol (0,0
59 mol) was added thereto, and the mixture was stirred at 70°C for 20 minutes. After the reaction was completed, the solvent was distilled off under reduced pressure, and the resulting residue was dissolved in chloroform, washed with saturated aqueous sodium bicarbonate, and then dried.
クロロホルム層を減圧濃縮し、残渣を塩化メチレン−メ
タノール(1: 2)で再結晶することによりシクロア
ルテノール−3−メトキシ−4−二トロ安息香酸エステ
ル30.5gを得た。The chloroform layer was concentrated under reduced pressure, and the residue was recrystallized from methylene chloride-methanol (1:2) to obtain 30.5 g of cycloartenol-3-methoxy-4-nitrobenzoic acid ester.
収率85.3%、融点182〜183℃比旋光度〔α〕
管・”+57.7° (C1,00、CICl3 )元
素分析結果 C止)(rrNO5
(分子量605.82として)
計算値(%): C75,33H9,15N 2.31
実測値(%) : C75,42H9,07N 2.
36IRν、K B r (am−1) : 29
40.1720.1610.1530.1410.13
50.1310.1290.1245゜PMR(CDC
13”) δ: 0.38 (IH,WABq、4.
2Hz )、0.62 (IH,!4ABq、4.2H
z ) 、0.50〜2.36 (27H。Yield 85.3%, melting point 182-183℃ Specific rotation [α]
Tube +57.7° (C1,00, CICl3) Elemental analysis result C stop) (rrNO5 (as molecular weight 605.82) Calculated value (%): C75,33H9,15N 2.31
Actual value (%): C75,42H9,07N 2.
36IRν, KBr (am-1): 29
40.1720.1610.1530.1410.13
50.1310.1290.1245゜PMR (CDC
13”) δ: 0.38 (IH, WABq, 4.
2Hz), 0.62 (IH, !4ABq, 4.2H
z), 0.50-2.36 (27H.
m ) 、0.95 (IH,s) 、0.97 (3
H,s) 、1.04 (3H,s)、1.60 (3
H,s) 、1.69 (3H,s) 、4.00 (
3H,s) 、4.50〜5.32 (2H,m) 、
7.42〜8.01 (3H,m) 。m), 0.95 (IH,s), 0.97 (3
H,s), 1.04 (3H,s), 1.60 (3
H,s), 1.69 (3H,s), 4.00 (
3H,s), 4.50-5.32 (2H,m),
7.42-8.01 (3H, m).
実施例55 シクロアルテノール−4−アミノ−3−
メトキシ安息香酸エステルの製法
実施例54で得たシクロアルテノール−3−メトキシ−
4−二トロ安息香酸エステル40.0g (0,066
モル)に酢酸400−とジオキサン400−を加え0℃
にて攪拌しながらそこへ6N−塩酸ジオキサン22m(
2当量)と亜鉛末40gを加えて25℃にて2時間攪拌
を続けた。反応終了後、亜鉛末をろ別し、ろ液を減圧濃
縮して得られた残渣をクロロホルムで抽出し、クロロホ
ルム層を水、続いて飽和重曹水で洗浄し、乾燥後濃縮し
、残渣を塩化メチレン−メタノール(1: 2)で再結
晶することによりシクロアルテノール−4−アミノ−3
−メトキシ安息香酸エステル32.0gを得た。Example 55 Cycloartenol-4-amino-3-
Cycloartenol-3-methoxy- obtained in Example 54 of the method for producing methoxybenzoic acid ester
4-nitrobenzoic acid ester 40.0g (0,066
Add 400-mol of acetic acid and 400-mol of dioxane to 0℃
While stirring, add 22 m of 6N-hydrochloric dioxane (
2 equivalents) and 40 g of zinc powder were added, and stirring was continued at 25° C. for 2 hours. After the reaction, the zinc powder is filtered off, the filtrate is concentrated under reduced pressure, the resulting residue is extracted with chloroform, the chloroform layer is washed with water, then saturated sodium bicarbonate solution, dried and concentrated, and the residue is chlorinated. Cycloartenol-4-amino-3 was obtained by recrystallizing with methylene-methanol (1:2).
-Methoxybenzoic acid ester (32.0 g) was obtained.
収率84.1%、融点186〜188℃比旋光度〔α〕
菅・S+64.3° (C1,00、CICl3 )元
素分析結果 C39Hr7N O3
(分子量575.83として)
計算値(%”) : C79,26H9,98N 2
.43実測値(%) : C79,32H9,99N
2.39IRν、K B r (am−’) :
3450.3350.2930.1700.1620
.1520.1460.1305.1285.12eo
。Yield 84.1%, melting point 186-188℃ Specific rotation [α]
Suga・S+64.3° (C1,00, CICl3) Elemental analysis result C39Hr7N O3 (as molecular weight 575.83) Calculated value (%"): C79,26H9,98N 2
.. 43 Actual value (%): C79,32H9,99N
2.39IRν, KBr (am-'):
3450.3350.2930.1700.1620
.. 1520.1460.1305.1285.12eo
.
1220.1180.1105゜
PMR(CDC13’) δ: 0.36 (IO,
〃ABq、4.2Hz )、0.61 (1B、 54
ABq、4.2Hz ) 、0.48〜2.39 (2
7H。1220.1180.1105゜PMR (CDC13') δ: 0.36 (IO,
〃ABq, 4.2Hz), 0.61 (1B, 54
ABq, 4.2Hz), 0.48-2.39 (2
7H.
ta ) 、1.61 (3H,s) 、1.67 (
3H,s) 、3.88 (3H。ta ), 1.61 (3H,s), 1.67 (
3H,s), 3.88 (3H.
s ) 、4.20 (2H,bs) 、4.51〜5
.31 (2Lm)、6.46〜6.77 (LH,m
) 、7.30〜7.71 (2H,a+) 。s), 4.20 (2H, bs), 4.51-5
.. 31 (2Lm), 6.46~6.77 (LH,m
), 7.30-7.71 (2H, a+).
実施例56 シクロブラノール−3−メトキシ−4−
二トロ安息香酸エステルの製法
3−メトキシ−4−二トロ安息香酸50.Og(0,2
54モル)に塩化チオニル60m1! (3,2当量)
とジメチルホルムアミド0.5 ylを加え60℃にて
2時間加熱攪拌した。反応液を減圧濃縮後、ジオキサン
100−を加え0℃にて攪拌し、そこへ150−のピリ
ジンに溶解させたシクロブラノール93.0g(0,2
11モル)を加え70℃にて30分間攪拌した。Example 56 Cyclobranol-3-methoxy-4-
Preparation of nitrobenzoic acid ester 3-methoxy-4-nitrobenzoic acid 50. Og(0,2
54 mol) to 60 ml of thionyl chloride! (3,2 equivalents)
and 0.5 yl of dimethylformamide were added, and the mixture was heated and stirred at 60°C for 2 hours. After concentrating the reaction solution under reduced pressure, 100-dioxane was added and stirred at 0°C, and 93.0 g (0,2
11 mol) was added thereto and stirred at 70°C for 30 minutes.
反応終了後、溶媒を減圧留去し、得られた残渣をクロロ
ホルムに熔解し、飽和重曹水で洗浄後乾燥した。クロロ
ホルム層を減圧濃縮し残渣をクロロホルム−エタノール
(1: 3)で再結晶することによりシクロブラノール
−3−メトキシ−4−二トロ安息香酸エステル94.4
gを得た。After the reaction was completed, the solvent was distilled off under reduced pressure, and the resulting residue was dissolved in chloroform, washed with saturated aqueous sodium bicarbonate, and then dried. The chloroform layer was concentrated under reduced pressure and the residue was recrystallized with chloroform-ethanol (1:3) to obtain cyclobranol-3-methoxy-4-nitrobenzoic acid ester (94.4%).
I got g.
収率72.1%、融点213〜214℃比旋光度〔α〕
管・’+53.9° (C1,00、CICl3 >元
素分析結果 C39Hr7N OS
(分子量619.85として)
計算値(%) : C75,57H9,27N 2.
26実測値(%) : C75,63H9,22N
2.33IRν、K B r (cm−’) :
2930.1715.1610.1530.1410.
1360.1310.1285.1240゜P M R
(CDC13) δ: 0.39 (LH,AABq、
4.8Hz )、0.62 (IH,54ABq、4.
8Hz ) 、0.50〜2.28 (27H。Yield 72.1%, melting point 213-214℃ Specific rotation [α]
Tube +53.9° (C1,00, CICl3 > Elemental analysis result C39Hr7N OS (assuming molecular weight 619.85) Calculated value (%): C75,57H9,27N 2.
26 Actual value (%): C75,63H9,22N
2.33IRν, KBr (cm-'):
2930.1715.1610.1530.1410.
1360.1310.1285.1240゜P M R
(CDC13) δ: 0.39 (LH, AABq,
4.8Hz), 0.62 (IH, 54ABq, 4.
8Hz), 0.50-2.28 (27H.
m ) 、0.92 (61,s) 、0.99
(3H,s) 、1.05 (31,s)、1.63
(9H,s) 、4.01 (3H,s) 、4
.62〜5.03 (LH、m) 、7.48〜7.
96 (3H,a) 。m), 0.92 (61,s), 0.99
(3H,s), 1.05 (31,s), 1.63
(9H,s) ,4.01 (3H,s) ,4
.. 62-5.03 (LH, m), 7.48-7.
96 (3H, a).
実施例57 シクロブラノール−4−アミノ−3−メ
トキシ安息香酸エステルの製法
実施例56の方法にて得たシクロブラノール−3−メト
キシ−4−二トロ安息香酸エステル94.3 g(0,
152モル)を酢酸1.2βとテトラヒドロフラン1.
21に懸濁し、そこへ6N−塩酸−ジオキサン100−
と亜鉛末94gを加えて25℃にて2時間攪拌した。反
応終了後、亜鉛末をろ別しろ液を減圧濃縮して得られた
残渣をクロロホルムで抽出した。Example 57 Preparation of cyclobranol-4-amino-3-methoxybenzoate 94.3 g (0,
152 mol) of acetic acid 1.2β and tetrahydrofuran 1.
21, and 6N-hydrochloric acid-dioxane 100-
and 94 g of zinc powder were added and stirred at 25° C. for 2 hours. After the reaction was completed, the zinc dust was filtered off, the filtrate was concentrated under reduced pressure, and the resulting residue was extracted with chloroform.
クロロホルム層を水、続いて飽和重曹水で洗浄し、乾燥
後濃縮し、残渣をクロロホルム−エタノール(1: 4
)で再結晶することによりシクロブラノール−4−アミ
ノ−3−メトキシ安息香酸エステル64.2gを得た。The chloroform layer was washed with water and then with saturated sodium bicarbonate solution, dried and concentrated, and the residue was diluted with chloroform-ethanol (1:4
) to obtain 64.2 g of cyclobranol-4-amino-3-methoxybenzoic acid ester.
収率71.5%、融点235〜236℃比旋光度〔α〕
管 +60.8° (C1,00SCHCI:s )元
素分析結果 C39Hr7 N O3(分子量589.
86として)
計算値(%) : C79,4L H10,08N
2.37実測値(%) : C79,49H10,
12N 2.42IRν、K B r (aa−’)
: 3450.3350.2900.1680.1
620.1310.1280.1260.1110゜P
MR(CDC13) δ: 0.36 (LH,%AB
q、4.8Hz )、0.61 (11,%ABq、4
.8Hz ) 、0.50〜2.20 (27H。Yield 71.5%, melting point 235-236℃ Specific rotation [α]
Tube +60.8° (C1,00SCHCI:s) Elemental analysis result C39Hr7 N O3 (molecular weight 589.
86) Calculated value (%): C79.4L H10.08N
2.37 Actual value (%): C79,49H10,
12N 2.42IRν, K B r (aa-')
: 3450.3350.2900.1680.1
620.1310.1280.1260.1110゜P
MR (CDC13) δ: 0.36 (LH,%AB
q, 4.8Hz), 0.61 (11,% ABq, 4
.. 8Hz), 0.50-2.20 (27H.
w+ ) 、0.89 (6H,s) 、0.96 (
3H,s) 、1.01 (3H。w+ ), 0.89 (6H,s), 0.96 (
3H,s), 1.01 (3H.
s ) 、3.85 (3H,s) 、3.92〜4.
36 (2H,bs )、4.51〜4.91 (IH
,a) 、6.42〜6.72 (IH,m) 、7.
26〜7.72 (2H,a+) 。s), 3.85 (3H, s), 3.92-4.
36 (2H, bs), 4.51-4.91 (IH
, a) , 6.42-6.72 (IH, m) , 7.
26-7.72 (2H, a+).
実施例58 シクロアルテノール−2−メトキシ−5
−二トロ安息香酸エステルの製法
2−メトキシ−5−二トロ安息香酸17.3g(0,0
88モル)に塩化チオニル65me (10当量)とジ
メチルホルムアミド0.3ml!を加え、50℃にて1
.5時間攪拌した。反応液を減圧濃縮後、ジオキサン1
25m1!を加え0℃で攪拌し、そこへピリジン125
mに溶解させたシクロアルテノール25.0g(0,0
59モル)を滴下後、60℃にて1.5時間攪拌した。Example 58 Cycloartenol-2-methoxy-5
-Production method of nitrobenzoic acid ester 2-methoxy-5-nitrobenzoic acid 17.3g (0,0
88 mol), 65 me (10 equivalents) of thionyl chloride and 0.3 ml of dimethylformamide! 1 at 50℃.
.. Stirred for 5 hours. After concentrating the reaction solution under reduced pressure, dioxane 1
25m1! was added and stirred at 0℃, and pyridine 125
25.0 g of cycloartenol (0,0
59 mol) was added dropwise, and the mixture was stirred at 60°C for 1.5 hours.
反応終了後、溶媒を減圧留去し、残渣をクロロホルムで
抽出し、クロロホルム層を水、続いて飽和重曹水にて洗
浄し、乾燥、濃縮後、残渣を塩化メチレン−ヘキサン(
1: 3)にて再結晶し、シクロアルテノール−2−メ
トキシ−5−二トロ安息香酸エステル31.5gを得た
。After the reaction was completed, the solvent was distilled off under reduced pressure, the residue was extracted with chloroform, the chloroform layer was washed with water and then with saturated sodium bicarbonate solution, dried and concentrated, and the residue was extracted with methylene chloride-hexane (
1:3) to obtain 31.5 g of cycloartenol-2-methoxy-5-nitrobenzoic acid ester.
収率88.7%、融点186〜187℃比旋光度〔α〕
管 +43.9° (C1,0OSCIICI3 )元
素分析結果 C39Her N Os(分子量605.
82として)
計算値(%”) : C75,33H9,15N 2
.31実測値(%’) : C75,30H9,22
N 2.29IR$7、l(13r(cm−リ : 2
930.1695.1610゜1520.1340.1
280.1135゜PMR(CDCl2 ) δ: 0
.39 (LH1%ABq、4.2Hz )、0.62
(IH,AABq、4.2Hz ) 、0.50〜2
.40 (2711゜m ) 、0.90 (3H,s
) 、0.96 (6H,s) 、1.01 (3H,
s)、2.60 (3H,bs ) 、2.68 (3
H,bs ) 、4.00 (3H,s)、4.65〜
5.30 (2H,m) 、7.08 (IH,d、9
.411z)、8.34 (IH,dd、3.0Hz、
9.4Hz ) 、8.64 (LH,d、3.0H
z) 。Yield 88.7%, melting point 186-187℃ Specific rotation [α]
Tube +43.9° (C1,0OSCIICI3) Elemental analysis result C39HerNOs (molecular weight 605.
82) Calculated value (%”): C75, 33H9, 15N 2
.. 31 Actual value (%'): C75, 30H9, 22
N 2.29IR $7, l (13r (cm-li: 2
930.1695.1610゜1520.1340.1
280.1135°PMR (CDCl2) δ: 0
.. 39 (LH1%ABq, 4.2Hz), 0.62
(IH, AABq, 4.2Hz), 0.50-2
.. 40 (2711゜m), 0.90 (3H,s
), 0.96 (6H,s), 1.01 (3H,
s), 2.60 (3H, bs), 2.68 (3
H, bs), 4.00 (3H, s), 4.65~
5.30 (2H, m), 7.08 (IH, d, 9
.. 411z), 8.34 (IH, dd, 3.0Hz,
9.4Hz), 8.64 (LH, d, 3.0H
z).
実施例59 シクロアルテノール−5−アミノ−2−
メトキシ安息香酸エステルの製法
実施例58で得たシクロアルテノール−2−メトキシ−
5−二トロ安息香酸エステル34.0g (0,056
モル)を酢酸1.21に、20℃で懸濁させ、そこへ6
N塩酸−ジオキサン19m(2当量)と亜鉛末68gを
加え30℃にて1時間攪拌した。反応終了後、亜鉛末を
ろ別し、ろ液を減圧濃縮したのちクロロホルムで抽出し
た。クロロホルム層を水、続いて飽和重曹水で洗浄後、
乾燥、濃縮し、残渣を塩化メチレン−ヘキサン(1:
4)にて再結晶し、シクロアルテノール−5−アミノ−
2−メトキシ安息香酸エステル27.2gを得た。Example 59 Cycloartenol-5-amino-2-
Cycloartenol-2-methoxy- obtained in Example 58 of the method for producing methoxybenzoic acid ester
5-nitrobenzoic acid ester 34.0g (0,056
6 mol) was suspended in 1.21 mol of acetic acid at 20°C, and 6 mol)
19 m (2 equivalents) of N-hydrochloric acid-dioxane and 68 g of zinc powder were added and stirred at 30°C for 1 hour. After the reaction was completed, the zinc dust was filtered off, the filtrate was concentrated under reduced pressure, and then extracted with chloroform. After washing the chloroform layer with water and then with saturated sodium bicarbonate solution,
Dry, concentrate, and dissolve the residue in methylene chloride-hexane (1:
4) to obtain cycloartenol-5-amino-
27.2 g of 2-methoxybenzoic acid ester was obtained.
収率84.4%、融点180〜182℃比旋光度〔α〕
管・5+47.8° (C1,00、ClICl3 )
元素分析結果 Cl9比けN03
(分子量575.83として)
計算値(%) : C79,26H9,98N 2.
43実測値(%’) : C79,32H9,94N
2.41TRV、KBr (cm−1) : 3
450,3350.2900.2860.1690,1
630.1500,1440.1300,1270.1
245゜
PMR(CDC13) δ: 0.3B (Ill、
”A^Bq、4.2Hz )、0.59 (LH,
%ABq、4.2Hz ) 、−0,50〜2.30
(27H。Yield 84.4%, melting point 180-182℃ Specific rotation [α]
Tube・5+47.8° (C1,00, ClICl3)
Elemental analysis results N03 compared to Cl9 (as molecular weight 575.83) Calculated value (%): C79,26H9,98N 2.
43 Actual value (%'): C79, 32H9, 94N
2.41TRV, KBr (cm-1): 3
450,3350.2900.2860.1690,1
630.1500, 1440.1300, 1270.1
245°PMR (CDC13) δ: 0.3B (Ill,
"A^Bq, 4.2Hz), 0.59 (LH,
%ABq, 4.2Hz), -0,50~2.30
(27H.
m ) 、0.90 (6H,s) 、0.93
(6H,s) 、1.59 (3H。m), 0.90 (6H,s), 0.93
(6H,s), 1.59 (3H.
bs) 、1.67 (3H,bs) 、3.55
(2H,bQ) 、3.88(3■、s) 、4
.50〜5.30 (2H,m) 、6.68〜7.
24 (38、ff1)。bs), 1.67 (3H, bs), 3.55
(2H, bQ) , 3.88 (3■, s) , 4
.. 50-5.30 (2H, m), 6.68-7.
24 (38, ff1).
実施例60 シクロブラノール−2−メトキシ−5−
二トロ安息香酸エステルの製法
2−メトキシ−5−ニトロ安息香酸11.6g(0,0
59モル)に塩化チオニル20m1とジメチルホルムア
ミド0.2−を加え50℃にて2時間攪拌した。Example 60 Cyclobranol-2-methoxy-5-
Process for producing nitrobenzoic acid ester 11.6 g (0,0
20ml of thionyl chloride and 0.2ml of dimethylformamide were added to the mixture (59mol) and stirred at 50°C for 2 hours.
反応液を減圧濃縮後、トルエン150rn1とピリジン
30−を加え、さらにシクロブラノール20g (0,
045モル)を加えて60℃にて2時間攪拌した。反応
終了後、溶媒を減圧留去し、残渣をクロロホルムで抽出
した。クロロホルム層を水、続いて飽和食塩水にて洗浄
し、乾燥濃縮後、残渣をクロロホルム−エタノール(1
: 3)で再結晶してシクロブラノール−2−メトキシ
−5−二トロ安息香酸エステル25.9gを得た。After concentrating the reaction solution under reduced pressure, 150rn1 of toluene and 30ml of pyridine were added, and 20g of cyclobranol (0,
045 mol) was added thereto and stirred at 60°C for 2 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was extracted with chloroform. The chloroform layer was washed with water and then with saturated saline, and after drying and concentration, the residue was diluted with chloroform-ethanol (1
: 3) to obtain 25.9 g of cyclobranol-2-methoxy-5-nitrobenzoic acid ester.
収率92.O%、融点207〜208℃比旋光度〔α〕
習 +32.5° (C1,00、CHCl3 )元素
分析結果 C3りHP7N OS
(分子量619.85として)
計算値(%) : C75,57H9,27N 2.
26実測値(%) : C75,52H9,34N
2.30IRJ/、KBr (cm−’) : 2
930.1700.1610゜1520.1345.1
280.1130゜PMR(CDC13) δ: 0.
39 (11,%ABq、4.8Hz )、0.62
(1)1. %ABq、4.8Hz ) 、0.76〜
2.24 (271゜n+ ) 、0.91 (3H,
s) 、0.96 (6H,s) 、1.01 (3H
,s)、1.63 (9H,s) 、4.01 (3H
,s) 、4.64〜5.02 (1)1、m) 、7
.06 (IH,d、9.6Hz) 、8.34 (I
H,dd、9.6Hz。Yield: 92. O%, melting point 207-208℃ Specific optical rotation [α]
+32.5° (C1,00, CHCl3) Elemental analysis result C3 HP7N OS (as molecular weight 619.85) Calculated value (%): C75,57H9,27N 2.
26 Actual value (%): C75,52H9,34N
2.30IRJ/, KBr (cm-'): 2
930.1700.1610゜1520.1345.1
280.1130°PMR (CDC13) δ: 0.
39 (11,% ABq, 4.8Hz), 0.62
(1)1. %ABq, 4.8Hz), 0.76~
2.24 (271°n+), 0.91 (3H,
s), 0.96 (6H,s), 1.01 (3H
,s), 1.63 (9H,s), 4.01 (3H
,s) ,4.64~5.02 (1)1,m) ,7
.. 06 (IH, d, 9.6Hz), 8.34 (I
H, dd, 9.6Hz.
3.6Hz ) 、8.67 (Iff、d、3.6H
z) 。3.6Hz), 8.67 (Iff, d, 3.6H
z).
実施例61 シクロブラノール−5−アミノ−2−メ
トキシ安息香酸エステルの製法
実施例60で得たシクロブラノール−2−メトキシ−5
−ニトロ安息香酸エステル25.0g (0,040モ
ル)を酢酸1βに懸濁させ、そこへ6N−塩酸−ジオキ
サン21mと亜鉛末25.0gを加え30℃にて2時間
攪拌した。反応終了後、亜鉛末をろ別し、ろ液を減圧濃
縮したのち、クロロホルムで抽出した。クロロホルム層
を水、続いて飽和重曹水で洗浄後、乾燥、濃縮し残渣を
クロロホルム−エタノール(1,:2)で再結晶するこ
とによりシクロブラノール−5−アミノ−2−メトキシ
安息香酸エステル13.7gを得た。Example 61 Preparation of cyclobranol-5-amino-2-methoxybenzoic acid ester Cyclobranol-2-methoxy-5 obtained in Example 60
25.0 g (0,040 mol) of -nitrobenzoic acid ester was suspended in 1β acetic acid, and 21 m of 6N-hydrochloric acid-dioxane and 25.0 g of zinc powder were added thereto and stirred at 30° C. for 2 hours. After the reaction was completed, the zinc dust was filtered off, the filtrate was concentrated under reduced pressure, and then extracted with chloroform. The chloroform layer was washed with water and then with saturated sodium bicarbonate solution, dried and concentrated, and the residue was recrystallized from chloroform-ethanol (1:2) to obtain cyclobranol-5-amino-2-methoxybenzoic acid ester 13. .7g was obtained.
収率57.5%、融点193〜195℃比旋光度〔α〕
菅・5+41.5° (C1,00、CHCl3 )元
素分析結果 C);+ Ht7 N O3(分子量58
9.86として)
計算値(%) : C79,4L HIQ、08
N 2.37実測値(%) : C79,35H1
0,15N 2.35IR4、K B r (am−
1) : 3430.3350.2930.1690
.1500.1460.1430.1310.1270
.1245゜PMR(CDC13) δ : 0
.36 (LH,!4ABq+4.8Hz )、0
.61 (IH,%ABq、4.8Hz ) 、0.5
0〜2.28 (2711゜m ) 、0.92 (3
11,s) 、0.96 (6H,s) 、1.00
(3H。Yield 57.5%, melting point 193-195℃ Specific rotation [α]
Suga・5+41.5° (C1,00, CHCl3) Elemental analysis results C); + Ht7 N O3 (molecular weight 58
9.86) Calculated value (%): C79.4L HIQ, 08
N 2.37 Actual value (%): C79,35H1
0.15N 2.35IR4, K B r (am-
1): 3430.3350.2930.1690
.. 1500.1460.1430.1310.1270
.. 1245゜PMR (CDC13) δ: 0
.. 36 (LH,!4ABq+4.8Hz), 0
.. 61 (IH, %ABq, 4.8Hz), 0.5
0~2.28 (2711゜m), 0.92 (3
11,s), 0.96 (6H,s), 1.00
(3H.
s ) 、1.64 (9H,s) 、2.88〜3.
26 (2H,n+) 、3.81(3H,s) 、4
.52〜5.02 (1)1.m) 、6.74〜6.
90 (IH、+n) 、7.08〜7.22 (2H
,a+) 。s), 1.64 (9H, s), 2.88-3.
26 (2H, n+) , 3.81 (3H, s) , 4
.. 52-5.02 (1)1. m), 6.74-6.
90 (IH, +n), 7.08~7.22 (2H
, a+).
)[例62〜64 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−3−メ
トキシ−4−ニトロケイヒ酸エステルの製法
3−メトキシ−4−ニトロケイヒ酸17.0g(0,0
76モル)とシクロアルテノール25.0g、シクロブ
ラノール26.0g又は24−メチレンシクロアルタノ
ール26.0gの各0.059モルを用いた以外は、実
施例54と同じ操作により、表記目的化合物を得た。こ
れらの収率(%)、融点(’c )及び比旋光度((z
) 9 (C1,00,CHCl3 )は次のとおりで
あった。) [Examples 62 to 64 Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-3-methoxy-4-nitrocinnamic acid ester 17.0 g of 3-methoxy-4-nitrocinnamic acid (0,0
76 mol) and 0.059 mol each of 25.0 g of cycloartenol, 26.0 g of cyclobranol, or 26.0 g of 24-methylenecycloartanol were used to obtain the title compound by the same procedure as in Example 54. I got it. These yields (%), melting points ('c) and specific optical rotations ((z
) 9 (C1,00, CHCl3) was as follows.
(以下余白)
実施例65〜67 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−4−ア
ミノ−3−メトキシケイヒ酸エステルの製法
前記実施例62〜64で得たシクロアルテノール、シク
ロブラノール又は24−メチレンシクロアルタノール−
3−メトキシ−4−ニトロケイヒ酸エステルの41.7
g 、42.6g又は42.6gの各0.066モルを
用い、実施例55と同じ操作により、表記目的化合物を
得た。これらの収率(%)、融点(℃)、比旋光度(〔
α) ’fl (C1,OO,CICl3 ) )は次
のとおりであった。(Left below) Examples 65 to 67 Process for producing cycloartenol, cyclobranol or 24-methylenecycloartanol-4-amino-3-methoxycinnamic acid ester Cycloartenol and cycloartenol obtained in Examples 62 to 64 above Branol or 24-methylenecycloartanol-
41.7 of 3-methoxy-4-nitrocinnamic acid ester
The title compound was obtained in the same manner as in Example 55 using 0.066 mol of each of g, 42.6 g, and 42.6 g. Yield (%), melting point (℃), specific optical rotation ([
α)'fl(C1,OO,CICl3)) was as follows.
実施例68〜70 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−2−エ
トキシ−5−ニトロヶイヒ酸エステルの製法
2−エトキシ−5−4ニトロケイヒ酸19.5g(0,
082%ル)と’i’) ロフルf) −71z25.
0g 、 シクロブラノール26.0g又は24−メチ
レンシクロアルタノール26.0gの各0.059モル
を用いた以外は、実施例58と同じ操作により、表記目
的化合物を得た。これらの収率(%)、融点(”C)及
び比旋光度(〔α)、W (C1,0O1CHC13”
) ) は次のとおりであった。Examples 68-70 Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-2-ethoxy-5-nitrocinnamic acid 2-ethoxy-5-4-nitrocinnamic acid 19.5 g (0,
082%le) and 'i') Rofurf) -71z25.
The title compound was obtained by the same operation as in Example 58, except that 0.059 mol of each of 0 g, 26.0 g of cyclobranol, and 26.0 g of 24-methylenecycloartanol were used. These yield (%), melting point ("C) and specific optical rotation ([α)", W (C1,0O1CHC13"
) ) was as follows.
実雄側71〜73 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−5−ア
ミノ−2−ニトキシケイヒ酸エステルの製法
実施例68〜70で得たシクロアルテノール、シクロブ
ラノール又は24−メチレンシクロアルタノール−2−
エトキシ−5−ニトロケイヒ酸エステルの36.2g
、37.0g又は37.0gの各0.056モルを用い
、実施例59と同じ操作により、表記目的化合物を得た
。これらの収率(%)、融点(℃)、比旋光度(〔α〕
菅(C1,00、CHCl3 ) )は次のとおりであ
った。Male side 71 to 73 Cycloartenol, cyclobranol or 24-methylene Cycloartenol, cyclobranol or 24-methylene obtained in Examples 68 to 70 of the method for producing cycloartanol-5-amino-2-nitoxycinnamate ester Cycloartanol-2-
36.2 g of ethoxy-5-nitrocinnamic acid ester
, 37.0 g, or 37.0 g, respectively, in the same manner as in Example 59, to obtain the title compound. These yield (%), melting point (℃), specific optical rotation ([α]
Suga (C1,00, CHCl3) was as follows.
実施例74〜76 シクロアルテノール、シクロブラ
ノール又は24=メチレンシクロアルタノール−3−メ
トキシ−4−ニトロ−α−メチルケイヒ酸エステルの製
法
3−メトキシ−4−ニトロ−α−メチルケイヒ酸17.
3g (0,073モル)とシクロアルテノール25.
0g、シクロブラノール26.0g又は24−メチレン
シクロアルタノール26.0gの各0.059モルを用
いた以外は、実施例54と同じ操作により、表記の目的
化合物を得た。これらの収率(%)、融点(t”)及び
比旋光度((Q’) V (C1,0O1CIC13)
)は次のとおりであった。Examples 74-76 Preparation of cycloartenol, cyclobranol or 24=methylenecycloartanol-3-methoxy-4-nitro-α-methylcinnamic acid ester 3-methoxy-4-nitro-α-methylcinnamic acid 17.
3 g (0,073 mol) and cycloartenol 25.
The title compound was obtained by the same operation as in Example 54, except that 0.059 mol of each of 0 g, 26.0 g of cyclobranol, and 26.0 g of 24-methylenecycloartanol were used. Their yield (%), melting point (t'') and specific optical rotation ((Q') V (C1,0O1CIC13)
) were as follows.
実施例77〜79 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−4−ア
ミノ−3−メトキシ−α−メチルケイヒ酸エステルの製
法
実施例74〜76で得たシクロアルテノール、シクロブ
ラノール又は24−メチレンシクロアルタノール−3−
メトキシ−4−ニトロ−α−メチルケイヒ酸エステルの
43.6g 、44.5g又は44.5gの各0.06
6モルを用いた以外は、実施例55と同じ操作により、
表記の目的化合物を得た。これらの収率(%)、融点(
℃)、比旋光度(〔α〕菅(C1,OO,CHCl3)
)は次のとおりであった。Examples 77 to 79 Cycloartenol, cyclobranol or 24-methylenecycloartanol-4-amino-3-methoxy-α-methylcinnamic acid ester Cycloartenol and cyclobranol obtained in Examples 74 to 76 or 24-methylenecycloartanol-3-
0.06 each of 43.6g, 44.5g or 44.5g of methoxy-4-nitro-α-methylcinnamate
By the same operation as Example 55 except that 6 mol was used,
The indicated target compound was obtained. These yields (%), melting points (
°C), specific rotation ([α] tube (C1, OO, CHCl3)
) were as follows.
実施例80〜82 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−5−ニ
トロ−2−プロポキシ−α−メチルケイヒ酸エステルの
製法
5−ニトロ−2−プロポキシ−α−メチルケイヒ酸21
.2g (0,080モル)とシクロアルテノール25
.0g、シクロブラノール26.0g又は24−メチレ
ンシクロアルタノール26.0gの各0.059モルヲ
用いた以外は、実施例58と同じ操作により、表記の目
的化合物を得た。これらの収率(%)、融点(’C)及
び比旋光度(〔α) V (C1,00、CICl3
))は次のとおりであった。Examples 80-82 Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-5-nitro-2-propoxy-α-methylcinnamic acid ester 5-nitro-2-propoxy-α-methylcinnamic acid 21
.. 2g (0,080 mol) and cycloartenol 25
.. The title compound was obtained by the same operation as in Example 58, except that 0.059 mol of each of 0 g, 26.0 g of cyclobranol, or 26.0 g of 24-methylenecycloartanol was used. These yields (%), melting points ('C) and specific optical rotations ([α) V (C1,00, CICl3
)) was as follows.
実施例83〜85 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−5−ア
ミノ−2−プロポキシ−α−メチルケイヒ酸エステルの
製法
実施例80〜82で得たシクロアルテノール、シクロブ
ラノール又は24−メチレンシクロアルタノール−5−
ニトロ−2−プロポキシ−α−メチルケイヒ酸エステル
の37.7g 、38.5g又は38.5gの各0.0
56モルを用いた以外は、実施例59と同じ操作により
、表記の目的化合物を得た。これらの収率(%)、融点
(℃)、比旋光度(〔α〕管(C1,00、CHCl3
) )は次のとおりであった。Examples 83 to 85 Cycloartenol, cyclobranol or 24-methylenecycloartanol-5-amino-2-propoxy-α-methylcinnamic acid ester Cycloartenol and cyclobranol obtained in Examples 80 to 82 or 24-methylenecycloartanol-5-
0.0 each of 37.7g, 38.5g or 38.5g of nitro-2-propoxy-α-methylcinnamate ester
The title compound was obtained by the same operation as in Example 59 except that 56 mol was used. These yields (%), melting points (℃), specific optical rotations ([α] tubes (C1,00, CHCl3
) ) was as follows.
実施例86〜87 シクロアルテノール又はシクロブ
ラノール−3−メトキシ−4−ニトロ−α−iso−プ
ロピルケイヒ酸エステルの製法3−メトキシ−4−ニト
ロ−α−i 5o−7”ロピルケイヒ酸19.1g (
0,072モル)とシクロアルテノール25.0g又は
シクロブラノール26.0gの各0.059モルを用い
た以外は、実施例54と同じ操作により、表記の目的化
合物を得た。これらの収率(%)、融点(’C)及び比
旋光度(〔α〕管(C1,00、CICl3 > )は
次のとおりであった。Examples 86-87 Preparation of cycloartenol or cyclobranol-3-methoxy-4-nitro-α-iso-propylcinnamic acid ester 3-methoxy-4-nitro-α-i 5o-7”ropylcinnamic acid 19. 1g (
The title compound was obtained by the same operation as in Example 54, except that 0.059 mol of each of 0.072 mol) and 25.0 g of cycloartenol or 26.0 g of cyclobranol were used. The yield (%), melting point ('C), and specific optical rotation ([α] tube (C1,00, CICl3>) of these were as follows.
実施例88〜89 シクロアルテノール又はシクロブ
ラノール−4−アミノ−3−メトキシ−α−1ao−プ
ロピルケイヒ酸エステルの製法実施例86〜87で得た
シクロアルテノール又はシクロブラノール−3−メトキ
シ−4−ニトロ−α−iso−プロピルケイヒ酸エステ
ルの44.5g 、45.4g又は45.4gの各0.
066モルを用いた以外は、実施例55と同じ操作によ
り、表記目的化合物を得た。Examples 88 to 89 Preparation of cycloartenol or cyclobranol-4-amino-3-methoxy-α-1ao-propylcinnamic acid ester Cycloartenol or cyclobranol-3-methoxy obtained in Examples 86 to 87 -4-nitro-α-iso-propylcinnamic acid ester of 44.5 g, 45.4 g or 45.4 g of each 0.
The title compound was obtained by the same operation as in Example 55, except that 0.066 mol was used.
これらの収率(%)、融点(℃)、比旋光度((α)
W (C1,0O1CICI3 ) ) は次のとおり
であった。These yield (%), melting point (℃), specific optical rotation ((α)
W(C1,0O1CICI3)) was as follows.
実施例90〜92 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−p−ニ
トロ−α−メチルケイヒ酸エステルの製法
p−ニトロ−α−メチルケイヒ酸78.3g (0,
378モル)に塩化チオニル112d (4,0当量)
とジメチルホルムアミドlteを加え、60℃にて2時
間攪拌した。反応液を減圧濃縮後、ジオキサン25〇−
とピリジン250m1を加え、続いてシクロアルテノー
ル125.0g 、シクロブラノール129.1g又は
24−メチレンシクロアルタノール129.1gの各0
.293モルを加え60℃にて2時間攪拌した。反応終
了後、溶媒を減圧留去し、得られた残渣をクロロホルム
で抽出した。クロロホルム層を水、続いて飽和重曹水で
洗浄後、乾燥、減圧濃縮し、残渣をクロロホルム−エタ
ノール(1: 3)で再結晶し、それぞれ表記目的化合
物を得た。これらの収率(%)、融点(℃)、比旋光度
(〔α〕管(C1,0O1CI(C13))は次のとお
りであった。Examples 90-92 Preparation of cycloartenol, cyclobranol or 24-methylenecycloartanol-p-nitro-α-methylcinnamic acid ester p-nitro-α-methylcinnamic acid 78.3 g (0,
378 mol) to thionyl chloride 112d (4.0 equivalents)
and dimethylformamide lte were added thereto, and the mixture was stirred at 60°C for 2 hours. After concentrating the reaction solution under reduced pressure, dioxane 250-
and 250 ml of pyridine, followed by 125.0 g of cycloartenol, 129.1 g of cyclobranol, or 129.1 g of 24-methylenecycloartanol.
.. 293 mol was added and stirred at 60°C for 2 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the resulting residue was extracted with chloroform. The chloroform layer was washed with water and then with saturated aqueous sodium bicarbonate, dried, and concentrated under reduced pressure. The residue was recrystallized from chloroform-ethanol (1:3) to obtain the desired compounds. The yield (%), melting point (°C), and specific optical rotation ([α] tube (C1,0O1CI (C13)) of these were as follows.
実mfi193〜95 シクロアルテノール、シクロ
ブラノール又は24−メチレンシクロアルタノール−p
−アミノ−α−メチルケイヒ酸エステルの製法
実施例90〜92で得たシクロアルテノール、シクロブ
ラノール又は24−メチレンシクロアルタノール−p−
ニトロ−α−メチルケイヒ酸エステルの16.6g、
17.0g又は17.0gの各0.027モルを酢酸1
50−とジオキサン150−の混合液に懸濁し、そこへ
6N−塩酸−ジオキサン9.5mと亜鉛末8gを加え、
40℃で3時間攪拌した0反応終了後、亜鉛末をろ別し
、ろ液を減圧濃縮して得られた残渣をクロロホルムで抽
出した。クロロホルム層を水、続いて飽和重曹水で洗浄
し、乾燥後、濃縮し、残渣をクロロホルム−エタノール
(1: 3)で再結晶し、それぞれ表記目的化合物を得
た。これらの収率(%)、融点(℃)、比旋光度(〔α
〕管(C1,00,ClCl5) ) は次のとおりで
あった。Fruit mfi193-95 cycloartenol, cyclobranol or 24-methylenecycloartanol-p
-Production method of amino-α-methylcinnamic acid ester Cycloartenol, cyclobranol or 24-methylenecycloartanol-p- obtained in Examples 90 to 92
16.6 g of nitro-α-methylcinnamic acid ester,
17.0 g or 0.027 mol of each of 17.0 g to 1 acetic acid
Suspend in a mixture of 50- and dioxane 150-, add 9.5 m of 6N-hydrochloric acid-dioxane and 8 g of zinc powder,
After the reaction was completed by stirring at 40° C. for 3 hours, the zinc dust was filtered off, the filtrate was concentrated under reduced pressure, and the resulting residue was extracted with chloroform. The chloroform layer was washed with water and then with saturated aqueous sodium bicarbonate, dried, and concentrated, and the residue was recrystallized from chloroform-ethanol (1:3) to obtain the title compounds. These yields (%), melting points (℃), specific optical rotations ([α
] tube (C1,00,ClCl5)) was as follows.
(以下余白)
実施例96〜98 シクロアルテノール、シクロブラ
ノール又は24−メチレンシクロアルタノール−m−ニ
トロ−α−メチルケイヒ酸エステルの製法
m−ニトロ−α−メチルケイヒ酸80.4g (0,
388モル)に塩化チオニル60m1! (2,1当量
)とジメチルホルムアミド1−を加え、60℃で2時間
攪拌した。反応液を減圧濃縮後、ジオキサン300dと
ピリジン200−を加え、続い了シクロアルテノール1
25.9g 、シクロブラノール130.0g又は24
−メチレンシクロアルタノール130.0gの各0.2
95モルを加え、60℃にて2時間攪拌した。反応終了
後、減圧濃縮し、得られた残渣をクロロホルムで抽出し
た。クロロホルム層を水、続いて飽和重曹水で洗浄後、
乾燥、減圧濃縮し、残渣をクロロホルム−エタノール(
1: 4)で再結晶し、それぞれ表記目的化合物を得た
。これらの収率(%)、融点(℃)、比旋光度(〔α)
V (C1,0O1CHC13) )は次のとおりで
あった。(Left below) Examples 96-98 Process for producing cycloartenol, cyclobranol or 24-methylenecycloartanol-m-nitro-α-methylcinnamic acid ester m-nitro-α-methylcinnamic acid 80.4 g (0,
388 mol) to 60 ml of thionyl chloride! (2.1 equivalents) and dimethylformamide 1- were added, and the mixture was stirred at 60°C for 2 hours. After concentrating the reaction solution under reduced pressure, 300 d of dioxane and 200 d of pyridine were added, followed by 1 d of cycloartenol.
25.9g, cyclobranol 130.0g or 24
- 0.2 each of 130.0 g of methylenecycloartanol
95 mol was added and stirred at 60°C for 2 hours. After the reaction was completed, the mixture was concentrated under reduced pressure, and the resulting residue was extracted with chloroform. After washing the chloroform layer with water and then with saturated sodium bicarbonate solution,
Dry, concentrate under reduced pressure, and dissolve the residue in chloroform-ethanol (
1:4) to obtain the desired compounds. These yield (%), melting point (℃), specific optical rotation ([α)
V(C1,0O1CHC13)) was as follows.
実施例99〜101シクロアルテノール、シクロブラノ
ール又は24−メチレンシクロアルタノール−m−アミ
ノ−α−メチルケイヒ酸エステルの製法
実施例96〜98で得たシクロアルテノール、シクロブ
ラノール又は24−メチレンシクロアルタノール−m−
ニトロ−α−メチルケイヒ酸エステルの16.6g、
17.0g又は17.0gの各0.027モルを酢酸1
50−とテトラヒドロフラン200−の混合液に懸濁し
、そこへ6N−塩酸−ジオキサン12.5−と亜鉛末1
6.5gを加え、20℃で2時間攪拌した。反応終了後
、亜鉛末をろ別し、ろ液を減圧濃縮して得られた残渣を
クロロホルムで抽出した。クロロホルム層を水、続いて
飽和重曹水で洗浄し、乾燥後、濃縮し、残渣をクロロホ
ルム−エタノール(1:2)で再結晶し、それぞれ表記
目的化合物を得た。Examples 99 to 101 Cycloartenol, cyclobranol or 24-methyleneProduction of cycloartanol-m-amino-α-methylcinnamic acid ester Cycloartenol, cyclobranol or 24-methylene obtained in Examples 96 to 98 Cycloartanol-m-
16.6 g of nitro-α-methylcinnamic acid ester,
17.0 g or 0.027 mol of each of 17.0 g to 1 acetic acid
50- and tetrahydrofuran, and 6N-hydrochloric acid-dioxane 12.5- and zinc powder 1-1 were suspended therein.
6.5 g was added and stirred at 20°C for 2 hours. After the reaction was completed, the zinc dust was filtered off, the filtrate was concentrated under reduced pressure, and the resulting residue was extracted with chloroform. The chloroform layer was washed with water and then with saturated aqueous sodium bicarbonate, dried, and concentrated, and the residue was recrystallized from chloroform-ethanol (1:2) to obtain the desired compounds.
これらの収率(%)、融点(℃)、比旋光度(〔α〕習
(C1,0O1C)IC13) )は次のとおりであっ
た。The yield (%), melting point (°C), and specific optical rotation ([α] (C1,0O1C)IC13) of these were as follows.
(以下余白)
実施例102〜103 シクロアルテノール又はシク
ロブラノール−p−ニトロ−α−エチルケイヒ酸エステ
ルの製法
p−ニトロ−α−エチルケイヒ酸8.9g (0,04
0モル)にジオキサン30me、塩化チオニル6me(
2,0当量)とジメチルホルムアミド0.1−を加え、
60℃で2時間攪拌した。反応液を減圧濃縮後、ジオキ
サン30−とピリジン20−を加え、続いてシクロアル
テノール12.8g又はシクロブラノール13.2gの
各0.030モルを加え、60℃で2時間攪拌した。(Left below) Examples 102 to 103 Process for producing cycloartenol or cyclobranol-p-nitro-α-ethylcinnamic acid ester p-nitro-α-ethylcinnamic acid 8.9 g (0.04
0 mol) dioxane 30me, thionyl chloride 6me (
2.0 equivalents) and 0.1-dimethylformamide,
The mixture was stirred at 60°C for 2 hours. After concentrating the reaction solution under reduced pressure, 30-dioxane and 20-pyridine were added, followed by 0.030 mol each of 12.8 g of cycloartenol or 13.2 g of cyclobranol, and the mixture was stirred at 60° C. for 2 hours.
反応後、減圧濃縮し、得られた残渣をクロロホルムで抽
出した。クロロホルム層を水、続いて飽和重曹水で洗浄
後、乾燥、減圧濃縮し、残渣をクロロホルム−エタノー
ル(1: 3)で再結晶し、それぞれ表記目的化合物を
得た。これらの収率(%)、°融点(℃)、比旋光度(
〔α) W (C1,0O1CHC13) ) は次の
とおりであった。After the reaction, the mixture was concentrated under reduced pressure, and the resulting residue was extracted with chloroform. The chloroform layer was washed with water and then with saturated aqueous sodium bicarbonate, dried, and concentrated under reduced pressure. The residue was recrystallized from chloroform-ethanol (1:3) to obtain the desired compounds. These yields (%), melting point (℃), specific optical rotation (
[α) W (C1,0O1CHC13) ) was as follows.
実施例104〜105 シクロアルテノール又はシク
ロブラノール−p−アミノ−α−エチルケイヒ酸エステ
ルの製法
実施例102〜103で得たシクロアルテノール又はシ
クロブラノール−p−ニトロ−α−エチルケイヒ酸エス
テルの17.0g又は17.4gの各0.027モルを
酢酸150−とテトラヒドロフラン200艷の混合液に
懸濁し、そこへ6N−塩酸−ジオキサン12.5ml!
と亜鉛末16.5gを加え、22℃で2時間攪拌した。Examples 104-105 Preparation of cycloartenol or cyclobranol-p-amino-α-ethylcinnamate ester Preparation of cycloartenol or cyclobranol-p-nitro-α-ethylcinnamate obtained in Examples 102-103 0.027 mol of each of 17.0 g or 17.4 g was suspended in a mixture of 150 g of acetic acid and 200 g of tetrahydrofuran, and 12.5 ml of 6N-hydrochloric acid-dioxane was added thereto.
and 16.5 g of zinc powder were added thereto, and the mixture was stirred at 22°C for 2 hours.
反応後、亜鉛末をろ別し、ろ液を減圧濃縮して得られた
残渣をクロロホルムで抽出した。クロロホルム層を水、
続いて飽和重曹水で洗浄し、乾燥し、減圧濃縮後、残渣
をクロロホルム−エタノール(1: 3)で再結晶し、
それぞれ表記の目的化合物を得た。これらの収率(%)
、融点(℃)、比旋光度(〔α) 9 (C1,0O1
CHC13) )は次のとおりであった。After the reaction, the zinc dust was filtered off, the filtrate was concentrated under reduced pressure, and the resulting residue was extracted with chloroform. chloroform layer with water,
Subsequently, it was washed with saturated sodium bicarbonate solution, dried, and concentrated under reduced pressure, and the residue was recrystallized from chloroform-ethanol (1:3).
The indicated target compounds were obtained. These yields (%)
, melting point (℃), specific optical rotation ([α) 9 (C1,0O1
CHC13)) was as follows.
’lJi例106 24−メチレンシクロアルタノール
−3−メトキシ−4−二トロ安息香酸エ
ステルの製法
24−メチレンシクロアルタノール93.0g (0,
211モル)を用いた以外は、実施例56と同じ操作法
により24−メチレンシクロアルタノール−3−メトキ
シ−4−二トロ安息香酸エステル93.7gを得た。'lJi Example 106 Preparation of 24-methylenecycloartanol-3-methoxy-4-nitrobenzoic acid ester 24-methylenecycloartanol 93.0g (0,
93.7 g of 24-methylenecycloartanol-3-methoxy-4-nitrobenzoic acid ester was obtained by the same procedure as in Example 56, except that 211 mol) was used.
収率71.6%、融点205〜206℃比旋光度〔α〕
菅・S+56.5° (C1,00、CHCl3 )元
素分析結果 C70HP7N O5
(分子量619.85として)
計算値(%’) : C75,57H9,27N 2
.26実測値(%) : C75,5L H9,3
8N 2.2850%例107 24−メチレンシクロ
アルタノール−4−アミノ−3−メトキシ安息香酸エ
ステルの製法
実施例106の方法にて得た24−メチレンシクロアル
タノール−3−メトキシ−4−二トロ安息香酸エステル
92.2g (0,149モル)を用いた以外は、実施
例57と同じ操作法により24−メチレンシクロアルタ
ノール−4−アミノ−3−メトキシ安息香酸エステル6
2.8gを得た。Yield 71.6%, melting point 205-206℃ Specific rotation [α]
Suga・S+56.5° (C1,00, CHCl3) Elemental analysis result C70HP7N O5 (as molecular weight 619.85) Calculated value (%'): C75,57H9,27N 2
.. 26 Actual value (%): C75.5L H9.3
8N 2.2850% Example 107 Preparation of 24-methylenecycloartanol-4-amino-3-methoxybenzoic acid ester 24-methylenecycloartanol-3-methoxy-4-nitro obtained by the method of Example 106 24-methylenecycloartanol-4-amino-3-methoxybenzoic acid ester 6 was prepared using the same procedure as in Example 57, except that 92.2 g (0,149 mol) of benzoic acid ester was used.
2.8g was obtained.
収率71.5%、融点222〜223℃比旋光度〔α〕
菅 +63.2° (C1,00、CHCl3 )元素
分析結果 037 HF9 N O3(分子量589.
86として)
計算値(%) : C79,41H10,08N 2
.37実測値(%) : C79,38H10,14
N 2.35実施例108 シクロアルテノール−4
−アミノ−3−メトキシ安息香酸エステルの製法
4−アセタミド−3−メトキシ安息香酸6.5g(0,
031モル)をジオキサン110−に熔解した。Yield 71.5%, melting point 222-223℃ Specific rotation [α]
Suga +63.2° (C1,00, CHCl3) Elemental analysis result 037 HF9 N O3 (molecular weight 589.
86) Calculated value (%): C79,41H10,08N 2
.. 37 Actual value (%): C79,38H10,14
N 2.35 Example 108 Cycloartenol-4
-Production method of amino-3-methoxybenzoic acid ester 4-acetamido-3-methoxybenzoic acid 6.5g (0,
031 mol) was dissolved in dioxane 110-.
この溶液を20℃で攪拌し、そこへ塩化チオニル21.
0−を滴下し、次いで0.5−のピリジンを加え50℃
で5分間反応させた。反応液を減圧濃縮し塩化チオニル
を除去後、ジオキサン50−とベンゼン50−の混合液
に熔解したシクロアルテノール10.0g(0,023
モル)を20℃で加え、さらにピリジン20m1’を加
えた。これを70℃で3時間反応させた後、溶媒を減圧
下留去し、得られた残渣をクロロホルム100−に熔解
後、飽和重曹水で洗浄した。さらに飽和重曹水をクロロ
ホルム100meで5回抽出した。クロロホルム層をあ
わせて乾燥、減圧濃縮後、シリカゲルカラムクロマトグ
ラフィー〔溶媒 クロロホルム−酢酸エチル、(1:
6) )により精製を行うことによりジクロフルテノー
ル−4−アセタミド−3−メトキシ安息香酸エステル1
0.8gを得た。This solution was stirred at 20°C and 21.
Add 0- and then add 0.5-pyridine at 50°C.
The mixture was allowed to react for 5 minutes. After concentrating the reaction solution under reduced pressure to remove thionyl chloride, 10.0 g of cycloartenol (0,023
mol) was added at 20° C., and 20 ml of pyridine was further added. After reacting this at 70°C for 3 hours, the solvent was distilled off under reduced pressure, and the resulting residue was dissolved in 100% chloroform and washed with saturated aqueous sodium bicarbonate. Furthermore, the saturated sodium bicarbonate solution was extracted five times with 100 ml of chloroform. The chloroform layers were combined and dried, concentrated under reduced pressure, and then subjected to silica gel column chromatography [solvent chloroform-ethyl acetate, (1:
6) Dichloroflutenol-4-acetamido-3-methoxybenzoic acid ester 1 was obtained by purification according to ).
0.8g was obtained.
収率76.5%、融点224〜225℃比旋光度〔α〕
管 +61.5° (c i、oo、CICl3 )前
記で得たシクロアルテノール−4−アセタミド−3−メ
トキシ安息香酸エステル10.0g (0,016モル
)にテトラヒドロフラン200w1と30%塩酸2〇−
を加え2時間加熱還流を行った0反応終了後、溶媒を減
圧留去し、クロロホルム300w1に溶解し、クロロホ
ルム層をINカセイソーダ水200−1次に飽和食塩水
で洗浄した0次いで飽和食塩水をクロロホルムで3回抽
出した。クロロホルム層をあわせて乾燥後減圧濃縮し、
シリカゲルカラムクロマトグラフィー〔溶媒 酢酸エチ
ル−ヘキサン、(1: 6) )で精製することにより
シクロアルテノール−4−アミノ−3−メトキシ安息香
酸エステル5.4gを得た。Yield 76.5%, melting point 224-225℃ Specific rotation [α]
Tube +61.5° (ci, oo, CICl3) To 10.0 g (0,016 mol) of the cycloartenol-4-acetamido-3-methoxybenzoic acid ester obtained above, add 200 w1 of tetrahydrofuran and 20% of 30% hydrochloric acid.
After the reaction was completed, the solvent was distilled off under reduced pressure, dissolved in 300 w1 of chloroform, and the chloroform layer was washed with 200 w1 of IN caustic soda water and then with saturated brine. Extracted with chloroform three times. The chloroform layers were combined, dried and concentrated under reduced pressure.
Purification by silica gel column chromatography [solvent: ethyl acetate-hexane, (1:6)] gave 5.4 g of cycloartenol-4-amino-3-methoxybenzoate.
収率58.7%、融点186〜187℃比旋光度〔α〕
管 +64.4° (C1,00,CHCl3 )実施
例109 シクロブラノール−4−アミノ−3−メト
キシ−α−メチルケイヒ酸の製法
4−アセタミド−3−メトキシ−α−メチルケイヒ酸2
1.93g (0,088モル)をジオキサン15〇−
に溶解し、これに塩化チオニル25.7−を加えて60
℃で2時間加温攪拌した。反応終了後減圧下にて溶媒を
留去した。この残渣を再びジオキサン15M、続いてピ
リジン50meに溶解し、これにシクロブラノール30
g (0,06Bモル)を加え、60℃で2時間攪拌し
た。反応終了後、減圧下に溶媒を濃縮し残渣に酢酸エチ
ル300111!を加え、析出した結晶をろ取した。結
晶をシリカゲルカラムクロマトグラフィー〔溶媒 クロ
ロホルム−酢酸エチル、(1: 6) )により精製す
ることによりシクロブラノール−4−アセタミド−3−
メトキシ−α−メチルケイヒ酸エステル38.5gを得
た。Yield 58.7%, melting point 186-187℃ Specific rotation [α]
Tube +64.4° (C1,00, CHCl3) Example 109 Preparation of cyclobranol-4-amino-3-methoxy-α-methylcinnamic acid 4-acetamido-3-methoxy-α-methylcinnamic acid 2
1.93g (0,088mol) of dioxane 150-
To this, add 25.7-thionyl chloride to make 60
The mixture was heated and stirred at ℃ for 2 hours. After the reaction was completed, the solvent was distilled off under reduced pressure. This residue was dissolved again in 15M dioxane and then in 50M pyridine, and to this was added 30M cyclobranol.
g (0.06 B mol) was added and stirred at 60° C. for 2 hours. After the reaction is completed, the solvent is concentrated under reduced pressure and the residue is ethyl acetate (300111!). was added, and the precipitated crystals were collected by filtration. Cyclobranol-4-acetamide-3- was purified by purifying the crystals by silica gel column chromatography [solvent chloroform-ethyl acetate, (1:6)].
38.5 g of methoxy-α-methylcinnamic acid ester was obtained.
収率84.2%、融点248〜249℃比旋光度〔α〕
菅 +38.2° < c i、oo、CBCl3 )
上記のシクロブラノール−4−アセタミド−3−メトキ
シーα−メチルケイヒ酸エステル34.4g(0,05
1モル)をテトラヒドロフラン300−に溶、解し、3
0%塩酸60111を加えて70℃で2時間攪拌した。Yield 84.2%, melting point 248-249℃ Specific rotation [α]
Suga +38.2° < c i, oo, CBCl3)
34.4 g (0,05
1 mol) in 300% of tetrahydrofuran.
0% hydrochloric acid 60111 was added and stirred at 70°C for 2 hours.
反応終了後、溶媒を減圧留去し、その残渣をシリカゲル
クロマトグラフィー〔溶媒 クロロホルム−酢酸エチル
、(1: 6) )により2回精製しシクロブラノール
−4−アミノ−3−メトキシ−α−メチルケイヒ酸エス
テル18.9gを得た。After the reaction, the solvent was distilled off under reduced pressure, and the residue was purified twice by silica gel chromatography [solvent: chloroform-ethyl acetate, (1:6)] to give cyclobranol-4-amino-3-methoxy-α-methylcinnamate. 18.9 g of acid ester was obtained.
収率58.8%、融点225〜226℃比旋光度〔α〕
管 +42.0° (C1,00、CHCl3 )実施
例110 24−メチレンシクロアルタノール−4−ア
ミノ−3−メトキシケイヒ酸エ
ステルの製法
実施例109の方法において4−アセタミド−3−メト
キシ−α−メチルケイヒ酸の代りに4−プロピオアミド
−3−メトキシーケイヒ酸21.93g(0,088モ
ル)、シクロブラノールの代すに24−メチレンシクロ
アルクノール30g (0,068モル)を用いる以外
は同じ操作法により24−メチレンシクロアルタノール
−4−プロピオアミド−3−メトキシ安息香酸エステル
38.4gを得た。Yield 58.8%, melting point 225-226℃ Specific rotation [α]
Tube +42.0° (C1,00, CHCl3) Example 110 Preparation of 24-methylenecycloartanol-4-amino-3-methoxycinnamic acid ester In the method of Example 109, 4-acetamido-3-methoxy-α- Same except that 21.93 g (0,088 mol) of 4-propioamide-3-methoxycinnamic acid was used instead of methylcinnamic acid, and 30 g (0,068 mol) of 24-methylenecycloalknol was used instead of cyclobranol. 38.4 g of 24-methylenecycloartanol-4-propioamide-3-methoxybenzoic acid ester was obtained by the operating method.
収率83.8%、融点210〜211℃比旋光度〔α〕
菅 +39.4° (C1,0O1CIC13)又、シ
クロブラノール−4−アセタミド−3−メトキシ−α−
メチルケイヒ酸の代りに24−メチレンシクロアルタノ
ール−4−プロピオアミド−3−メトキシケイヒ酸エス
テル35.2g (0,052モル)を用いたほかは、
実施例109と同じ操作法により24−メチレンシクロ
アルタノール−4−アミノ−3−メトキシケイヒ酸エス
テル18.7gを得た。Yield 83.8%, melting point 210-211℃ Specific rotation [α]
Suga +39.4° (C1,0O1CIC13) Also, cyclobranol-4-acetamido-3-methoxy-α-
Except that 35.2 g (0,052 mol) of 24-methylenecycloartanol-4-propioamido-3-methoxycinnamic acid ester was used instead of methylcinnamic acid.
By the same procedure as in Example 109, 18.7 g of 24-methylenecycloartanol-4-amino-3-methoxycinnamic acid ester was obtained.
Claims (1)
ベンゼン核に結有するα−炭素数1〜4のアルキルケイ
ヒ酸エステル、又は炭素数1〜4のアルコキシ基とニト
ロ基、炭素数1〜4のアルコキシ基とアミノ基又は炭素
数1〜4のアルコキシ基と炭素数2〜5のアシルアミノ
基の二置換基をベンゼン核に結有する安息香酸もしくは
ケイヒ酸エステル。 2、トリテルペンアルコールがシクロアルテノール、シ
クロブラノール、24−メチレンシクロアルタノール、
ラノステロール、ラノステノール、アグノステロール、
シクロサドール、ジヒドロアグノステロール、シクロラ
ウデノール、シクロアルタノール、シクロユーカレノー
ル、ユーホール、ブチロスパーモール、チルカロール、
ユーホルボール又はダマラジエノールである特許請求の
範囲第1項記載の有機酸エステル。 3、一置換基がアミノ基、ニトロ基、ヒドロキシ基、炭
素数1〜4のアルコキシ基、炭素数2〜5のアシルアミ
ノ基又は炭素数2〜6のアルキルカルボキシ基である特
許請求の範囲第1項又は第2項記載のα−炭素数1〜4
のアルキルケイヒ酸エステル。 4、二置換基がヒドロキシ基と炭素数1〜4のアルコキ
シ基、ヒドロキシ基と炭素数2〜6のアルキルカルボキ
シ基、炭素数1〜4のアルコキシ基と炭素数2〜6のア
ルキルカルボキシ基、炭素数1〜4のアルコキシ基とニ
トロ基、炭素数1〜4のアルコキシ基とアミノ基、炭素
数1〜4のアルコキシ基と炭素数2〜5のアシルアミノ
基、炭素数1〜4のアルコキシ基の2個、炭素数2〜6
のアルキルカルボキシ基の2個又はヒドロキシ基の2個
である特許請求の範囲第1項又は第2項記載のα−炭素
数1〜4のアルキルケイヒ酸エステル。 5、シクロアルテノール又はシクロブラノールの3−メ
トキシ−4−ニトロケイヒ酸; 4−アミノ−3−メトキシケイヒ酸; 2−ニトキシ−5−ニトロケイヒ酸; 5−アミノ−2−ニトキシケイヒ酸; 3−メトキシ−4−ニトロ安息香酸; 4−アミノ−3−メトキシ安息香酸; 2−メトキシ−5−ニトロ安息香酸又は 5−アミノ−2−メトキシ安息香酸のエステルである特
許請求の範囲第1項記載の有機酸エステル。 6、24−メチレンシクロアルタノールの 3−メトキシ−4−ニトロケイヒ酸; 4−アミノ−3−メトキシケイヒ酸; 2−ニトキシ−5−ニトロケイヒ酸; 5−アミノ−2−ニトキシケイヒ酸; 3−メトキシ−4−ニトロ安息香酸又は 4−アミノ−3−メトキシ安息香酸のエステルである特
許請求の範囲第1項記載の有機酸エステル。 7、シクロアルテノール又はシクロブラノールのm−又
はp−ニトロ−α−メチルケイヒ酸;m−又はp−アミ
ノ−α−メチルケイヒ酸;3−又は4−プロピオニルオ
キシ−α−メチルケイヒ酸; 3−又は4−ヒドロキシ−α−メチルケイヒ酸;3−又
は4−ブチリルオキシ−α−エチル ケイヒ酸; 3−又は4−ヒドロキシ−α−エチルケイヒ酸;2−ヒ
ドロキシ−α−メチルケイヒ酸; p−ニトロ−α−エチルケイヒ酸又は p−アミノ−α−エチルケイヒ酸のエステルである特許
請求の範囲第3項記載のα−炭素数1〜4のアルキルケ
イヒ酸エステル。 8、24−メチレンシクロアルタノールの m−又はp−ニトロ−α−メチルケイヒ酸;m−又はp
−アミノ−α−メチルケイヒ酸;3−又は4−プロピオ
ニルオキシ−α−メチルケイヒ酸; 3−又は4−ヒドロキシ−α−メチルケイヒ酸;3−ブ
チリルオキシ−α−エチルケイヒ酸又は3−ヒドロキシ
−α−エチルケイヒ酸のエステルある特許請求の範囲第
3項記載のα−炭素数1〜4のアルキルケイヒ酸エステ
ル。 9、シクロアルテノール又はシクロブラノールの3−メ
トキシ−4−プロピオニルオキシ−α−メチルケイヒ酸
; 4−ヒドロキシ−3−メトキシ−α−メチルケイヒ酸; 4−ブチリルオキシ−3−メトキシ−α− エチルケイヒ酸: 4−ヒドロキシ−3−メトキシ−α−エチルケイヒ酸; 4−ヒドロキシ−3−メトキシ−α−ブチルケイヒ酸; 3−ニトキシ−4−ヒドロキシ−α−メチルケイヒ酸; 3−ニトキシ−4−ヒドロキシ−α−プロピルケイヒ酸
; 3−メトキシ−4−ニトロ−α−メチルケイヒ酸; 4−アミノ−3−メトキシ−α−メチルケイヒ酸; 5−ニトロ−2−プロポキシ−α−メチルケイヒ酸; 5−アミノ−2−プロポキシ−α−メチルケイヒ酸; 3−メトキシ−4−ニトロ−α−iso−プロピルケイ
ヒ酸又は 4−アミノ−3−メトキシ−α−iso−プロピルケイ
ヒ酸のエステル である特許請求の範囲第4項記載のα−炭素数1〜4の
アルキルケイヒ酸エステル。 10、24−メチレンシクロアルタノールの3−メトキ
シ−4−プロピオニルオキシ−α−メチルケイヒ酸; 4−ヒドロキシ−3−メトキシ−α−メチルケイヒ酸; 4−ブチリルオキシ−3−メトキシ−α−エチルケイヒ
酸; 4−ヒドロキシ−3−メトキシ−α−エチルケイヒ酸: 4−ヒドロキシ−3−メトキシ−α−ブチルケイヒ酸; 3−エトキシ−4−ヒドロキシ−α−メチルケイヒ酸; 4−ヒドロキシ−3−プロポキシ−α−プロピルケイヒ
酸; 3−メトキシ−4−ニトロ−α−メチルケイヒ酸; 4−アミノ−3−メトキシ−α−メチルケイヒ酸; 5−ニトロ−2−プロポキシ−α−メチルケイヒ酸又は 5−アミノ−2−プロポキシ−α−メチルケイヒ酸のエ ステルである特許請求の範囲第4項記載のα一炭素数1
〜4のアルキルケイヒ酸エステル。 11、シクロアルテノールの3−メトキシ−4−プロピ
オニルオキシケイヒ酸; 3−メトキシ−4−バレリルオキシ−α−プロピルケイ
ヒ酸; 4−ヒドロキシ−3−メトキシ−α−プロピルケイヒ酸
; 4−カプリルオキシ−3−メトキシ−α−ブチルケイヒ
酸; 3−エトキシ−4−ヒドロキシ−α−エチルケイヒ酸; 3−エトキシ−4−ヒドロキシ−α−ブチルケイヒ酸; 4−ヒドロキシ−3−プロポキシ−α−メチルケイヒ酸
又は 4−ヒドロキシ−3−ブトキシ−α−メチルケイヒ酸の エステルである特許請求の範囲第4項記載の有機酸エス
テル。 12、シクロブラノール−4−ヒドロキシ−3−プロポ
キシ−α−エチルケイヒ酸エステルである特許請求の範
囲第4項記載の有機酸エステル。 13、トリテルペンアルコールと一置換基又は二置換基
をベンゼン核に結有するα−炭素数1〜4のアルキルケ
イヒ酸、又は炭素数1〜4のアルコキシ基とニトロ基、
炭素数1〜4のアルコキシ基とアミノ基又は炭素数1〜
4のアルコキシ基と炭素数2〜5のアシルアミノ基の二
置換基をベンゼン核に結有する安息香酸又はケイヒ酸の
酸ハロゲナイドを反応させることを特徴とするトリテル
ペンアルコール有機酸エステルの製造法。 14、トリテルペンアルコールがシクロアルテノール、
シクロブラノール、24−メチレンシクロアルタノール
、ラノステロール、ラノステノール、アグノステロール
、シクロサドール、ジヒドロアグノステロール、シクロ
ラウデノール、シクロアルタノール、シクロユーカレノ
ール、ユーホール、ブチロスパーモール、チルカロール
、ユーホルボール又はダマラジエノールである特許請求
の範囲第13項記載の有機酸エステルの製造法。 15、有機酸の酸ハロゲナイドがニトロ基、炭素数2〜
5のアシルアミノ基、炭素数1〜4のアルコキシ基又は
炭素数2〜6のアルキルカルボキシ基の一置換基をベン
ゼン核に結有するα−炭素数1〜4のアルキルケイヒ酸
の酸ハロゲナイドである特許請求の範囲第13項又は第
14項記載の有機酸エステルの製造法。 16、有機酸の酸ハロゲナイドが炭素数1〜4のアルコ
キシ基とニトロ基;炭素数1〜4のアルコキシ基と炭素
数2〜5のアシルアミノ基;炭素数1〜4のアルコキシ
基及び/又は炭素数2〜6のアルキルカルボキシ基の二
置換基をベンゼン核に結有するα−炭素数1〜4のアル
キルケイヒ酸の酸ハロゲナイドである特許請求の範囲第
13項又は第14項記載の有機酸エステルの製造法。 17、有機酸の酸ハロゲナイドが炭素数1〜4のアルコ
キシ基とニトロ基又は炭素数1〜4のアルコキシ基と炭
素数2〜5のアシルアミノ基の二置換基をベンゼン核に
結有するケイヒ酸又は安息香酸の酸ハロゲナイドである
特許請求の範囲第13項又は第14項記載の有機酸エス
テルの製造法。 18、炭素数2〜5のアシルアミノ基又は炭素数2〜6
のアルキルカルボキシ基の一置換基;炭素数1〜4のア
ルコキシ基と炭素数2〜6のアルキルカルボキシ基;炭
素数1〜4のアルコキシ基と炭素数2〜5のアシルアミ
ノ基の二置換基又は炭素数2〜6のアルキルカルボキシ
基の二置換基をベンゼン核に結有するα−炭素数1〜4
のアルキルケイヒ酸のトリテルペンアルコールエステル
より脱アシル化することを特徴とするヒドロキシ基又は
アミノ基の一置換基;炭素数1〜4のアルコキシ基とヒ
ドロキシ基又は炭素数1〜4のアルコキシ基とアミノ基
の二置換基又はヒドロキシ基の二置換基をベンゼン核に
結有するα−炭素数1〜4のアルキルケイヒ酸のトリテ
ルペンアルコールエステルの製造法。 19、炭素数1〜4のアルコキシ基と炭素数2〜5のア
シルアミノ基の二置換基をベンゼン核に結有するケイヒ
酸又は安息香酸のトリテルペンアルコールエステルより
脱アシル化することを特徴とする炭素数1〜4のアルコ
キシ基とアミノ基の二置換基をベンゼン核に結有するケ
イヒ酸又は安息香酸のトリテルペンアルコールエステル
の製造法。 20、ニトロ基の一置換基又はニトロ基と炭素数1〜4
のアルコキシ基の二置換基をベンゼン核に結有するα−
炭素数1〜4のアルキルケイヒ酸のトリテルペンアルコ
ールエステルを金属と酸で還元することを特徴とするア
ミノ基の一置換基又はアミノ基と炭素数1〜4のアルコ
キシ基の二置換基をベンゼン核に結有するα−炭素数1
〜4のアルキルケイヒ酸のトリテルペンアルコールエス
テルの製造法。 21、ニトロ基と炭素数1〜4のアルコキシ基の二置換
基をベンゼン核に結有するケイヒ酸又は安息香酸のトリ
テルペンアルコールエステルを金属と酸で還元すること
を特徴とするアミノ基と炭素数1〜4のアルコキシ基の
二置換基をベンゼン核に結有するケイヒ酸又は安息香酸
のトリテルペンアルコールエステルの製造法。 22、トリテルペンアルコールがシクロアルテノール、
シクロブラノール、24−メチレンシクロアルタノール
、ラノステロール、ラノステノール、アグノステロール
、シクロサドール、ジヒドロアグノステロール、シクロ
ラウデノール、シクロアルタノール、シクロユーカレノ
ール、ユーホール、ブチロスパーモール、チルカロール
、ユーホルボール又はダマラジエノールである特許請求
の範囲第18項、第19項、第20項又は第21項記載
の製造法。[Scope of Claims] 1. an α-alkylcinnamic acid ester having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms and a nitro group, which has a triterpene alcohol monosubstituent or disubstituent group attached to a benzene nucleus; A benzoic acid or cinnamic acid ester having a disubstituted group of an alkoxy group having 1 to 4 carbon atoms and an amino group, or an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms, to a benzene nucleus. 2. The triterpene alcohol is cycloartenol, cyclobranol, 24-methylenecycloartanol,
lanosterol, lanosterol, agnosterol,
Cyclosadol, dihydroagnosterol, cyclolaudenol, cycloartanol, cycloeucalenol, Uhol, butyrospermol, circalol,
The organic acid ester according to claim 1, which is euphorbol or damaradienol. 3. Claim 1 in which one substituent is an amino group, a nitro group, a hydroxy group, an alkoxy group having 1 to 4 carbon atoms, an acylamino group having 2 to 5 carbon atoms, or an alkylcarboxy group having 2 to 6 carbon atoms α-carbon number 1 to 4 as described in item or item 2
Alkyl cinnamic acid ester. 4. The disubstituted groups are a hydroxy group and an alkylcarboxy group having 1 to 4 carbon atoms, a hydroxy group and an alkylcarboxy group having 2 to 6 carbon atoms, an alkoxy group having 1 to 4 carbon atoms and an alkylcarboxy group having 2 to 6 carbon atoms, An alkoxy group having 1 to 4 carbon atoms and a nitro group, an alkoxy group having 1 to 4 carbon atoms and an amino group, an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms, an alkoxy group having 1 to 4 carbon atoms 2 pieces, carbon number 2-6
The α-alkyl cinnamic acid ester having 1 to 4 carbon atoms according to claim 1 or 2, which has two alkylcarboxy groups or two hydroxy groups. 5, 3-methoxy-4-nitrocinnamic acid of cycloartenol or cyclobranol; 4-amino-3-methoxycinnamic acid; 2-nitoxy-5-nitrocinnamic acid; 5-amino-2-nitoxycinnamic acid; 3-methoxy -4-nitrobenzoic acid; 4-amino-3-methoxybenzoic acid; 2-methoxy-5-nitrobenzoic acid or an ester of 5-amino-2-methoxybenzoic acid; acid ester. 3-methoxy-4-nitrocinnamic acid of 6,24-methylenecycloartanol; 4-amino-3-methoxycinnamic acid; 2-nitoxy-5-nitrocinnamic acid; 5-amino-2-nitoxycinnamic acid; 3-methoxy- The organic acid ester according to claim 1, which is an ester of 4-nitrobenzoic acid or 4-amino-3-methoxybenzoic acid. 7. m- or p-nitro-α-methylcinnamic acid of cycloartenol or cyclobranol; m- or p-amino-α-methylcinnamic acid; 3- or 4-propionyloxy-α-methylcinnamic acid; 3- or 4-Hydroxy-α-methylcinnamic acid; 3- or 4-butyryloxy-α-ethylcinnamic acid; 3- or 4-hydroxy-α-ethylcinnamic acid; 2-hydroxy-α-methylcinnamic acid; p-nitro-α-ethylcinnamic acid or the α-alkylcinnamic acid ester having 1 to 4 carbon atoms according to claim 3, which is an ester of p-amino-α-ethylcinnamic acid. m- or p-nitro-α-methylcinnamic acid of 8,24-methylenecycloartanol; m- or p
-Amino-α-methylcinnamic acid; 3- or 4-propionyloxy-α-methylcinnamic acid; 3- or 4-hydroxy-α-methylcinnamic acid; 3-butyryloxy-α-ethylcinnamic acid or 3-hydroxy-α-ethylcinnamic acid An α-alkyl cinnamic acid ester having 1 to 4 carbon atoms according to claim 3. 9. 3-methoxy-4-propionyloxy-α-methylcinnamic acid of cycloartenol or cyclobranol; 4-hydroxy-3-methoxy-α-methylcinnamic acid; 4-butyryloxy-3-methoxy-α-ethylcinnamic acid: 4-hydroxy-3-methoxy-α-ethylcinnamic acid; 4-hydroxy-3-methoxy-α-butylcinnamic acid; 3-nitoxy-4-hydroxy-α-methylcinnamic acid; 3-nitoxy-4-hydroxy-α-propyl cinnamic acid; 3-methoxy-4-nitro-α-methylcinnamic acid; 4-amino-3-methoxy-α-methylcinnamic acid; 5-nitro-2-propoxy-α-methylcinnamic acid; 5-amino-2-propoxy- α-Methylcinnamic acid; α according to claim 4, which is an ester of 3-methoxy-4-nitro-α-iso-propylcinnamic acid or 4-amino-3-methoxy-α-iso-propylcinnamic acid. - Alkylcinnamic acid ester having 1 to 4 carbon atoms. 10,24-methylenecycloartanol 3-methoxy-4-propionyloxy-α-methylcinnamic acid; 4-hydroxy-3-methoxy-α-methylcinnamic acid; 4-butyryloxy-3-methoxy-α-ethylcinnamic acid; 4 -Hydroxy-3-methoxy-α-ethylcinnamic acid: 4-hydroxy-3-methoxy-α-butylcinnamic acid; 3-ethoxy-4-hydroxy-α-methylcinnamic acid; 4-hydroxy-3-propoxy-α-propylcinnamic acid Acid; 3-methoxy-4-nitro-α-methylcinnamic acid; 4-amino-3-methoxy-α-methylcinnamic acid; 5-nitro-2-propoxy-α-methylcinnamic acid or 5-amino-2-propoxy-α -α1 carbon number 1 according to claim 4, which is an ester of methylcinnamic acid
~4 alkylcinnamic acid esters. 11. Cycloartenol 3-methoxy-4-propionyloxycinnamic acid; 3-methoxy-4-valeryloxy-α-propylcinnamic acid; 4-hydroxy-3-methoxy-α-propylcinnamic acid; 4-capryloxy- 3-methoxy-α-butylcinnamic acid; 3-ethoxy-4-hydroxy-α-ethylcinnamic acid; 3-ethoxy-4-hydroxy-α-butylcinnamic acid; 4-hydroxy-3-propoxy-α-methylcinnamic acid or 4- The organic acid ester according to claim 4, which is an ester of hydroxy-3-butoxy-α-methylcinnamic acid. 12. The organic acid ester according to claim 4, which is cyclobranol-4-hydroxy-3-propoxy-α-ethylcinnamic acid ester. 13, an α-alkylcinnamic acid having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms and a nitro group, which has a triterpene alcohol and one or two substituents attached to the benzene nucleus;
Alkoxy group with 1 to 4 carbon atoms and amino group or 1 to 4 carbon atoms
1. A method for producing a triterpene alcohol organic acid ester, which comprises reacting an acid halide of benzoic acid or cinnamic acid in which a disubstituted group of an alkoxy group of 4 and an acylamino group having 2 to 5 carbon atoms is bonded to a benzene nucleus. 14. The triterpene alcohol is cycloartenol,
Cyclobranol, 24-methylenecycloartanol, lanosterol, lanosterol, agnosterol, cyclosadol, dihydroagnosterol, cyclolaudenol, cycloartanol, cycloeucalenol, uhol, butyrospermol, circalol, eupholbol or damas 14. The method for producing an organic acid ester according to claim 13, which is radienol. 15. The acid halide of the organic acid has a nitro group and 2 or more carbon atoms.
A patent which is an acid halide of α-alkylcinnamic acid having 1 to 4 carbon atoms, in which one substituent of an acylamino group of 5, an alkoxy group having 1 to 4 carbon atoms, or an alkylcarboxy group having 2 to 6 carbon atoms is bonded to a benzene nucleus. A method for producing an organic acid ester according to claim 13 or 14. 16. The acid halide of organic acid is an alkoxy group having 1 to 4 carbon atoms and a nitro group; an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms; an alkoxy group having 1 to 4 carbon atoms and/or a carbon The organic acid ester according to claim 13 or 14, which is an acid halide of α-alkylcinnamic acid having 1 to 4 carbon atoms, in which a disubstituted group of 2 to 6 alkyl carboxy groups is bonded to a benzene nucleus. manufacturing method. 17. Cinnamic acid or cinnamic acid in which the acid halide of the organic acid has disubstituted groups of an alkoxy group having 1 to 4 carbon atoms and a nitro group, or an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms, to a benzene nucleus; 15. The method for producing an organic acid ester according to claim 13 or 14, which is an acid halide of benzoic acid. 18, acylamino group having 2 to 5 carbon atoms or 2 to 6 carbon atoms
One substituent for an alkylcarboxy group; an alkoxy group having 1 to 4 carbon atoms and an alkylcarboxy group having 2 to 6 carbon atoms; a disubstituent for an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms; or α-C1-C4 having a disubstituent of an alkylcarboxy group having C2-C6 attached to a benzene nucleus
A monosubstituent of a hydroxy group or an amino group characterized by being deacylated from a triterpene alcohol ester of an alkylcinnamic acid; A method for producing a triterpene alcohol ester of α-alkylcinnamic acid having 1 to 4 carbon atoms, in which a disubstituted group or a disubstituted hydroxy group is bonded to a benzene nucleus. 19. A carbon number characterized by deacylation from a triterpene alcohol ester of cinnamic acid or benzoic acid in which a disubstituted group of an alkoxy group having 1 to 4 carbon atoms and an acylamino group having 2 to 5 carbon atoms is bonded to a benzene nucleus. A method for producing a triterpene alcohol ester of cinnamic acid or benzoic acid in which 1 to 4 disubstituents of an alkoxy group and an amino group are bonded to a benzene nucleus. 20, one substituent of nitro group or nitro group and carbon number 1 to 4
α-, which has a disubstituted alkoxy group of
A triterpene alcohol ester of an alkylcinnamic acid having 1 to 4 carbon atoms is reduced with a metal and an acid. A monosubstituent of an amino group or a disubstituent of an amino group and an alkoxy group having 1 to 4 carbon atoms is added to a benzene nucleus. α-carbon number 1 bonded to
-4 Method for producing triterpene alcohol ester of alkylcinnamic acid. 21. Amino group and carbon number 1 characterized by reducing triterpene alcohol ester of cinnamic acid or benzoic acid, which has a disubstituted group of a nitro group and an alkoxy group having 1 to 4 carbon atoms attached to a benzene nucleus, with a metal and an acid. A method for producing a triterpene alcohol ester of cinnamic acid or benzoic acid in which a benzene nucleus has a disubstituted alkoxy group of -4. 22. The triterpene alcohol is cycloartenol,
Cyclobranol, 24-methylenecycloartanol, lanosterol, lanosterol, agnosterol, cyclosadol, dihydroagnosterol, cyclolaudenol, cycloartanol, cycloeucalenol, uhol, butyrospermol, circalol, eupholbol or damas The manufacturing method according to claim 18, 19, 20 or 21, wherein the radienol is radienol.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60085254A JPS61243099A (en) | 1985-04-19 | 1985-04-19 | Triterpene alcohol organic acid ester and production thereof |
CA000481808A CA1265785A (en) | 1984-06-04 | 1985-05-17 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them |
EP85303839A EP0166542B1 (en) | 1984-06-04 | 1985-05-30 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them |
US06/739,183 US4748161A (en) | 1984-06-04 | 1985-05-30 | Triterpenyl esters of organic acids and hypolipidemic agents composed of them |
DE8585303839T DE3579064D1 (en) | 1984-06-04 | 1985-05-30 | TRITERPENE ESTERS OF ORGANIC ACID, METHOD FOR THE PRODUCTION THEREOF AND HYPOLIPEINIC COMPOSITIONS THAT CONTAIN IT. |
KR1019850003819A KR920007235B1 (en) | 1984-06-04 | 1985-05-31 | Method for preparing triterphenyl ester of organic acid |
SU853913136A SU1538892A3 (en) | 1984-06-04 | 1985-06-03 | Method of producing tritherphenyl esters of organic acids |
FI852216A FI852216L (en) | 1984-06-04 | 1985-06-03 | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA TRITERPENYLESTRAR AV ORGANISKA SYROR. |
DK246985A DK246985A (en) | 1984-06-04 | 1985-06-03 | TRITERPENYL ESTERS OF ORGANIC ACIDS, PROCEDURES FOR PRODUCING THEREOF, AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH TRITERPENYL ESTERS |
NO85852246A NO852246L (en) | 1984-06-04 | 1985-06-03 | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TRITERPENYL ESTERS OF ORGANIC ACIDS. |
ES544466A ES8708125A1 (en) | 1984-06-04 | 1985-06-04 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60085254A JPS61243099A (en) | 1985-04-19 | 1985-04-19 | Triterpene alcohol organic acid ester and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61243099A true JPS61243099A (en) | 1986-10-29 |
JPH0533713B2 JPH0533713B2 (en) | 1993-05-20 |
Family
ID=13853435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60085254A Granted JPS61243099A (en) | 1984-06-04 | 1985-04-19 | Triterpene alcohol organic acid ester and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61243099A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000063328A (en) * | 1998-02-13 | 2000-02-29 | Givaudan Roure Internatl Sa | Aryl acrylate ester |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101360817B1 (en) | 2008-11-19 | 2014-02-11 | 모리나가 뉴교 가부시키가이샤 | A drug for treating or preventing arteriosclerosis |
-
1985
- 1985-04-19 JP JP60085254A patent/JPS61243099A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000063328A (en) * | 1998-02-13 | 2000-02-29 | Givaudan Roure Internatl Sa | Aryl acrylate ester |
Also Published As
Publication number | Publication date |
---|---|
JPH0533713B2 (en) | 1993-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5698527A (en) | Steroidal glycosides as antihyperlipidemic agents | |
JP2019503392A (en) | Steroid derivative FXR agonist | |
CN109833319B (en) | Application of Compounds in Prevention and Treatment of Metabolic Diseases | |
KR920007235B1 (en) | Method for preparing triterphenyl ester of organic acid | |
JP2724114B2 (en) | Triterpene derivatives and endothelin receptor antagonists containing the same | |
JP2001240573A (en) | Triterpene derivative and liver disease medical treatment agent | |
EP3830103A1 (en) | Fluorinated bile acid derivatives | |
JPS61243099A (en) | Triterpene alcohol organic acid ester and production thereof | |
JP3295426B2 (en) | Anti-hypercholesterolemic compounds and related pharmaceutical compositions and methods of use | |
DE3103144C2 (en) | ||
JPH0925235A (en) | Suppressant for cancer metastasis containing 1-o-acylglycerol 2,3-phosphate derivative as active ingredient | |
CN116375582A (en) | Isosteviol derivatives and their applications | |
EP1828137A1 (en) | 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments | |
WO2003068736A2 (en) | Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof | |
JPS61243022A (en) | Remedy for hyperlipemia | |
JPS60258119A (en) | Remedy for hyperlipemia | |
JPS60258198A (en) | Triterpene alcohol organic acid ester and its preparation | |
JPH01249733A (en) | Metabolic substance of pentane diacid derivative | |
AU598724B2 (en) | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | |
WO2015179293A1 (en) | Small molecule activators and inhibitors of lecithin: cholesterol acyltransferase | |
US4375478A (en) | Aminobenzoic acid derivatives | |
DE4109735A1 (en) | NEW SULPHONAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
DE102004060998A1 (en) | New 2,4-dicyclopentyl-3-(fluoro-(4-trifluoromethyl-phenyl)-methyl)-7,7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent e.g. coronary heart diseases | |
DE102004061002A1 (en) | New (5'S)-2',4'-dicyclopentyl -3'-9(S)-fluoro(4-(trifluoromethyl) phenyl)methyl)-5',8' -dihydro-6'H-spiro(cyclopropane-1,7'-quinoline)-5'-ol is a cholesterol ester transfer protein inhibitor useful for treating e.g. coronary heart diseases | |
IE44384B1 (en) | Cyclopentanol derivatives |